CUMULATIVE SUPPLEMENT 8

JAN'93-AUG'93



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Cumulative Supplement 8

AUGUST 1993

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

CUMULATIVE SUPPLEMENT 8

AUGUST 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing overstruck print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AH ROBINS CO (ROBINS)	AH ROBINS CO (ROBINS AH)
ASTRA PHARMACEUTICAL PRODUCTS INC (ASTRA)	ASTRA USA INC (ASTRA)
BAKER CUMMINS PHARMACEUTICALS INC (BAKER CUMMINS)	BAKER NORTON PHARMACEUTICALS INC (BAKER NORTON)
BENEDICT NUCLEAR PHARMACEUTICALS INC (BENEDICT)	NORTH AMERICAN CHEMICAL CORPORATION (NORTH AM CHEM)
BOLAR PHARMACEUTICAL CO INC (BOLAR)	CIRCA PHARMACEUTICALS INC (CIRCA)
CIS US INC (CIS)	CIS US INC (CIS US)
CUTTER BIOLOGICAL DIV MILES LABORATORIES INC (CUTTER)	MILES LABORATORIES INC (MILES LABS)
DANBURY PHARMACAL INC (DANBURY)	DANBURY PHARMACAL INC (DANBURY PHARMA)
FUJISAWA PHARMACEUTICAL CO (FUJISAWA)	FUJISAWA USA INC (FUJISAWA)
HERBERT LABORATORIES DIV SMITH KLINE AND FRENCH CO (HERBERT)	ALLERGAN HERBERT DIV ALLERGAN INC (ALLERGAN HERBERT)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ICI PHARMACEUTICALS GROUP DIV ICI AMERICAS (ICI)	ZENECA PHARMACEUTICALS GROUP (ZENECA)
LYPHOMED DIV FUJISAWA USA INC (LYPHOMED)	FUJISAWA USA INC (FUJISAWA)
ROXANE LABORATORIES INC (ROXANE)	ROXANE LABORATORIES INC (ROXANE LABS)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV MCNEILAB (JOHNSON RW)	RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)
SCHIAPPARELLI SEARLE (SCHIAPPARELLI SEARLE)	SCS PHARMACEUTICALS (SCS PHARMS)
SOMERSET PHARMACEUTICALS INC (SOMERSET)	SOMERSET PHARMACEUTICALS INC (SOMERSET PHARMS)
STERLING DRUG INC (STERLING)	STERLING WINTHROP INC (STERLING WINTHROP)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF AUGUST 1993.

.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1992	MAR 1993	JUN 1993	SEP 1993
DRUG PRODUCTS LISTED	9488	9392	9194	
SINGLE SOURCE	2245 (23.7%)	2243 (23.9%)	2119 (23.0%)	
MULTISOURCE	7243 (76.3%)	7149 (76.1%)	7075 (77.0%)	
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6432 (68.5%)	6357 (69.1%)	
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	562 (5.9%)	555 (6.1%)	
EXCEPTIONS[1]	150 (1.6%)	155 (1.7%)	163 (1.8%)	
NEW MOLECULAR ENTITIES APPROVED	--	3	2	
NUMBER OF APPLICANTS	477	484	508	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	AHOQUAH			
/AB/	/HALLAND/	/325MG;50MG;40MG/	/N87628/001/	/OCT/01,/1986/
AB	ROBERTS HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986

TABLET; ORAL

	ESGIC			
/AB/	/FOREST/PHARMS/	/325MG;50MG;40MG/	/N89660/001/	/DEC/23,/1988/
∂	FOREST PHARMS	325MG;50MG;40MG	N89660 001	DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

	COMPAL			
AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986
/AA/	/SOLVAY/	/356.4MG;30MG;16MG/	/N88584/001/	/MAR/04,/1986/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
	∂ LEMMON	300MG;30MG	N88324 001	DEC 29, 1983
	/ACETAMINOPHEN/W/CODEINE/#3/			
	/LEMMON/	/300MG;30MG/	/N88324/001/	/DEC/29,/1983/

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE			
> ADD >	AA	PENNEX PHARMS	120MG/5ML;12MG/5ML	N87006 001	
> DLT >	/AA/	/PHARM/BASICS/	/120MG/5ML;12MG/5ML/	/N87006/001/	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ALLAY			
/AA/	/LUCHEM/	/500MG;5MG/	/N89907/001/	/JAN/13,/1989/
AA	NORTON HN	500MG;5MG	N89907 001	JAN 13, 1989

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

> DLT >		/BANCAP HC/			
> DLT >	/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87961/001/	/MAR/17,/1983/
> DLT >					
> ADD >	∂	FOREST PHARMS	500MG;5MG	N87961 001	MAR 17, 1983
> ADD >					

TABLET; ORAL

	ANEXSIA			
AA	BOEHRINGER MANNHEIM	500MG;5MG	N89160 001	APR 23, 1987
/AA/	/SKCP/	/500MG;5MG/	/N89160/001/	/APR/23,/1987/
	ANEXSIA 7.5/650			
AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001	SEP 30, 1987
/AA/	/SKCP/	/650MG;7.5MG/	/N89725/001/	/SEP/30,/1987/
	/DURADYNE DHC/			
/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87809/001/	/MAR/17,/1983/
∂	FOREST PHARMS	500MG;5MG	N87809 001	MAR 17, 1983

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AA/	/LUCHEM/	/500MG;5MG/	/N89696/001/	/APR/21,/1988/
AA	NORTON HN	500MG;5MG	N89696 001	APR 21, 1988
	/NORCET/			
/AA/	/ABANA/	/500MG;5MG/	/N88871/001/	/MAY/15,/1986/
∂	ABANA	500MG;5MG	N88871 001	MAY 15, 1986
	/TYCOLET/			
/AA/	/JOHNSON/RW/	/500MG;5MG/	/N89385/001/	/AUG/27,/1986/
∂	JOHNSON RW	500MG;5MG	N89385 001	AUG 27, 1986

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
/AB/	/HALSEY/	/650MG;100MG/	/N72106/001/	/MAY/13,/1988/
∂	HALSEY	650MG;100MG	N72106 001	MAY 13, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

/ACETAZOLAMIDE SODIUM/			
/AP/ /QUAD/	/EQ 500MG/VIAL/	/N89619/001/ /JAN/13,/1988/	
@ QUAD	EQ 500MG/VIAL	N89619 001 JAN 13, 1988	
DIAMOX			
/AP/ /LEDERLE/	/EQ 500MG/VIAL/	/N09388/001/ /DEC/05,/1990/	
LEDERLE	EQ 500MG/VIAL	N09388 001 DEC 05, 1990	

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ZOVIRAX			
+ BURROUGHS WELLCOME	EQ 1GM BASE/VIAL	N18603 002 JUN 29, 1989	
@	EQ 250MG BASE/VIAL	N18603 003 AUG 30, 1983	

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE			
AN COPLEY	EQ 0.083% BASE	N73495 001 MAY 28, 1993	

SYRUP; ORAL

ALBUTEROL SULFATE			
AA WATSON LABS	EQ 2MG BASE/5ML	N73165 001 APR 29, 1993	

TABLET; ORAL

ALBUTEROL SULFATE			
AB NOVOPHARM	EQ 2MG BASE	N72779 001 JUN 25, 1993	
AB	EQ 4MG BASE	N72780 001 JUN 25, 1993	

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL			
/BC/+//SCHERING/	/EQ/4MG/BASE/	/N19383/001/ /JUL/13,/1987/	
BC SCHERING	EQ 4MG BASE	N19383 001 JUL 13, 1987	
VOLMAX			
/BC/ /GLAXO/	/EQ/4MG/BASE/	/N19604/002/ /DEC/23,/1992/	
/+/	/EQ/8MG/BASE/	/N19604/001/ /DEC/23,/1992/	
BC + MURO	EQ 4MG BASE	N19604 002 DEC 23, 1992	
+	EQ 8MG BASE	N19604 001 DEC 23, 1992	

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL			
/AB/ /CIRCA/	/100MG/	/N71382/001/ /JAN/21,/1987/	
@ CIRCA	100MG	N71382 001 JAN 21, 1987	

SYRUP; ORAL

AMANTADINE HCL			
AA MIKART	50MG/5ML	N74028 001 JUN 28, 1993	

/TABLET;/ORAL/			
/SYMMETREL/			
/+//DUPONT/	/100MG/	/N18101/001/	
@ DUPONT	100MG	N18101 001	

AMDINOCILLIN

/INJECTABLE;/INJECTION/			
/COACTIN/			
/ROCHE/	/250MG/VIAL/	/N50565/001/ /DEC/21,/1984/	
	/500MG/VIAL/	/N50565/002/ /DEC/21,/1984/	
	/1GM/VIAL/	/N50565/003/ /DEC/21,/1984/	

AMDINOCILLIN

/INJECTABLE;/INJECTION/
/COACTIN/
@ ROCHE 250MG/VIAL N50565 001
DEC 21, 1984
@ 500MG/VIAL N50565 002
DEC 21, 1984
@ 1GM/VIAL N50565 003
DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN
AP DUPONT MERCK EQ 50MG BASE/ML N63350 001
JUL 30, 1993
AP EQ 250MG BASE/ML N63350 002
JUL 30, 1993
/AMIKIN/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/
/BRISTOL/ /EQ/5MG/BASE/ML/ /N50618/002/
/NOV/30,/1987/
/EQ/10MG/BASE/ML/ /N50618/001/
/NOV/30,/1987/
@ BRISTOL EQ 5MG BASE/ML N50618 002
NOV 30, 1987
@ EQ 10MG BASE/ML N50618 001
NOV 30, 1987

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER 15% N20107 001
FEB 05, 1993
/NOVAMINE/8.5%/
/KABIVITRUM/ /8.5%/ /N17957/002/
/AUG/09,/1982/
@ KABIVITRUM 8.5% N17957 002
AUG 09, 1982
TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER 10% N18931 003
AUG 23, 1984
/10%/ /N18931/004/
/APR/27,/1988/
/TRAVASOL/10%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /10%/ /N18931/003/
/AUG/23,/1984/
TRAVASOL 5.5% IN PLASTIC CONTAINER
BAXTER 5.5% N18931 001
AUG 23, 1984

AMINO ACIDS

INJECTABLE; INJECTION
/TRAVASOL/5.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /5.5%/ /N18931/001/
/AUG/23,/1984/
TRAVASOL 8.5% IN PLASTIC CONTAINER
BAXTER 8.5% N18931 002
AUG 23, 1984
/TRAVASOL/8.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /8.5%/ /N18931/002/
/AUG/23,/1984/

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
/AMINOSYN/II/7%/W/ELECTROLYTES/
/ABBOTT/ /7%;102MG/100ML;45MG/100ML;/
/522MG/100ML;410MG/100ML//N19437/006/
/APR/03,/1986/
@ ABBOTT 7%;102MG/100ML;45MG/100ML;
522MG/100ML;410MG/100ML N19437 006
APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
/AMINOSYN/II/3.5%/W/
/ABBOTT/ /3.5%;30MG/100ML;97MG/100ML;/
/120MG/100ML;49MG/100ML/ /N19437/007/
/APR/03,/1986/
@ ABBOTT 3.5%;30MG/100ML;97MG/100ML;
120MG/100ML;49MG/100ML N19437 007
APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID
/AP/ /LYPHOMED/ /250MG/ML/ /N70522/001/
/JUN/17,/1986/
@ LYPHOMED 250MG/ML N70522 001
JUN 17, 1986

AMINOPHYLLINE

/ENEMA;/RECTAL/
/SOMOPHYLLIN/

/FISONS/	/300MG/5ML/	/N18232/001/	
		/APR/02,/1982/	
ə FISONS	300MG/5ML	N18232 001	
		APR 02, 1982	

INJECTABLE; INJECTION

AMINOPHYLLINE

/AP/ /BRISTOL/	/25MG/ML/	/N87431/001/	
AP FUJISAWA	25MG/ML	N88407 001	
		JAN 25, 1984	
ə	25MG/ML	N87431 001	
/AP/ /LYPHOMED/	/25MG/ML/	/N88407/001/	
		/JAN/25,/1984/	

SOLUTION; ORAL

AMINOPHYLLINE

> ADD > ə PENNEX PHARMS	105MG/5ML	N88156 001	
> ADD >		DEC 05, 1983	
> DLT >/AA/ /PHARM/BASICS/	/105MG/5ML/	/N88156/001/	
> DLT >		/DEC/05,/1983/	

TABLET; ORAL

/AMINOPHYLLIN/

/AB//+/SEARLE/	/100MG/	/N02386/002/	
/AB//+/	/200MG/	/N02386/003/	
ə SEARLE	100MG	N02386 002	
ə	200MG	N02386 003	

AMINOPHYLLINE

/AB/ /ROXANE/	/100MG/	/N87500/001/	
		/FEB/09,/1982/	
AB + ROXANE	100MG	N87500 001	
		FEB 09, 1982	
/AB/	/200MG/	/N87501/001/	
		/FEB/09,/1982/	
AB +	200MG	N87501 001	
		FEB 09, 1982	

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

/AP/ /MSD/	/10MG/ML/	/N12704/001/	
AP ZENECA	10MG/ML	N12704 001	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

ELAVIL

/AB/ /MSD/	/10MG/	/N12703/001/	
/AB//+/	/25MG/	/N12703/003/	
/AB/	/50MG/	/N12703/004/	
/AB/	/75MG/	/N12703/005/	
/AB/	/100MG/	/N12703/006/	
/AB/	/150MG/	/N12703/007/	
AB ZENECA	10MG	N12703 001	
AB +	25MG	N12703 003	
AB	50MG	N12703 004	
AB	75MG	N12703 005	
AB	100MG	N12703 006	
AB	150MG	N12703 007	

AMOXICILLIN

CAPSULE; ORAL

> DLT > /POLYMOX/

> DLT >/AB/ /BRISTOL/	/250MG/	/N61885/001/	
> DLT >/AB/	/500MG/	/N61885/002/	
/TRIMOX/			
/AB/ /SQUIBB/	/250MG/	/N62098/001/	
/AB/	/250MG/	/N62152/001/	
/AB/	/500MG/	/N62098/002/	
/AB/	/500MG/	/N62152/002/	
> ADD > TRIMOX			
> ADD > AB APOTHECON	250MG	N61885 001	
> ADD > AB	500MG	N61885 002	
ə APOTHECON	250MG	N62098 001	
ə	250MG	N62152 001	
ə	500MG	N62098 002	
ə	500MG	N62152 002	

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB CLONMEL	125MG/5ML	N62927 001	
		NOV 25, 1988	
AB	250MG/5ML	N62927 002	
		NOV 25, 1988	
/BX/	/125MG/5ML/	/N62927/001/	
		/NOV/25,/1988/	
/BX/	/250MG/5ML/	/N62927/002/	
		/NOV/25,/1988/	

> DLT > /POLYMOX/

> DLT >/AB/ /BRISTOL/	/125MG/5ML/	/N61886/002/	
> DLT >/AB/	/50MG/ML/	/N61886/001/	
> DLT >/AB/	/250MG/5ML/	/N61886/003/	

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL

>DLT>		/DOLYMOX/			
>DLT>/AB/		/BRISTOL/MYERS/	/125MG/5ML/	/N62885/001/	
>DLT>				/MAR/08,/1988/	
>DLT>/AB/			/250MG/5ML/	/N62885/002/	
>DLT>				/MAR/08,/1988/	
	/TRIMOX/				
/AB/	/SQUIBB/		/125MG/5ML/	/N62099/001/	
/AB/			/125MG/5ML/	/N62154/001/	
/AB/			/250MG/5ML/	/N62099/002/	
/AB/			/250MG/5ML/	/N62154/002/	
>ADD>	**TRIMOX**				
>ADD> AB		APOTHECON	125MG/5ML	N61886 002	
>ADD> AB			125MG/5ML	N62885 001	
>ADD>				MAR 08, 1988	
>ADD> AB			50MG/ML	N61886 001	
>ADD> AB			250MG/5ML	N61886 003	
>ADD> AB			250MG/5ML	N62885 002	
>ADD>				MAR 08, 1988	
		∂ APOTHECON	125MG/5ML	N62099 001	
		∂	125MG/5ML	N62154 001	
		∂	250MG/5ML	N62099 002	
		∂	250MG/5ML	N62154 002	

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/CAPSULE;/ORAL/
/DELCOBESE/
/LEMMON/

/1.25MG;1.25MG;1.25MG;/		
/1.25MG/	/N83564/001/	
/2.5MG;2.5MG;2.5MG;2.5MG/	/N83564/002/	
/3.75MG;3.75MG;3.75MG;/		
/3.75MG/	/N83564/003/	
/5MG;5MG;5MG;5MG/	/N83564/004/	
∂ LEMMON	1.25MG;1.25MG;1.25MG;	
	1.25MG	N83564 001
∂	2.5MG;2.5MG;2.5MG;2.5MG	N83564 002
	3.75MG;3.75MG;3.75MG;	
	3.75MG	N83564 003
∂	5MG;5MG;5MG;5MG	N83564 004

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/TABLET;/ORAL/
/DELCOBESE/
/LEMMON/

/1.25MG;1.25MG;1.25MG;/		
/1.25MG/	/N83563/004/	
/2.5MG;2.5MG;2.5MG;2.5MG/	/N83563/003/	
/3.75MG;3.75MG;3.75MG;/		
/3.75MG/	/N83563/002/	
/5MG;5MG;5MG;5MG/	/N83563/001/	
∂ LEMMON	1.25MG;1.25MG;1.25MG;	
	1.25MG	N83563 004
∂	2.5MG;2.5MG;2.5MG;2.5MG	N83563 003
∂	3.75MG;3.75MG;3.75MG;	
	3.75MG	N83563 002
∂	5MG;5MG;5MG;5MG	N83563 001

AMPHOTERICIN B

CREAM; TOPICAL

		FUNGIZONE		
>ADD>		+ APOTHECON	3%	N50314 001
>DLT>		/SQUIBB/	/3%/	/N50314/001/

INJECTABLE; INJECTION

		FUNGIZONE		
>ADD>	AP	+ APOTHECON	50MG/VIAL	N60517 001
>DLT>/AP/		/SQUIBB/	/50MG/VIAL/	/N60517/001/

LOTION; TOPICAL

		FUNGIZONE		
>ADD>		+ APOTHECON	3%	N60570 001
>DLT>		/SQUIBB/	/3%/	/N60570/001/

OINTMENT; TOPICAL

		FUNGIZONE		
>ADD>		+ APOTHECON	3%	N50313 001
>DLT>		/SQUIBB/	/3%/	/N50313/001/

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	HANFORD	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993
AP		EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993
AP		EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993
AP		EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993
AP		EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993
AP	IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993
AP		EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993
/AP/	/LILLY/	/EQ 500MG BASE/VIAL/	/N62565/001/	/APR/04,/1985/
/AP/		/EQ 1GM BASE/VIAL/	/N62565/002/	/APR/04,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62565/003/	/JUN/24,/1986/
	∂ LILLY	EQ 500MG BASE/VIAL	N62565 001	APR 04, 1985
	∂	EQ 1GM BASE/VIAL	N62565 002	APR 04, 1985
	∂	EQ 2GM BASE/VIAL	N62565 003	JUN 24, 1986
	PENBRITIN-S			
	/WYETH/AYERST/	/EQ/4GM/BASE/VIAL/	/N50072/006/	
	∂ WYETH AYERST	EQ 4GM BASE/VIAL	N50072 006	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

>DLT>	/POLYCILLIN-N/			
>DLT>/AP/	/BRISTOL/	/EQ 125MG BASE/VIAL/	/N61395/001/	
>DLT>/AP/		/EQ 125MG BASE/VIAL/	/N62860/001/	/FEB/05,/1988/
>DLT>				
>DLT>/AP/		/EQ 250MG BASE/VIAL/	/N61395/002/	
>DLT>/AP/		/EQ 250MG BASE/VIAL/	/N62860/002/	/FEB/05,/1988/
>DLT>				
>DLT>/AP/		/EQ 500MG BASE/VIAL/	/N61395/003/	
>DLT>/AP/		/EQ 500MG BASE/VIAL/	/N62860/003/	/FEB/05,/1988/
>DLT>				
>DLT>/AP/		/EQ 1GM BASE/VIAL/	/N61395/004/	
>DLT>				
>DLT>/AP/		/EQ 1GM BASE/VIAL/	/N62738/001/	/FEB/19,/1987/
>DLT>				
>DLT>/AP/		/EQ 1GM BASE/VIAL/	/N62860/004/	/FEB/05,/1988/
>DLT>				
>DLT>/AP/		/EQ 2GM BASE/VIAL/	/N61395/005/	
>DLT>				
>DLT>/AP/		/EQ 2GM BASE/VIAL/	/N62738/002/	/FEB/19,/1987/
>DLT>				
>DLT>/AP/		/EQ 2GM BASE/VIAL/	/N62860/005/	/FEB/05,/1988/
>DLT>				
>DLT>/AP/		/EQ 10GM BASE/VIAL/	/N61395/006/	
>DLT>				
>ADD>	PRINCIPEN			
>ADD> AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001	
>ADD> AP		EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988
>ADD>				
>ADD> AP		EQ 250MG BASE/VIAL	N61395 002	
>ADD> AP		EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988
>ADD>				
>ADD> AP		EQ 500MG BASE/VIAL	N61395 003	
>ADD> AP		EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988
>ADD>				
>ADD> AP		EQ 1GM BASE/VIAL	N61395 004	
>ADD>				
>ADD> AP		EQ 1GM BASE/VIAL	N62738 001	FEB 19, 1987
>ADD>				
>ADD> AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988
>ADD>				
>ADD> AP		EQ 2GM BASE/VIAL	N61395 005	
>ADD>				
>ADD> AP		EQ 2GM BASE/VIAL	N62738 002	FEB 19, 1987
>ADD>				
>ADD> AP		EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988
>ADD>				
>ADD> AP +		EQ 10GM BASE/VIAL	N61395 006	
>ADD>				

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN			
/PFIZER/	/EQ/500MG/BASE/VIAL;/		
	/EQ/250MG/BASE/VIAL/	/N50608/003/	
		DEC/31,/1986/	
@ PFIZER	EQ 500MG BASE/VIAL;		
	EQ 250MG BASE/VIAL	N50608 003	
		DEC 31, 1986	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

> DLT >	/POLYCILLIN/		
> DLT >/AB/	/+//BRISTOL/	/EQ 250MG BASE/	/N61392/001/
> DLT >/AB/		/EQ 500MG BASE/	/N61392/002/
> DLT >/AB/	/BRISTOL/MYERS/	/EQ 250MG BASE/	/N62888/001/
> DLT >			/MAR/04,/1988/
> DLT >/AB//+/		/EQ 500MG BASE/	/N62888/002/
> DLT >			/MAR/04,/1988/
> ADD >	PRINCIPEN		
> ADD > AB +	APOTHECON	EQ 250MG BASE	N61392 001
> ADD > AB		EQ 250MG BASE	N62888 001
> ADD >			MAR 04, 1988
> ADD > AB		EQ 500MG BASE	N61392 002
> ADD > AB +		EQ 500MG BASE	N62888 002
> ADD >			MAR 04, 1988
	/PRINCIPEN '250'/		
/AB/	/SQUIBB/	/EQ 250MG BASE/	/N50056/001/
/AB/		/EQ 250MG BASE/	/N62157/002/
@	APOTHECON	EQ 250MG BASE	N50056 001
@		EQ 250MG BASE	N62157 002
	/PRINCIPEN '500'/		
/AB/	/SQUIBB/	/EQ 500MG BASE/	/N50056/002/
/AB/		/EQ 500MG BASE/	/N62157/001/
@	APOTHECON	EQ 500MG BASE	N50056 002
@		EQ 500MG BASE	N62157 001
	TOTACILLIN		
> DLT >/AB/	/SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60060/001/
> DLT >/AB/		/EQ 500MG BASE/	/N60060/002/
> ADD > @	SMITHKLINE BEECHAM	EQ 250MG BASE	N60060 001
> ADD > @		EQ 500MG BASE	N60060 002

POWDER FOR RECONSTITUTION; ORAL

> DLT >	/POLYCILLIN/		
> DLT >/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N61394/002/
> DLT >/AB/		/EQ 250MG BASE/5ML/	/N61394/003/
> DLT >		/EQ/100MG/BASE/ML/	/N61394/001/

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

> ADD >	PRINCIPEN		
> ADD > AB	APOTHECON	EQ 125MG BASE/5ML	N61394 002
> ADD > AB		EQ 250MG BASE/5ML	N61394 003
> ADD > AB		EQ 100MG BASE/ML	N61394 001
	/PRINCIPEN '125'/		
/AB/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N60127/002/
/AB/		/EQ 125MG BASE/5ML/	/N62151/001/
@	APOTHECON	EQ 125MG BASE/5ML	N60127 002
@		EQ 125MG BASE/5ML	N62151 001
	/PRINCIPEN '250'/		
/AB/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N60127/001/
/AB/		/EQ 250MG BASE/5ML/	/N62151/002/
@	APOTHECON	EQ 250MG BASE/5ML	N60127 001
@		EQ 250MG BASE/5ML	N62151 002

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

/PRINCIPEN/W//PROBENECID/			
/+//SQUIBB/	/EQ/389MG/BASE;111MG/	/N50488/001/	
	/EQ/389MG/BASE;111MG/	/N62150/001/	
@ APOTHECON	EQ 389MG BASE;111MG	N50488 001	
@	EQ 389MG BASE;111MG	N62150 001	

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB		
> ADD > AB +	APOTHECON	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001
> ADD >			
> DLT >/AB//+//BRISTOL/		/EQ 3.5GM BASE/BOT;/	
> DLT >		/1GM/BOT/	/N61898/001/

ANISOTROPINE METHYLBROMIDE

/TABLET;ORAL/			
/VALPIN/50/			
/DUPONT/	/50MG/		/N13428/001/
@ DUPONT	50MG		N13428 001

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE			
+ ALCON	EQ 0.5% BASE		N20258 001
			JUL 30, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

/INJECTABLE;/INJECTION/
/M.V.I.-12/LYOPHILIZED/
/ASTRA/ /100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL/
/15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;/
/40MG/VIAL;4MG/VIAL;3.6MG/VIAL;/
/3MG/VIAL;1MG/VIAL;/
/10MG/VIAL/ /N18933/002/
/AUG/08,/1985/

@ ASTRA 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL
15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;
40MG/VIAL;4MG/VIAL;3.6MG/VIAL;
3MG/VIAL;1MG/VIAL;
10MG/VIAL N18933 002
AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.C. 9+3
AP FUJISAWA 10MG/ML;0.006MG/ML;0.5UGM/ML;
1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;
0.4MG/ML;0.36MG/ML;0.3MG/ML;
330 UNITS/ML;1 IU/ML N18440 002
AUG 08, 1985
/AP/ /LYPHOMED/ /10MG/ML;0.006MG/ML;0.5UGM/ML;/
/1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/
/0.4MG/ML;0.36MG/ML;0.3MG/ML;/
/330 UNITS/ML;1 IU/ML/ /N18440/002/
/AUG/08,/1985/

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL
/+//ADRIA/ /650MG;50MG/ /N88305/001/
/OCT/13,/1983/
+ SAVAGE 650MG;50MG N88305 001
OCT 13, 1983

ATENOLOL

TABLET; ORAL
ATENOLOL
AB MUTUAL PHARM 50MG N73475 001
MAR 30, 1993
AB 100MG N73476 001
MAR 30, 1993
AB NOVOPHARM 50MG N73315 001
MAY 28, 1993
AB 100MG N73316 001
MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE
AB MUTUAL PHARM 50MG;25MG N73581 001
APR 29, 1993
AB 100MG;25MG N73582 001
APR 29, 1993

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
/AZATHIOPRINE/
/AP/ /QUAD/ /EQ 100MG BASE/VIAL/ /N71056/001/
/JUN/08,/1988/
@ QUAD EQ 100MG BASE/VIAL N71056 001
JUN 08, 1988

IMURAN
/AP/ /BURROUGHS/WELLCOME/ /EQ 100MG BASE/VIAL/ /N17391/001/
BURROUGHS WELLCOME EQ 100MG BASE/VIAL N17391 001

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

	AZLIN		
	/MILES/	/EQ/2GM/BASE/VIAL/	/N62388/001/ /SEP/08,/1982/
	∂ MILES	EQ 2GM BASE/VIAL	N62388 001 SEP 08, 1982
		/EQ/2GM/BASE/VIAL/	/N62417/001/ /OCT/12,/1982/
	∂	EQ 2GM BASE/VIAL	N62417 001 OCT 12, 1982
		/EQ/4GM/BASE/VIAL/	/N62388/003/ /SEP/08,/1982/
	∂	EQ 4GM BASE/VIAL	N62388 003 SEP 08, 1982
		/EQ/4GM/BASE/VIAL/	/N62417/003/ /OCT/12,/1982/
	∂	EQ 4GM BASE/VIAL	N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION

	AZACTAM IN PLASTIC CONTAINER		
	/SQUIBB/	/10MG/ML/	/N50632/003/ /MAY/24,/1989/
	∂ SQUIBB	10MG/ML	N50632 003 MAY 24, 1989

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	CORTISPORIN		
/AT/	/BURROUGHS/WELLCOME/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/	/N50416/002/
	+ BURROUGHS WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002
	/ZINC BACITRACIN;NEOMYCIN SULFATE;POLYMYXIN B SULFATE;/ /HYDROCORTISONE/		
/AT/	/PHARMAFAIR/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/	/N62389/001/ /JUL/02,/1982/
	∂ PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62389 001 JUL 02, 1982

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	/BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE/		
/AT/	/PHARMAFAIR/	/400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/	/N62386/001/ /SEP/09,/1982/
	∂ PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62386 001 SEP 09, 1982
	BACITRACIN-NEOMYCIN-POLYMYXIN		
	/PHARMADERM/	/400/UNITS/GM;EQ/3.5MG/BASE/GM;/ /5,000/UNITS/GM/	/N62167/001/
	∂ PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N62167 001

BENTIROMIDE

SOLUTION; ORAL

	CHYMEX		
	/ADRIA/	/500MG/7.5ML/	/N18366/001/ /DEC/29,/1983/
	SAVAGE	500MG/7.5ML	N18366 001 DEC 29, 1983

BENTONITE; SULFUR

	/POWDER;/TOPICAL/		
	/BENSULFOID/ /POYTHRESS/	/66.64%;33.32%/	/N02918/001/
	∂ POYTHRESS	66.64%;33.32%	N02918 001

BENZONATATE

CAPSULE; ORAL

	BENZONATATE		
AA	PHARMACAPS	100MG	N81297 001 JAN 29, 1993
	TESSALON		
AA	FOREST LABS	100MG	N11210 001

BENZTHIAZIDE

TABLET; ORAL

	AQUATAG		
/BP/	/SOLVAY/	/50MG/	/N16001/002/
	∂ SOLVAY	50MG	N16001 002

BENZTHIAZIDE

TABLET; ORAL

EXNA

/BP/+//ROBINS/AH/ /50MG/ /N12489/001/

\+ ROBINS AH 50MG N12489 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

/BEPADIN/

/AB/ /WALLACE/ /200MG/ /N19001/001/ /DEC/28,/1990/

/AB/ /300MG/ /N19001/002/ /DEC/28,/1990/

/AB/ /400MG/ /N19001/003/ /DEC/28,/1990/

@ WALLACE 200MG N19001 001 DEC 28, 1990

@ 300MG N19001 002 DEC 28, 1990

@ 400MG N19001 003 DEC 28, 1990

VASCOR

/AB/ /JOHNSON/RW/ /200MG/ /N19002/001/ /DEC/28,/1990/

/AB/ /300MG/ /N19002/002/ /DEC/28,/1990/

/AB/+/ /400MG/ /N19002/003/ /DEC/28,/1990/

\+ JOHNSON RW 400MG N19002 003 DEC 28, 1990

200MG N19002 001 DEC 28, 1990

300MG N19002 002 DEC 28, 1990

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/ /PHARMADERM/ /EQ 0.05% BASE/ /N19136/001/ /JUN/26,/1984/

@ PHARMADERM EQ 0.05% BASE N19136 001 JUN 26, 1984

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/ /PHARMADERM/ /EQ 0.05% BASE/ /N70274/001/ /AUG/12,/1985/

@ PHARMADERM EQ 0.05% BASE N70274 001 AUG 12, 1985

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/ /PHARMADERM/ /EQ 0.05% BASE/ /N19140/001/ /SEP/04,/1984/

@ PHARMADERM EQ 0.05% BASE N19140 001 SEP 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE

/AB/ /PHARMADERM/ /EQ 0.1% BASE/ /N18860/002/ /AUG/31,/1983/

@ PHARMADERM EQ 0.1% BASE N18860 002 AUG 31, 1983

LOTION; TOPICAL

BETAMETHASONE VALERATE

/AB/ /PHARMADERM/ /EQ 0.1% BASE/ /N18870/001/ /AUG/31,/1983/

@ PHARMADERM EQ 0.1% BASE N18870 001 AUG 31, 1983

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB NMC EQ 0.1% BASE N70051 001 OCT 10, 1984

BETAMETHASONE VALERATE

/AB/ /PHARMADERM/ /EQ 0.1% BASE/ /N18864/001/ /AUG/31,/1983/

@ PHARMADERM EQ 0.1% BASE N18864 001 AUG 31, 1983

/VALHAC/

/AB/ /NMC/ /EQ 0.1% BASE/ /N70051/001/ /OCT/10,/1984/

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ZIAC
+ LEDERLE

10MG;6.25MG	N20186 002	MAR 26, 1993
2.5MG;6.25MG	N20186 003	MAR 26, 1993
5MG;6.25MG	N20186 001	MAR 26, 1993

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL
MYBAMCIL

>ADD > AA	PENNEX PHARMS	12.5MG/5ML;10MG/5ML	N88626 001	OCT 12, 1984
>ADD >				
>DLT >/AA/	/PHARM/BASICS/	/12.5MG/5ML;10MG/5ML/	/N88626/001/	/OCT/12,/1984/
>DLT >				

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/ANABOLICS/	/4MG/	/N86187/001/	
	@ ANABOLICS	4MG	N86187 001	
/AA/	/NEWTRON/	/4MG/	/N86987/001/	
	@ NEWTRON	4MG	N86987 001	
AA	NYLOS TRADING	4MG	N85592 001	
/AA/	/TABLICAPS/	/4MG/	/N85592/001/	
/AA/	/ZENITH/	/4MG/	/N84351/001/	
	@ ZENITH	4MG	N84351 001	

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DC

>ADD > AA	PENNEX PHARMS	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001	FEB 21, 1985
>ADD >				
>ADD >				
>DLT >/AA/	/PHARM/BASICS/	/2MG/5ML;10MG/5ML;/ /12.5MG/5ML/	/N88904/001/	/FEB/21,/1985/
>DLT >				
>DLT >				

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DX

>ADD > AA	PENNEX PHARMS	2MG/5ML;10MG/5ML; 30MG/5ML	N88811 001	JUN 07, 1985
>ADD >				
>ADD >				
>DLT >/AA/	/PHARM/BASICS/	/2MG/5ML;10MG/5ML;/ /30MG/5ML/	/N88811/001/	/JUN/07,/1985/
>DLT >				
>DLT >				

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
BIPHETAP

>ADD >	@ PENNEX PHARMS	4MG/5ML;25MG/5ML	N88687 001	SEP 26, 1984
>ADD >				
>DLT >	/@/PHARM/BASICS/	/4MG/5ML;25MG/5ML/	/N88687/001/	/SEP/26,/1984/
>DLT >				

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTABARBITAL SODIUM

>ADD >	@ PENNEX PHARMS	30MG/5ML	N85383 001	
>DLT >/AA/	/PHARM/BASICS/	/30MG/5ML/	/N85383/001/	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
STADOL

>ADD >	+ APOTHECON	1MG/ML	N17857 001
>ADD >	+	2MG/ML	N17857 002
>DLT >	/BRISTOL/	/1MG/ML/	/N17857/001/
>DLT >		/2MG/ML/	/N17857/002/

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL
CALDEROL
+ ORGANON

	0.05MG		N18312 002
	0.02MG		N18312 001
/+//UPJOHN/		/0.05MG/	/N18312/002/
		/0.02MG/	/N18312/001/

CALCITONIN, SALMON

INJECTABLE; INJECTION

CALCIMAR			
/AP/ /RHONE/POULENC/RORER/	/200 IU/ML/		/N17769/001/
AP + RHONE POULENC RORER	200 IU/ML		N17769 001
MIACALCIN			
/SANDOZ/	/100/IU/ML/		/N17808/001/ /JUL/03,/1986/
@ SANDOZ	100 IU/ML		N17808 001 JUL 03, 1986

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

ENDOSOL EXTRA			
AT ALLERGAN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML		N20079 001 NOV 27, 1991
ENDOSOL PLUS			
/AT/ /ALLERGAN/	/0.154MG/ML;0.92MG/ML;0.184MG/ML;/ /0.2MG/ML;0.38MG/ML;2.1MG/ML;/ /7.14MG/ML;0.42MG/ML/		/N20079/001/ /NOV/27,/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML		N19864 001 JUN 10, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE			
/AP/ /ABBOTT/	/EQ 90MG CALCIUM/5ML/		/N80001/001/
+ ABBOTT	EQ 90MG CALCIUM/5ML		N80001 001
/AP/ /LILLY/	/EQ 90MG CALCIUM/5ML/		/N06470/001/
@ LILLY	EQ 90MG CALCIUM/5ML		N06470 001
/AP/ /LYPHOMED/	/EQ 90MG CALCIUM/5ML/		/N89373/001/ /APR/30,/1987/
@ LYPHOMED	EQ 90MG CALCIUM/5ML		N89373 001 APR 30, 1987

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN			
/AP/ /ROERIG/	/EQ 1GM BASE/VIAL/		/N50306/001/
/AP/	/EQ 2GM BASE/VIAL/		/N50306/004/
/AP/	/EQ 5GM BASE/VIAL/		/N50306/002/
/AP/	/EQ 10GM BASE/VIAL/		/N50306/006/
ROERIG	EQ 1GM BASE/VIAL		N50306 001
	EQ 2GM BASE/VIAL		N50306 004
	EQ 5GM BASE/VIAL		N50306 002
	EQ 10GM BASE/VIAL		N50306 006
PYOPEN			
/AP/ /SMITHKLINE/BEECHAM/	/EQ 1GM BASE/VIAL/		/N50298/001/
/AP/	/EQ 2GM BASE/VIAL/		/N50298/002/
/AP/	/EQ 5GM BASE/VIAL/		/N50298/003/
/AP/	/EQ 10GM BASE/VIAL/		/N50298/006/
@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL		N50298 001
@	EQ 2GM BASE/VIAL		N50298 002
@	EQ 5GM BASE/VIAL		N50298 003
@	EQ 10GM BASE/VIAL		N50298 006
	/EQ/20GM/BASE/VIAL/		/N50298/007/
@	EQ 20GM BASE/VIAL		N50298 007

CARBINOXAMINE MALEATE

/TABLET;/ORAL/			
/CLISTIN/			
/JOHNSON/RW/	/4MG/		/N08915/001/
@ JOHNSON RW	4MG		N08915 001

CARISOPRODOL

/CAPSULE;/ORAL/			
/SOMA/			
/WALLACE/	/250MG/		/N11792/003/
@ WALLACE	250MG		N11792 003

TABLET; ORAL

CARISOPRODOL			
/AA/ /PIONEER/PHARMS/	/350MG/		/N89390/001/ /OCT/13,/1988/
@ PIONEER PHARMS	350MG		N89390 001 OCT 13, 1988
/RELA/			
/AA/ /SCHERING/	/350MG/		/N12155/001/
@ SCHERING	350MG		N12155 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIPRESS
/BURROUGHS/WELLCOME/ /1%/ /N19972/001/
/MAY/23,/1990/
OTSUKA 1% N19972 001
MAY 23, 1990

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
DURICEF
>ADD > AB + BRISTOL MYERS SQUIBB EQ 500MG BASE N50512 001
>DLT >/AB/+//MEAD/JOHNSON/ /EQ 500MG BASE/ /N50512/001/

POWDER FOR RECONSTITUTION; ORAL
DURICEF
>ADD > AB + BRISTOL MYERS SQUIBB EQ 125MG BASE/5ML N50527 002
>ADD > AB + EQ 250MG BASE/5ML N50527 003
>ADD > AB + EQ 500MG BASE/5ML N50527 001
>DLT >/AB/+//MEAD/JOHNSON/ /EQ 125MG BASE/5ML/ /N50527/002/
>DLT >/AB/+/ /EQ 250MG BASE/5ML/ /N50527/003/
>DLT >/AB/+/ /EQ 500MG BASE/5ML/ /N50527/001/

TABLET; ORAL
DURICEF
>ADD > AB + BRISTOL MYERS SQUIBB EQ 1GM BASE N50528 001
>DLT >/AB/+//MEAD/JOHNSON/ /EQ 1GM BASE/ /N50528/001/

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL
+ LILLY EQ 10GM BASE/VIAL N50504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM
>DLT >/AP/ /BEN/VENUE/ /EQ 250MG BASE/VIAL/ /N62894/001/
>DLT > /JUL/21,/1988/
>DLT >/AP/ /EQ 500MG BASE/VIAL/ /N62894/002/
>DLT > /JUL/21,/1988/
>DLT >/AP/ /EQ 1GM BASE/VIAL/ /N62894/003/
>DLT > /JUL/21,/1988/
>DLT >/AP/ /EQ 5GM BASE/VIAL/ /N62894/004/
>DLT > /JUL/21,/1988/
>DLT >/AP/ /EQ 10GM BASE/VIAL/ /N62894/005/
>DLT > /JUL/21,/1988/
>ADD > @ BEN VENUE EQ 250MG BASE/VIAL N62894 001
>ADD > JUL 21, 1988
>ADD > @ EQ 500MG BASE/VIAL N62894 002
>ADD > JUL 21, 1988
>ADD > @ EQ 1GM BASE/VIAL N62894 003
>ADD > JUL 21, 1988
>ADD > @ EQ 5GM BASE/VIAL N62894 004
>ADD > JUL 21, 1988
>ADD > @ EQ 10GM BASE/VIAL N62894 005
>ADD > JUL 21, 1988

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CEFMAX/
/TAP/ /EQ/500MG/BASE/VIAL/ /N50571/001/
/DEC/30,/1987/
/EQ/1GM/BASE/VIAL/ /N50571/002/
/DEC/30,/1987/
/EQ/2GM/BASE/VIAL/ /N50571/003/
/DEC/30,/1987/
@ TAP EQ 500MG BASE/VIAL N50571 001
DEC 30, 1987
@ EQ 1GM BASE/VIAL N50571 002
DEC 30, 1987
@ EQ 2GM BASE/VIAL N50571 003
DEC 30, 1987

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID

	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N63295 001 JUL 26, 1993
		/EQ/2GM/BASE/VIAL/	/N50579/003/ /MAY/23,/1984/
	ə	EQ 2GM BASE/VIAL	N50579 003 MAY 23, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN

> ADD >	HOECHST ROUSSEL	EQ 500MG BASE/VIAL	N50547 001

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

/AP/	/STUART/	/EQ 1GM BASE/VIAL/	/N50588/001/ /DEC/27,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N50588/002/ /DEC/27,/1985/
/AP/	/ZENECA/	/EQ 1GM BASE/VIAL/	/N63293/001/ /APR/29,/1993/
/AP/		/EQ 2GM BASE/VIAL/	/N63293/002/ /APR/29,/1993/
	+ ZENECA	EQ 1GM BASE/VIAL	N50588 001 DEC 27, 1985
	+	EQ 2GM BASE/VIAL	N50588 002 DEC 27, 1985
		EQ 1GM BASE/VIAL	N63293 001 APR 29, 1993
		EQ 2GM BASE/VIAL	N63293 002 APR 29, 1993

CEFOTAN IN PLASTIC CONTAINER

	+ ZENECA	EQ 20MG BASE/ML	N50694 002 JUL 30, 1993
	+	EQ 40MG BASE/ML	N50694 001 JUL 30, 1993

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CERADON/

	/TAKEDA/	/EQ/1GM/BASE/VIAL/	/N50601/001/ /DEC/30,/1988/

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CERADON/

	ə TAKEDA	EQ 1GM BASE/VIAL	N50601 001 DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER

	MERCK	EQ 20MG BASE/ML	N63182 001 JAN 25, 1993
		EQ 40MG BASE/ML	N63182 002 JAN 25, 1993

CEFPIRAMIDE SODIUM

/INJECTABLE;/INJECTION/
/CEFPIRAMIDE/SODIUM/

	/WYETH/AYERST/	/EQ/1GM/BASE/VIAL/	/N50633/002/ /JAN/31,/1989/
		/EQ/2GM/BASE/VIAL/	/N50633/003/ /JAN/31,/1989/
		/EQ/10GM/BASE/VIAL/	/N50633/005/ /JAN/31,/1989/
	ə WYETH AYERST	EQ 1GM BASE/VIAL	N50633 002 JAN 31, 1989
	ə	EQ 2GM BASE/VIAL	N50633 003 JAN 31, 1989
	ə	EQ 10GM BASE/VIAL	N50633 005 JAN 31, 1989

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER	EQ 10MG BASE/ML	N63221 001 APR 29, 1993
AP		EQ 20MG BASE/ML	N63221 002 APR 29, 1993
AP		EQ 40MG BASE/ML	N63221 003 APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

AP	GLAXO	EQ 10MG BASE/ML	N50634 001 APR 28, 1989
AP		EQ 20MG BASE/ML	N50634 002 APR 28, 1989
AP		EQ 40MG BASE/ML	N50634 003 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

>ADD >	FUJISAWA	EQ 500MG BASE/VIAL	N50560 001	
>ADD >			SEP 15, 1983	
		EQ 10GM BASE/VIAL	N50560 005	
			MAR 19, 1993	

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

>ADD >	ROCHE	EQ 250MG BASE/VIAL	N63239 001	
>ADD >			AUG 13, 1993	
>ADD >		EQ 500MG BASE/VIAL	N63239 002	
>ADD >			AUG 13, 1993	
>ADD >		EQ 1GM BASE/VIAL	N63239 003	
>ADD >			AUG 13, 1993	

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

/ROCHE/	/EQ/10MG/BASE/ML/	/N50624/001/	
		/FEB/11,/1987/	
∂ ROCHE	EQ 10MG BASE/ML	N50624 001	
		FEB 11, 1987	

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AP	MARSAM	EQ 750MG BASE/VIAL	N64035 001	
			FEB 26, 1993	
AP		EQ 1.5GM BASE/VIAL	N64035 002	
			FEB 26, 1993	
AP		EQ 7.5GM BASE/VIAL	N64036 001	
			FEB 26, 1993	

KEFUROX

AP	LILLY	EQ 7.5GM BASE/VIAL	N62591 003	
			DEC 17, 1987	

ZINACEF

AP	GLAXO	EQ 7.5GM BASE/VIAL	N50558 004	
			OCT 23, 1986	

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND

/#//MISSION/PHARMA/	/2.5GM/PACKET/	/N18757/002/	
		/DEC/28,/1982/	
∂ MISSION PHARMA	2.5GM/PACKET	N18757 002	
		DEC 28, 1982	

CEPHALEXIN

CAPSULE; ORAL
CEFANEX

>ADD > AB	APOTHECON	EQ 250MG BASE	N63063 001	
>ADD >			SEP 29, 1989	
>ADD > AB		EQ 500MG BASE	N63063 002	
>ADD >			SEP 29, 1989	
>DLT >/AB/	/BRISTOL/MYERS/	/EQ/250MG/BASE/	/N63063/001/	
>DLT >			/SEP/29,/1989/	
>DLT >/AB/		/EQ/500MG/BASE/	/N63063/002/	
>DLT >			/SEP/29,/1989/	

CEPHALEXIN

>ADD > AB	APOTHECON	EQ 250MG BASE	N62973 001	
>ADD >			NOV 08, 1988	
>ADD > AB		EQ 500MG BASE	N62974 001	
>ADD >			NOV 23, 1988	
>DLT >/AB/	/SQUIBB/MARK/	/EQ/250MG/BASE/	/N62973/001/	
>DLT >			/NOV/08,/1988/	
>DLT >/AB/		/EQ/500MG/BASE/	/N62974/001/	
>DLT >			/NOV/23,/1988/	

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

>ADD >	∂ APOTHECON	EQ 500MG BASE/VIAL	N50446 005
>ADD >		EQ 500MG BASE/VIAL	N62961 001
>ADD >			SEP 20, 1988
>ADD >	∂	EQ 1GM BASE/VIAL	N50446 001
>ADD >		EQ 1GM BASE/VIAL	N61769 001
>ADD >		EQ 1GM BASE/VIAL	N62724 001
>ADD >			DEC 23, 1986
>ADD >		EQ 1GM BASE/VIAL	N62961 002
>ADD >			SEP 20, 1988
>ADD >	∂	EQ 2GM BASE/VIAL	N50446 002
>ADD >			
>ADD >		EQ 2GM BASE/VIAL	N61769 002
>ADD >			
>ADD >		EQ 2GM BASE/VIAL	N62724 002
>ADD >			DEC 23, 1986
>ADD >		EQ 2GM BASE/VIAL	N62961 003
>ADD >			SEP 20, 1988
>ADD >	∂	EQ 4GM BASE/VIAL	N50446 003
>ADD >			
>ADD >		EQ 4GM BASE/VIAL	N61769 003
>ADD >			
>ADD >		EQ 4GM BASE/VIAL	N62961 004
>ADD >			SEP 20, 1988
>ADD >	∂	EQ 20GM BASE/VIAL	N50446 004
>ADD >			

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

>DLT >/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N50446/005/	
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N50446/001/	
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N61769/001/	
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N62724/001/	
>DLT >			/DEC/23,/1986/	
>DLT >/AP/		/EQ 2GM BASE/VIAL/	/N50446/002/	
>DLT >/AP/		/EQ 2GM BASE/VIAL/	/N61769/002/	
>DLT >/AP/		/EQ 2GM BASE/VIAL/	/N62724/002/	
>DLT >			/DEC/23,/1986/	
>DLT >/AP/		/EQ 4GM BASE/VIAL/	/N50446/003/	
>DLT >				
>DLT >/AP/		/EQ 4GM BASE/VIAL/	/N61769/003/	
>DLT >				
>DLT >		/EQ/2GM/BASE/VIAL/	/N50446/004/	
>DLT >/AP/	/BRISTOL/MYERS/	/EQ 500MG BASE/VIAL/	/N62961/001/	
>DLT >			/SEP/26,/1988/	
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N62961/002/	
>DLT >			/SEP/26,/1988/	
>DLT >/AP/		/EQ 2GM BASE/VIAL/	/N62961/003/	
>DLT >			/SEP/26,/1988/	
>DLT >/AP/		/EQ 4GM BASE/VIAL/	/N62961/004/	
>DLT >			/SEP/26,/1988/	

/CEPHAPIRIN SODIUM/

/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62723/001/	
			/NOV/17,/1986/	
/AP/		/EQ 1GM BASE/VIAL/	/N62723/002/	
			/NOV/17,/1986/	
/AP/		/EQ 2GM BASE/VIAL/	/N62723/003/	
			/NOV/17,/1986/	
/AP/		/EQ 4GM BASE/VIAL/	/N62723/004/	
			/NOV/17,/1986/	
	@ LYPHOMED	EQ 500MG BASE/VIAL	N62723 001	
			NOV 17, 1986	
	@	EQ 1GM BASE/VIAL	N62723 002	
			NOV 17, 1986	
	@	EQ 2GM BASE/VIAL	N62723 003	
			NOV 17, 1986	
	@	EQ 4GM BASE/VIAL	N62723 004	
			NOV 17, 1986	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

>DLT >	/MYCHEL-S/			
>DLT >/AP/	/RACHELLE/	/EQ 1GM BASE/VIAL/	/N60132/001/	
>ADD >	@ RACHELLE	EQ 1GM BASE/VIAL	N60132 001	

CHLORDIAZEPOXIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/

/LIBRELEASE/

/+//ROCHE/		/30MG/	/N17813/001/	
			/SEP/12,/1983/	
	@ ROCHE	30MG	N17813 001	
			SEP 12, 1983	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/PIONEER/PHARMS/	/25MG/	/N89558/001/	
			/JUL/15,/1988/	
	@ PIONEER PHARMS	25MG	N89558 001	
			JUL 15, 1988	

LIBRIUM

/AB/	/ROCHE/	/5MG/	/N12249/002/	
/AB/		/10MG/	/N12249/001/	
/AB//+/		/25MG/	/N12249/003/	
/AB/		/25MG/	/N85475/001/	
AB	+ ROCHE	25MG	N85475 001	
	@	5MG	N12249 002	
	@	10MG	N12249 001	
	@	25MG	N12249 003	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

/AB/	/MSD/	/150MG;250MG/	/N16016/001/	
	MSD	150MG;250MG	N16016 001	

ALDOCLOR-250

/AB//+//MSD/		/250MG;250MG/	/N16016/002/	
	+ MSD	250MG;250MG	N16016 002	

/METHYLDOPA AND CHLOROTHIAZIDE/

/AB/	/PAR/	/150MG;250MG/	/N70783/001/	
			/NOV/06,/1987/	
/AB/		/250MG;250MG/	/N70654/001/	
			/NOV/06,/1987/	
	@ PAR	150MG;250MG	N70783 001	
			NOV 06, 1987	
	@	250MG;250MG	N70654 001	
			NOV 06, 1987	

CHLOROTRIANISENE

CAPSULE; ORAL
TACE
/MERRELL/DOW/ /72MG/ /N16235/001/
@ MERRELL DOW 72MG N16235 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE
/AP/ /BEL/MAR/ /10MG/ML/ /N80821/001/
@ BEL MAR 10MG/ML N80821 001
/AP/ /STERIS/ /100MG/ML/ /N86095/001/
STERIS 100MG/ML N86095 001
/PYRIDAMAL 100/
/AP/ /BEL/MAR/ /100MG/ML/ /N83733/001/
@ BEL MAR 100MG/ML N83733 001

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /NEWTRON/ /4MG/ /N86519/001/
@ NEWTRON 4MG N86519 001

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
CHLORPROMAZINE HCL
>ADD > @ PENNEX PHARMS 30MG/ML N87032 001
>ADD > JUL 08, 1982
>ADD > @ 100MG/ML N87053 001
>DLT >/AA/ /PHARM/BASICS/ /30MG/ML/ /N87032/001/
>DLT > /JUL/08,/1982/
>DLT >/AA/ /100MG/ML/ /N87053/001/

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
/AP/ /LYPHOMED/ /25MG/ML/ /N84911/001/
@ LYPHOMED 25MG/ML N84911 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
/AB/ /PHARM/BASICS/ /50MG/ /N89052/001/
/JUN/01,/1987/
@ PHARM BASICS 50MG N89052 001
JUN 01, 1987

CHLORTHALIDONE; METOPROLOL TARTRATE

/CAPSULE;ORAL/
/CLOPRESSIDONE/
/+//CIBA/ /25MG;200MG/ /N19451/002/
/DEC/31,/1987/
/25MG;100MG/ /N19451/001/
/DEC/31,/1987/
@ CIBA 25MG;100MG N19451 001
DEC 31, 1987
@ 25MG;200MG N19451 002
DEC 31, 1987

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
/AA/ /PIONEER/PHARMS/ /250MG/ /N89592/001/
/JAN/06,/1989/
/AA/ /500MG/ /N89948/001/
/JAN/06,/1989/
@ PIONEER PHARMS 250MG N89592 001
JAN 06, 1989
@ 500MG N89948 001
JAN 06, 1989

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE
+ IOLAB 300 UNITS/VIAL N16938 001
/150/UNITS/VIAL/ /N18121/001/
@ 150 UNITS/VIAL N18121 001
/300/UNITS/VIAL/ /N16938/001/

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID
+ JANSSEN EQ 20MG BASE N20210 002
JUL 29, 1993
EQ 10MG BASE N20210 001
JUL 29, 1993

CLADRIBINE

INJECTABLE; INJECTION
LEUSTATIN
+ JOHNSON RW — 1MG/ML — N20229 001 FEB 26, 1993

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN

AB + UPJOHN	EQ 75MG BASE	N50162 001	
/AB//+/	/EQ 75MG BASE/	/N61809/001/	
AB +	EQ 150MG BASE	N50162 002	
/AB//+/	/EQ 150MG BASE/	/N61809/002/	
∂	EQ 75MG BASE	N61809 001	
∂	EQ 150MG BASE	N61809 002	

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE

AP + UPJOHN	EQ 150MG BASE/ML	N50441 001

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

/AP/ /LYPHOMED/	/EQ 12MG BASE/ML/	/N50636/001/ /DEC/22,/1989/
∂ LYPHOMED	EQ 12MG BASE/ML	N50636 001 DEC 22, 1989

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

/AB/ /BIOCRAFT/	/0.1MG/	/N70747/001/ /MAR/20,/1986/	
/AB/	/0.2MG/	/N70702/001/ /MAR/20,/1986/	
/AB/	/0.3MG/	/N70659/001/ /MAR/20,/1986/	
∂ BIOCRAFT	0.1MG	N70747 001 JUL 08, 1986	
∂	0.2MG	N70702 001 JUL 08, 1986	
∂	0.3MG	N70659 001 JUL 08, 1986	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

>DLT >/AB/ /PAR/	/0.1MG/	/N70461/001/ /NOV/22,/1985/	
>DLT >			
>DLT >/AB/	/0.2MG/	/N70460/001/ /NOV/22,/1985/	
>DLT >			
>DLT >/AB/	/0.3MG/	/N70459/001/ /NOV/22,/1985/	
>DLT >			
>ADD > ∂ PAR	0.1MG	N70461 001 JUL 08, 1986	
>ADD >			
>ADD > ∂	0.2MG	N70460 001 JUL 08, 1986	
>ADD >			
>ADD > ∂	0.3MG	N70459 001 JUL 08, 1986	
>ADD >			

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE

>ADD > AB TARO	1%	N72640 001 AUG 31, 1993	
>ADD >			

LOTRIMIN

>ADD > AB + SCHERING	1%	N17619 001	
>DLT > /BT/+/	/1%/	/N17619/001/	

/CREAM;/VAGINAL/
/GYNE-LOTRIMIN/

/BT/ /SCHERING/	/1%/	/N18052/001/	
/MYCELEX-G/			
/BT/ /MILES/	/1%/	/N18230/001/	

/TABLET;/VAGINAL/
/GYNE-LOTRIMIN/

/BT/ /SCHERING/	/100MG/	/N17717/001/	
/MYCELEX-G/			
/BT/ /MILES/	/100MG/	/N18182/001/	

CLOXACILLIN SODIUM

CAPSULE; ORAL
TEGOPEN

>ADD > AB + APOTHECON	EQ 250MG BASE	N61452 001	
>ADD > AB +	EQ 500MG BASE	N61452 002	
>DLT >/AB//+//BRISTOL/	/EQ 250MG BASE/	/N61452/001/	
>DLT >/AB//+/	/EQ 500MG BASE/	/N61452/002/	

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL
TEGOPEN

> ADD >	AA	APOTHECON	EQ 125MG BASE/5ML		N61453 001
> DLT >	/AA/	/BRISTOL/	/EQ 125MG BASE/5ML/		/N61453/001/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC W/ CODEINE

> ADD >		@ PENNEX PHARMS	10MG/5ML;5MG/5ML;	
> ADD >			6.25MG/5ML	N88896 001
> ADD >				JAN 04, 1985
> DLT >	/AA/	/PHARM/BASICS/	/10MG/5ML;5MG/5ML;/	
> DLT >			/6.25MG/5ML/	/N88896/001/
> DLT >				/JAN/04,/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ CODEINE

> DLT >	/AA/	/PENNEX/PHARMS/	/10MG/5ML;6.25MG/5ML/	/N88875/001/
> DLT >				/DEC/17,/1984/
> ADD >		@ PENNEX PHARMS	10MG/5ML;6.25MG/5ML	N88875 001
> ADD >				DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

> ADD >	AA	PENNEX PHARMS	10MG/5ML;30MG/5ML;	
> ADD >			1.25MG/5ML	N88833 001
> ADD >				NOV 16, 1984
> DLT >	/AA/	/PHARM/BASICS/	/10MG/5ML;30MG/5ML;/	
> DLT >			/1.25MG/5ML/	/N88833/001/
> DLT >				/NOV/16,/1984/

CORTICOTROPIN

INJECTABLE; INJECTION
ACTHAR

/AP/		/ARMOUR/	/25 UNITS/VIAL/	/N07504/002/
/AP/			/40 UNITS/VIAL/	/N07504/003/
AP		RHONE POULENC RORER	25 UNITS/VIAL	N07504 002
AP			40 UNITS/VIAL	N07504 003

CORTICOTROPIN

INJECTABLE; INJECTION
H.P. ACTHAR GEL

/BC/	/ARMOUR/	/40/UNITS/ML/	/N08372/006/
/BC/		/80/UNITS/ML/	/N08372/008/
BC	RHONE POULENC RORER	40 UNITS/ML	N08372 006
BC	+	80 UNITS/ML	N08372 008
	/PURIFIED/CORTROPHIN/GEL/		
/BC/	/ORGANON/	/40/UNITS/ML/	/N08975/001/
/BC/		/80/UNITS/ML/	/N08975/002/
	@ ORGANON	40 UNITS/ML	N08975 001
	@	80 UNITS/ML	N08975 002

CORTICOTROPIN-ZINC HYDROXIDE

/INJECTABLE;/INJECTION/			
/CORTROPHIN-ZINC/			
/+//ORGANON/		/40/UNITS/ML/	/N09854/001/
@ ORGANON		40 UNITS/ML	N09854 001

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

/BP/	/HEATHER/	/25MG/	/N85736/001/
@ HEATHER		25MG	N85736 001

CROMOLYN SODIUM

/SOLUTION;/NASAL/			
/NASALCROM/			
/FISONS/		/4%/	/N18306/001/
			/MAR/18,/1983/

SPRAY, METERED; NASAL
NASALCROM

+	FISONS	5.2MG/INH	N18306 001
			MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

/AP/		/DELL/	/0.03MG/ML/	/N80689/001/
		DELL	0.03MG/ML	N80689 001
/AP/		/FUJISAWA/	/1MG/ML/	/N83075/001/
@ FUJISAWA			1MG/ML	N83075 001

CYANOCOBALAMIN

INJECTABLE; INJECTION
/RUBIVITE/

/AP/	/BEL/MAR/	/0.03MG/ML/	/N10791/004/	
/AP/		/0.1MG/ML/	/N10791/002/	
/AP/		/1MG/ML/	/N10791/003/	
		/0.05MG/ML/	/N10791/001/	
		/0.12MG/ML/	/N10791/005/	
	@ BEL MAR	0.03MG/ML	N10791 004	
	@	0.05MG/ML	N10791 001	
	@	0.1MG/ML	N10791 002	
	@	0.12MG/ML	N10791 005	
	@	1MG/ML	N10791 003	

CYCLACILLIN

/POWDER/FOR/RECONSTITUTION;/ORAL/
/CYCLAPEN-W/

/+//WYETH/AYERST/	/500MG/5ML/	/N50508/003/	>_ADD_>	
	/125MG/5ML/	/N50508/001/	>_ADD_>	
	/250MG/5ML/	/N50508/002/	>_DLT_>	/AA/ /PHARM/BASICS/ /2MG/5ML/
@ WYETH AYERST	125MG/5ML	N50508 001	>_DLT_>	
@	250MG/5ML	N50508 002		
@	500MG/5ML	N50508 003		

CYCLIZINE LACTATE

/INJECTABLE;/INJECTION/
/MAREZINE/

/BURROUGHS/WELLCOME/	/50MG/ML/	/N09495/001/
@ BURROUGHS WELLCOME	50MG/ML	N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	INVAMED	10MG	N73683 001	FEB 26, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
NEOSAR

AP	ADRIA	100MG/VIAL	N40015 001 APR 29, 1993
AP		200MG/VIAL	N40015 002 APR 29, 1993
AP		500MG/VIAL	N40015 003 APR 29, 1993
AP		1GM/VIAL	N40015 004 APR 29, 1993
AP		2GM/VIAL	N40015 005 APR 29, 1993

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL

@ PENNEX PHARMS	2MG/5ML	N87001 001 NOV 04, 1982

TABLET; ORAL
CYPROHEPTADINE HCL

/AA/ /MYLAN/	/4MG/	/N86678/001/
@ MYLAN	4MG	N86678 001

DESIPRAMINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/PERTOFRANE/

/+//RHONE/POULENC/RORER/	/50MG/	/N13621/002/
	/25MG/	/N13621/001/
@ RHONE POULENC RORER	25MG	N13621 001
@	50MG	N13621 002

DESLANOSIDE

/INJECTABLE;/INJECTION/
/CEDILANID-D/

/SANDOZ/	/0.2MG/ML/	/N09282/002/
@ SANDOZ	0.2MG/ML	N09282 002

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

	RHONE POULENC RORER	0.01MG/INH	N17922 002 FEB 06, 1989

DESOXYCORTICOSTERONE PIVALATE

/INJECTABLE;/INJECTION/
/PERCORTEN/

	/CIBA/	/25MG/ML/	/N008822/001/
	@ CIBA	25MG/ML	N08822 001

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA	BARRE	0.5MG/5ML	N88997 001 OCT 10, 1986
/AA/	/NASKA/	/0.5MG/5ML/	/N088997/001/ /OCT/10,/1986/

MYMETHASONE

>ADD > AA	PENNEX PHARMS	0.5MG/5ML	N88254 001 JUL 27, 1983
>ADD >			
>DLT >/AA/	/PHARM/BASICS/	/0.5MG/5ML/	/N088254/001/ /JUL/27,/1983/
>DLT >			

SOLUTION; ORAL
DEXAMETHASONE

>DLT >	/@/ROXANE/	/0.5MG/5ML/	/N088248/001/ /SEP/01,/1983/
>DLT >			
>ADD >	ROXANE	0.5MG/5ML	N88248 001 SEP 01, 1983
>ADD >			

TABLET; ORAL
DECADRON

AB	MSD	0.5MG	N11664 001
AB	+	0.75MG	N11664 002
AB		1.5MG	N11664 003
AB		4MG	N11664 005
/BP/		/0.5MG/	/N011664/001/
/BP/+/		/0.75MG/	/N011664/002/
/BP/		/1.5MG/	/N011664/003/
/BP/		/4MG/	/N011664/005/

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

AB	ROXANE	0.5MG	N84611 001
AB		0.75MG	N84613 001
AB		1.5MG	N84610 001
AB		4MG	N84612 001
/BP/		/0.5MG/	/N084611/001/
/BP/		/0.75MG/	/N084613/001/
/BP/		/1.5MG/	/N084610/001/
/BP/		/4MG/	/N084612/001/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
/DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/	/N062411/001/ /MAY/16,/1983/
	@ PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62411 001 MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC
/DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N062428/001/ /MAY/18,/1983/
	@ PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62428 001 MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

/AP/	/BEL/MAR/	/EQ 4MG PHOSPHATE/ML/	/N084752/001/
	@ BEL MAR	EQ 4MG PHOSPHATE/ML	N84752 001
/AP/	/BRISTOL/	/EQ 4MG PHOSPHATE/ML/	/N087065/001/
	@ FUJISAWA	EQ 4MG PHOSPHATE/ML	N87065 001
>DLT >/AP/	/WYETH/AYERST/	/EQ 4MG PHOSPHATE/ML/	/N085641/001/
>ADD >	@ WYETH AYERST	EQ 4MG PHOSPHATE/ML	N85641 001

HEXADROL

	/ORGANON/	/EQ 20MG PHOSPHATE/ML/	/N014694/004/
	@ ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

MYLARAMINE

> ADD >	AA	PENNEX PHARMS	2MG/5ML	N88251 001	
> ADD >				MAR 23, 1984	
> DLT >	/AA/	/PHARM/BASICS/	/2MG/5ML/	/N88251/001/	
> DLT >				/MAR/23,/1984/	

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

/DEXAMPEX/

/AA/	/LEMMON/	/5MG/	/N83735/001/	
/AA/		/10MG/	/N83735/002/	
	ə LEMMON	5MG	N83735 001	
	ə	10MG	N83735 002	

/FERNDEX/

/AA/	/FERNDALE/	/5MG/	/N84001/001/	
	ə FERNDALE	5MG	N84001 001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

> DLT >		/PROMETHAZINE W/ DEXTROMETHORPHAN/		
> DLT >	/AA/	/PHARM/BASICS/	/15MG/5ML;6.25MG/5ML/	/N88864/001/
> DLT >				/JAN/04,/1985/
> ADD >		ə PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001
> ADD >				JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/500MG/ML/	/N19445/001/	
			/JUN/03,/1986/	
	ə ABBOTT	500MG/ML	N19445 001	
			JUN 03, 1986	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001
		JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001
		JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

> ADD >		ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER		
> ADD >	AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML;	
> ADD >			370MG/100ML;530MG/100ML;	
> ADD >			500MG/100ML	N19843 001
> ADD >				AUG 09, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001
		JUN 10, 1993

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/HYPAQUE-M;75%/

/STERLING/	/50%;25%/	/N10220/003/	
ə STERLING	50%;25%	N10220 003	

/HYPAQUE-M;90%/

/STERLING/	/60%;30%/	/N10220/002/	
ə STERLING	60%;30%	N10220 002	

DIATRIZOATE SODIUM

/SOLUTION;URETERAL/

/HYPAQUE/SODIUM/20%/

/STERLING/	/20%/	/N09561/002/	
ə STERLING	20%	N09561 002	

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP	MARSAM	5MG/ML	N72370 001 JAN 29, 1993
AP		5MG/ML	N72371 001 JAN 29, 1993
AP		5MG/ML	N72397 001 JAN 29, 1993

VALIUM

/AP/	/ROCHE/	/5MG/ML/	/N16087/001/
AP +	ROCHE	5MG/ML	N16087 001

INJECTABLE; INTRAVENOUS

DIZAC

+	KABI	5MG/ML	N19287 001 JUN 18, 1993

TABLET; ORAL

DIAZEPAM

	∂ FERNDALE	2MG	N70903 001 APR 01, 1987
	∂	5MG	N70904 001 APR 01, 1987
	∂	10MG	N70905 001 APR 01, 1987
/AB/	/PHARM/BASICS/	/2MG/	/N70903/001/ /APR/01,/1987/
/AB/		/5MG/	/N70904/001/ /APR/01,/1987/
/AB/		/10MG/	/N70905/001/ /APR/01,/1987/
/AB/	/ZENITH/	/2MG/	/N70360/001/ /SEP/04,/1985/
/AB/		/5MG/	/N70361/001/ /SEP/04,/1985/
	∂ ZENITH	2MG	N70360 001 SEP 04, 1985
	∂	5MG	N70361 001 SEP 04, 1985

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

+	BAKER NORTON	50MG	N17425 001
/+//MEDCL/MKTG/		/50MG/	/N17425/001/

DIAZOXIDE

INJECTABLE; INJECTION

/DIAZOXIDE/

/AP/	/QUAD/	/15MG/ML/	/N71908/001/ /JAN/26,/1988/
∂ QUAD		15MG/ML	N71908 001 JAN 26, 1988

HYPERSTAT

/AP/	/SCHERING/	/15MG/ML/	/N16996/001/
	SCHERING	15MG/ML	N16996 001

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

VOLTAREN

/CIBA/	/0.1%/	/N20037/001/ /MAR/28,/1991/
CIBA VISION	0.1%	N20037 001 MAR 28, 1991

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

> DLT > /AB/	/SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60254/002/
> DLT > /AB/		/EQ 500MG BASE/	/N60254/003/
> ADD >	∂ SMITHKLINE BEECHAM	EQ 250MG BASE	N60254 002
> ADD >	∂	EQ 500MG BASE	N60254 003

DYNAPEN

> ADD > AB	APOTHECON	EQ 125MG BASE	N61454 002
> ADD > AB		EQ 250MG BASE	N61454 001
> DLT > /AB/	/BRISTOL/	/EQ 125MG BASE/	/N61454/002/
> DLT > /AB/		/EQ 250MG BASE/	/N61454/001/

POWDER FOR RECONSTITUTION; ORAL

DYNAPEN

> ADD > AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
> DLT > /AB/	/BRISTOL/	/EQ 62.5MG BASE/5ML/	/N61455/001/

DICUMAROL

TABLET; ORAL

DICUMAROL

/+//ABBOTT/	/50MG/	/N05545/004/
∂ ABBOTT	50MG	N05545 004

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL		
/AB/	/PIONEER/PHARMS/	/10MG/	/N89361/001/ /JAN/10,/1989/
∂ PIONEER PHARMS		10MG	N89361 001 JAN 10, 1989

TABLET; ORAL

	DICYCLOMINE HCL		
/AB/	/PIONEER/PHARMS/	/20MG/	/N88585/001/ /AUG/20,/1986/
∂ PIONEER PHARMS		20MG	N88585 001 AUG 20, 1986

DIETHYLSTILBESTROL

/INJECTABLE;/INJECTION/

	/STILBESTROL/ /SQUIBB/		
		/0.2MG/ML/	/N04056/003/
		/0.5MG/ML/	/N04056/004/
		/1MG/ML/	/N04056/005/
		/5MG/ML/	/N04056/006/
∂ SQUIBB		0.2MG/ML	N04056 003
∂		0.5MG/ML	N04056 004
∂		1MG/ML	N04056 005
∂		5MG/ML	N04056 006

/SUPPOSITORY;/VAGINAL/

	/STILBESTROL/ /+//SQUIBB/		
	/+/	/0.1MG/	/N04056/001/
		/0.5MG/	/N04056/002/
∂ SQUIBB		0.1MG	N04056 001
∂		0.5MG	N04056 002

TABLET, DELAYED RELEASE; ORAL

	STILBETIN		
/BE/	/SQUIBB/	/0.1MG/	/N04056/011/
∂ SQUIBB		0.1MG	N04056 011

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD		
BC +	CARDERM	180MG	N20062 002 DEC 27, 1991
BC +		240MG	N20062 003 DEC 27, 1991
+		120MG	N20062 001 AUG 10, 1992
+		300MG	N20062 004 DEC 27, 1991
/BC/+//	/MARION/MERRELL/DOW/	/180MG/	/N20062/002/ /DEC/27,/1991/
/BC/+/		/240MG/	/N20062/003/ /DEC/27,/1991/
/+/		/120MG/	/N20062/001/ /AUG/10,/1992/
/+/		/300MG/	/N20062/004/ /DEC/27,/1991/

TABLET; ORAL

	DILTIAZEM HCL		
AB	APOTHECON	30MG	N74051 001 MAR 31, 1993
AB		60MG	N74051 002 MAR 31, 1993
AB		90MG	N74051 003 MAR 31, 1993
AB		120MG	N74051 004 MAR 31, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL		
/AA/	/LEMMON/	/25MG/	/N85874/001/
/AA/		/50MG/	/N85874/002/
∂ LEMMON		25MG	N85874 001
∂		50MG	N85874 002

INJECTABLE; INJECTION

	DIPHENHYDRAMINE HCL		
/AP/	/BEL/MAR/	/10MG/ML/	/N80822/001/
∂ BEL MAR		10MG/ML	N80822 001
/AP/	/BRISTOL/	/10MG/ML/	/N87066/001/
∂ FUJISAWA		10MG/ML	N87066 001

DIPHENYLPYRALINE HYDROCHLORIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/HISPRIL/

/+//SMITHKLINE/BEECHAM/	/5MG/	/N11945/001/		
@ SMITHKLINE BEECHAM	5MG	N11945 001		

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

>_DLT_>/AB/	/KV/	/EQ 100MG BASE/	/N71929/001/	
>_DLT_>			/AUG/19,/1988/	
>_ADD_> B*	KV	EQ 100MG BASE	N71929 001	
>_ADD_>			AUG 19, 1988	

DIVALPROEX SODIUM

/TABLET;/DELAYED/RELEASE;/ORAL/
/DEPAKOTE/CP/

/ABBOTT/	/EQ/250MG/BASE/	/N19794/001/	
		/JUL/11,/1990/	
	/EQ/500MG/BASE/	/N19794/002/	
		/JUL/11,/1990/	
@ ABBOTT	EQ 250MG BASE	N19794 001	
		JUL 11, 1990	
@	EQ 500MG BASE	N19794 002	
		JUL 11, 1990	

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

/AP/	/BRISTOL/	/40MG/ML/	/N18549/001/	
			/MAR/11,/1983/	
@ FUJISAWA		40MG/ML	N18549 001	
			MAR 11, 1983	
/AP/	/LYPHOMED/	/40MG/ML/	/N70012/001/	
			/JUN/12,/1985/	
@ LYPHOMED		40MG/ML	N70012 001	
			JUN 12, 1985	

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

>_ADD_> AA	PENNEX PHARMS	EQ 10MG BASE/ML	N71918 001	
>_ADD_>			JUL 20, 1988	

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

>_DLT_>/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N71918/001/	
>_DLT_>			/JUL/20,/1988/	

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE MONOHYDRATE

/+//MEDICOPHARMA/	/EQ/100MG/BASE/	/N50641/001/		
		/DEC/29,/1989/		
+ VINTAGE	EQ 100MG BASE	N50641 001		
		DEC 29, 1989		

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

/AB/	/PAR/	/EQ 50MG BASE/	/N62434/001/	
			/OCT/19,/1984/	
/AB/		/EQ 100MG BASE/	/N62442/001/	
			/DEC/22,/1983/	
@ PAR		EQ 50MG BASE	N62434 001	
			OCT 19, 1984	
@		EQ 100MG BASE	N62442 001	
			DEC 22, 1983	

TABLET; ORAL
DOXY-TABS

>_ADD_>	@ RACHELLE	EQ 50MG BASE	N62269 003

DOXYCYCLINE HYCLATE

/AB/	/HEATHER/	/EQ 100MG BASE/	/N62462/001/	
			/MAY/11,/1983/	
@ HEATHER		EQ 100MG BASE	N62462 001	
			MAY 11, 1983	

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/QUAD/	/2.5MG/ML/	/N71941/001/	
			/AUG/17,/1988/	
@ QUAD		2.5MG/ML	N71941 001	
			AUG 17, 1988	

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/SMITH/NEPHEW/SOLOPAK/	2.5MG/ML/	/N71754/001/	/SEP/06,/1988/
/AP/		2.5MG/ML/	/N71755/001/	/SEP/06,/1988/
AP	SOLOPAK	2.5MG/ML	N71754 001	SEP 06, 1988
AP		2.5MG/ML	N71755 001	SEP 06, 1988

EDETATE DISODIUM

INJECTABLE; INJECTION

DISODIUM EDETATE

/AP/	/STERIS/	150MG/ML/	/N84356/001/	
	@ STERIS	150MG/ML	N84356 001	

EFLORNITHINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/				
	/ORNIDYL/			
	/MERRELL/DOW/	200MG/ML/	/N19879/002/	/NOV/28,/1990/
	@ MERRELL DOW	200MG/ML	N19879 002	NOV 28, 1990

ENCAINIDE HYDROCHLORIDE

/CAPSULE;/ORAL/				
	/ENKAID/			
	/+//BRISTOL/	50MG/	/N18981/004/	/DEC/24,/1986/
		25MG/	/N18981/002/	/DEC/24,/1986/
		35MG/	/N18981/003/	/DEC/24,/1986/
	@ BRISTOL	25MG	N18981 002	DEC 24, 1986
	@	35MG	N18981 003	DEC 24, 1986
	@	50MG	N18981 004	DEC 24, 1986

ENOXACIN

TABLET; ORAL

PENETREX

/+//PARKE/DAVIS/		400MG/	/N19616/005/	/DEC/31,/1991/
		200MG/	/N19616/004/	/DEC/31,/1991/
+	RHONE POULENC RORER	400MG	N19616 005	DEC 31, 1991
		200MG	N19616 004	DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; INJECTION

LOVENOX

	RHONE POULENC RORER	30MG/0.3ML	N20164 001 MAR 29, 1993

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	STERLING WINTHROP	0.01MG/ML;2%	N40057 002	FEB 26, 1993
AP		0.02MG/ML;2%	N40057 001	FEB 26, 1993

LIDOCAINE HCL W/ EPINEPHRINE

/AP/	/BEL/MAR/	0.01MG/ML;1%/	/N80820/001/	
/AP/		0.01MG/ML;2%/	/N80757/001/	
	@ BEL MAR	0.01MG/ML;1%	N80820 001	
	@	0.01MG/ML;2%	N80757 001	

EPINEPHRINE; PROCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/				
	/PROCAINE/HCL/W/EPINEPHRINE/			
	/BEL/MAR/	0.02MG/ML;1%/	/N80758/001/	
		0.02MG/ML;2%/	/N80759/001/	
	@ BEL MAR	0.02MG/ML;1%	N80758 001	
	@	0.02MG/ML;2%	N80759 001	

ERGOLOID MESYLATES

TABLET; ORAL

HYDERGINE

/SANDOZ/	0.5MG/	/N17993/003/	
@ SANDOZ	0.5MG	N17993 003	

ERGOLOID MESYLATES

TABLET; SUBLINGUAL
HYDROGENATED ERGOT ALKALOIDS

/AA/	/ZENITH/	/0.5MG/	/N87186/001/
∂ ZENITH		0.5MG	N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR

/AA/	/FISONS/	/2MG/	/N87693/001/ /FEB/24,/1983/
AA	LOTUS	2MG	N87693 001 FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
/ERYC/SPRINKLES/

/+/	/FAULDING/	/125MG/	/N50593/001/ /JUL/22,/1985/
∂ FAULDING		125MG	N50593 001 JUL 22, 1985

GEL; TOPICAL
ERYGEL

/AT/	/HERBERT/	/2%/	/N50617/001/ /OCT/21,/1987/
AT +	HERBERT	2%	N50617 001 OCT 21, 1987

ERYTHROMYCIN

AT	STIEFEL	2%	N63211 001 JAN 29, 1993

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

/AT/	/PHARMADERM/	/5MG/GM/	/N62446/001/ /SEP/26,/1983/
∂ PHARMADERM		5MG/GM	N62446 001 SEP 26, 1983
/AT/	/PHARMAFAIR/	/5MG/GM/	/N62481/001/ /APR/05,/1984/
∂ PHARMAFAIR		5MG/GM	N62481 001 APR 05, 1984

ERYTHROMYCIN

/POWDER;/FOR/RX/COMPOUNDING/
/ERYTHROMYCIN/

/PADDOCK/	/100%/	/N50610/001/ /NOV/07,/1986/
∂ PADDOCK	100%	N50610 001 NOV 07, 1986

SOLUTION; TOPICAL
ERYTHRA-DERM

AT	PADDOCK	2%	N62687 001 FEB 05, 1988

ERYTHROMYCIN

AT	BARRE	2%	N62957 001 JUL 21, 1988
/AT/	/NASKA/	/2%/	/N62957/001/ /JUL/21,/1988/
>ADD> AT	PENNEX PHARMS	2%	N62825 001 OCT 23, 1987
>ADD> /AT/	/PHARM/BASICS/	/2%/	/N62825/001/ /OCT/23,/1987/
>DLT> /EIS-2/			
/AT/	/PADDOCK/	/2%/	/N62687/001/ /FEB/05,/1988/

SWAB; TOPICAL
C-SOLVE-2

AT	SYOSSET	2%	N62751 001 JUL 30, 1993

TABLET, COATED PARTICLES; ORAL
PCE

/+/	/ABBOTT/	/333MG/	/N50611/001/ /SEP/09,/1986/
+	ABBOTT	500MG	N50611 002 AUG 22, 1990
		333MG	N50611 001 SEP 09, 1986
		/500MG/	/N50611/002/ /AUG/22,/1990/

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE

∂ LIFE LABORATORIES	EQ 250MG BASE/5ML	N62362 001 DEC 17, 1982

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE

AP	GENSIA	EQ 500MG BASE/VIAL	N63253 001 JUL 30, 1993
AP		EQ 1GM BASE/VIAL	N63253 002 JUL 30, 1993
/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62604/001/ /NOV/24,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62604/002/ /NOV/24,/1986/
	∂ LYPHOMED	EQ 500MG BASE/VIAL	N62604 001 NOV 24, 1986
	∂	EQ 1GM BASE/VIAL	N62604 002 NOV 24, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

+ ANAQUEST	10MG/ML	N19386 001 AUG 15, 1988
+	250MG/ML	N19386 002 DEC 31, 1986
/DUPONT/	/10MG/ML/	/N19386/001/ /AUG/15,/1988/
	/250MG/ML/	/N19386/002/ /DEC/31,/1986/

ESTRADIOL

TABLET; ORAL
ESTRACE

BRISTOL MYERS SQUIBB	0.5MG	N81295 001 JUN 30, 1993

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN

+ AYERST	0.625MG/GM	N20216 001
/+//WYETH/AYERST/	/0.625MG/GM/	/N83273/001/

ESTROGENS, CONJUGATED

TABLET; ORAL
PREMARIN

+ WYETH AYERST	1.25MG	N04782 001
/+/	/2.5MG/	/N04782/002/
	/1.25MG/	/N04782/001/
	2.5MG	N04782 002

ESTROPIPATE

TABLET; ORAL
OGEN 1.25

/AB//+//ABBOTT/	/1.5MG/	/N83220/002/
AB ABBOTT	1.5MG	N83220 002
OGEN 2.5		
+ ABBOTT	3MG	N83220 003
	/3MG/	/N83220/003/

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

AB	ROBERTS	0.035MG;1MG	N71480 001 APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.035MG;1MG/	/N71480/001/ /APR/12,/1988/

TABLET; ORAL-28
NORETHIN 1/35E-28

AB	ROBERTS	0.035MG;1MG	N71481 001 APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.035MG;1MG/	/N71481/001/ /APR/12,/1988/

ETHOSUXIMIDE

SYRUP; ORAL
ETHOSUXIMIDE

AA	COPLEY	250MG/5ML	N81306 001 JUL 30, 1993

ZARONTIN

AA	PARKE DAVIS	250MG/5ML	N80258 001

ETHYNODIOL DIACETATE; MESTRANOL

/TABLET;ORAL-21/
/OVULEN-21/
/+//SEARLE/ /1MG;0.1MG/ /N16029/003/
@ SEARLE 1MG;0.1MG N16029 003

/TABLET;ORAL-28/
/OVULEN-28/
/SEARLE/ /1MG;0.1MG/ /N16705/001/
@ SEARLE 1MG;0.1MG N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
+ MGI 50MG/ML N19545 001
APR 20, 1987
/P/AND/G/ /50MG/ML/ /N19545/001/
/APR/20,/1987/

FELBAMATE

SUSPENSION; ORAL
FELBATOL
+ WALLACE 600MG/5ML N20189 003
JUL 29, 1993

TABLET; ORAL
FELBATOL
+ WALLACE 600MG N20189 002
JUL 29, 1993
400MG N20189 001
JUL 29, 1993

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.01%/ /N88047/001/
/DEC/16,/1982/
/AT/ /0.025%/ /N88045/001/
/DEC/16,/1982/
@ PHARMADERM 0.01% N88047 001
DEC 16, 1982
@ 0.025% N88045 001
DEC 16, 1982

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.025%/ /N88046/001/
/DEC/16,/1982/
@ PHARMADERM 0.025% N88046 001
DEC 16, 1982

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
>ADD> @ PENNEX PHARMS 0.01% N88312 001
>ADD> JAN 27, 1984
>DLT>/AT/ /PHARM/BASICS/ /0.01%/ /N88312/001/
>DLT> /JAN/27,/1984/

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
/AP/ /MARCHAR/ /50MG/ML/ /N87791/001/
/JAN/18,/1983/
@ MARCHAR 50MG/ML N87791 001
JAN 18, 1983

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC
LILLY EQ 10MG BASE N18936 006
DEC 23, 1992

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
PROLIXIN DECANOATE
>ADD> AO + APOTHECON 25MG/ML N16727 001
>DLT>/AO/ /APOTHECON/ /25MG/ML/ /N16727/001/

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION
PROLIXIN ENANTHATE
>ADD> + APOTHECON 25MG/ML N16110 001
>DLT> /APOTHECON/ /25MG/ML/ /N16110/001/

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

PROLIXIN

> ADD >	AA	APOTHECON	5MG/ML	N70533 001 NOV 07, 1985
> DLT >	/AA/	/SQUIBB/	/5MG/ML/	/N70533/001/ /NOV/07,/1985/

ELIXIR; ORAL

FLUPHENAZINE HCL

	AA	COPLEY	2.5MG/5ML	N81310 001 APR 29, 1993

PROLIXIN

> ADD >	AA	APOTHECON	2.5MG/5ML	N12145 003
> DLT >		/SQUIBB/	/2.5MG/5ML/	/N12145/003/

INJECTABLE; INJECTION

PROLIXIN

> ADD >	AP +	APOTHECON	2.5MG/ML	N11751 005
> DLT >	/AP/	/SQUIBB/	/2.5MG/ML/	/N11751/005/

TABLET; ORAL

PROLIXIN

> ADD >	AB	APOTHECON	1MG	N11751 004
> ADD >	AB		2.5MG	N11751 001
> ADD >	AB		5MG	N11751 003
> ADD >	AB +		10MG	N11751 002
> DLT >	/AB/	/SQUIBB/	/1MG/	/N11751/004/
> DLT >	/AB/		/2.5MG/	/N11751/001/
> DLT >	/AB/		/5MG/	/N11751/003/
> DLT >	/AB//+/		/10MG/	/N11751/002/

/TABLET,/EXTENDED/RELEASE;/ORAL/

PERMITIL

/+//SCHERING/	/1MG/	/N12419/004/
ə SCHERING	1MG	N12419 004

FOLIC ACID

TABLET; ORAL

FOLIC ACID

/AA/	/PIONEER/PHARMS/	/1MG/	/N88949/001/ /SEP/13,/1985/
ə PIONEER PHARMS	1MG	N88949 001 SEP 13, 1985	

FUROSEMIDE

SOLUTION; ORAL

FUROSEMIDE

> ADD >	AA	PENNEX PHARMS	10MG/ML	N70655 001 OCT 02, 1987
> DLT >	/AA/	/PHARM/BASICS/	/10MG/ML/	/N70655/001/ /OCT/02,/1987/

TABLET; ORAL

FUROSEMIDE

/AB/	/PARKE/DAVIS/	/20MG/	/N18419/001/ /JAN/31,/1983/
/AB/		/40MG/	/N18419/002/ /JAN/31,/1983/
/AB/		/80MG/	/N18419/003/ /NOV/13,/1984/
ə WARNER CHILCOTT		20MG	N18419 001 JAN 31, 1983
ə		40MG	N18419 002 JAN 31, 1983
ə		80MG	N18419 003 NOV 13, 1984

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

STERLING WINTHROP	287MG/ML	N20123 001 JAN 08, 1993

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

AB	MYLAN	300MG	N73466 001 JAN 25, 1993
AB	PUREPAC	300MG	N72929 001 JAN 29, 1993

LOPID

AB +	PARKE DAVIS	300MG	N18422 002

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE

/AT/	/PHARMADERM/	/EQ 1MG BASE/GM/	/N62530/001/ /JUL/05,/1984/
	∂ PHARMADERM	EQ 1MG BASE/GM	N62530 001 JUL 05, 1984

INJECTABLE; INJECTION
GENTAMICIN SULFATE

>DLT>	/AP/	/WYETH/AYERST/	/EQ 10MG BASE/ML/	/N62264/001/
>DLT>	/AP/		/EQ 40MG BASE/ML/	/N62264/002/
>ADD>		∂ WYETH AYERST	EQ 10MG BASE/ML	N62264 001
>ADD>		∂	EQ 40MG BASE/ML	N62264 002

OINTMENT; OPHTHALMIC
/GENTAFAIR/

/AT/	/PHARMAFAIR/	/EQ 3MG BASE/GM/	/N62443/001/ /MAY/26,/1983/
	∂ PHARMAFAIR	EQ 3MG BASE/GM	N62443 001 MAY 26, 1983

GLIPIZIDE

TABLET; ORAL
GLUCOTROL

	+ PFIZER	10MG	N17783 002 MAY 08, 1984
		2.5MG	N17783 003 MAY 11, 1993
		5MG	N17783 001 MAY 08, 1984
	/+//ROERIG/	/10MG/	/N17783/002/ /MAY/08,/1984/
		/5MG/	/N17783/001/ /MAY/08,/1984/

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON

/AP/	/LILLY/	/EQ 1MG BASE/VIAL/	/N12122/001/
	LILLY	EQ 1MG BASE/VIAL	N12122 001
/AP/	/QUAD/	/EQ 1MG BASE/VIAL/	/N71022/001/ /MAR/04,/1987/
	∂ QUAD	EQ 1MG BASE/VIAL	N71022 001 MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN

/∂/RHONE/POULENC/RORER//500MG/		/N09519/008/

GLYBURIDE

TABLET; ORAL
/GLYBATE/

/BX/	/HOECHST/ROUSSEL/	/1.5MG/	/N20055/001/ /APR/17,/1992/
/BX/		/3MG/	/N20055/002/ /APR/17,/1992/
	∂ HOECHST ROUSSEL	1.5MG	N20055 001 APR 17, 1992
	∂	3MG	N20055 002 APR 17, 1992

GLYNASE

/BX/	/UPJOHN/	/1.5MG/	/N20051/001/ /MAR/04,/1992/
/BX/+/		/3MG/	/N20051/002/ /MAR/04,/1992/
	+ UPJOHN	3MG	N20051 002 MAR 04, 1992
		1.5MG	N20051 001 MAR 04, 1992

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT

	+ FERRING	0.8MG/VIAL	N19687 001 OCT 10, 1989
	+	3.2MG/VIAL	N19687 002 OCT 10, 1989
	/LUTREPULSE/PUMP/KIT/ /FERRING/	/0.8MG/VIAL/	/N19687/001/ /OCT/10,/1989/
		/3.2MG/VIAL/	/N19687/002/ /OCT/10,/1989/

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

/AP/	/BEL/MAR/	/5,000 UNITS/VIAL/	/N17054/001/	
AP	@ BEL MAR	5,000 UNITS/VIAL	N17054 001	
/AP/		/10,000 UNITS/VIAL/	/N17054/002/	
AP	@	10,000 UNITS/VIAL	N17054 002	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

/+//IMPERIAL/CHEM/	/EQ 3.6MG BASE/	/N19726/001/	
		/DEC 29, 1989/	
+ ZENECA	EQ 3.6MG BASE	N19726 001	
		DEC 29, 1989	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

>DLT>				
>DLT>/AT/	/DOW/	/0.025MG/ML;EQ 1.75MG BASE/ML;/		
>DLT>		/10,000 UNITS/ML/	/N60427/001/	
>ADD>	@ DOW	0.025MG/ML;EQ 1.75MG BASE/ML;		
>ADD>		10,000 UNITS/ML	N60427 001	

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN

/WYETH/AYERST/	/125MG/	/N50051/002/	
@ WYETH AYERST	125MG	N50051 002	

HALOFANTRINE HYDROCHLORIDE

/TABLET;ORAL/

HALFAN

/+//SMITHKLINE/BEECHAM/	/250MG/	/N20250/001/	
		/JUL 24, 1992/	
@ SMITHKLINE BEECHAM	250MG	N20250 001	
		JUL 24, 1992	

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

>ADD>	@ PENNEX PHARMS	EQ 2MG BASE/ML	N70710 001	
			MAR 07, 1986	
>ADD>				
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001	
			FEB 26, 1993	
>DLT>/AA/	/PHARM/BASICS/	/EQ 2MG BASE/ML/	/N70710/001/	
>DLT>			/MAR/07,/1986/	

INJECTABLE; INJECTION

HALOPERIDOL

AP	MARSAM	EQ 5MG BASE/ML	N72516 001	
			FEB 25, 1993	
AP		EQ 5MG BASE/ML	N72517 001	
			FEB 25, 1993	
/AP/	/SMITH/NEPHEW/SOLOPAK/	/EQ 5MG BASE/ML/	/N70801/001/	
			/DEC/14,/1987/	
/AP/		/EQ 5MG BASE/ML/	/N70864/001/	
			/DEC/14,/1987/	
AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001	
			DEC 14, 1987	
AP		EQ 5MG BASE/ML	N70864 001	
			DEC 14, 1987	

HEPARIN SODIUM

INJECTABLE; INJECTION

LIQUAEMIN SODIUM

/AP/	/ORGANON/	/20,000 UNITS/ML/	/N00552/001/
/AP/		/40,000 UNITS/ML/	/N00552/002/
@ ORGANON		20,000 UNITS/ML	N00552 001
@		40,000 UNITS/ML	N00552 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

/TURGEX/

/XTTRIUM/	/3%/	/N18375/001/	
@ XTTRIUM	3%	N18375 001	

EMULSION; TOPICAL

HEXA-GERM

/AT/ /HUNTINGTON/	/3%/	/N17411/001/	
@ HUNTINGTON	3%	N17411 001	

PHISOHEX

/AT/ /STERLING/	/3%/	/N08402/001/	
@ STERLING	3%	N08402 001	

PHISOHEX

/AT/	/STERLING/	/3%/		/N08402/001/
	@ STERLING	3%		N08402 001

HEXACHLOROPHENE

EMULSION; TOPICAL

	/TURGEX/			
/AT/	/XTTRIUM/	/1%/	/N19055/001/	
			/NOV/30,/1984/	
	@ XTTRIUM	3%	N19055 001	
			NOV 30, 1984	

/SOLUTION;/TOPICAL/

	/DIAL/			
/AT/	/ARMOUR/DIAL/	/0.25%/	/N17421/002/	
	@ DIAL	0.25%	N17421 002	
	/GERMA-MEDICA/			
	/HUNTINGTON/	/1%/	/N17412/001/	
	@ HUNTINGTON	1%	N17412 001	
	/GERMA-MEDICA/"MG/"			
	/HUNTINGTON/	/0.25%/	/N17412/002/	
	@ HUNTINGTON	0.25%	N17412 002	

SPONGE; TOPICAL

	/HEXASCRUB/			
/AT/	/PROF/DSPLS/	/3%/	/N18363/001/	>_ADD_>
	@ PROF DSPLS	3%	N18363 001	>_ADD_>
	/PHISO-SCRUB/			>_DLT_>
/AT/	/STERLING/	/3%/	/N17446/001/	>_DLT_>
	@ STERLING	3%	N17446 001	>_DLT_>
	/SCRUBTEAM/SURGICAL/SPONGEBRUSH/			>_DLT_>
	/3M/	/330MG/	/N17413/001/	>_ADD_>
	@ 3M	330MG	N17413 001	>_ADD_>

HEXAFLUORENIUM BROMIDE

/INJECTABLE;/INJECTION/

	/MYLAXEN/		
	/WALLACE/	/20MG/ML/	/N09789/003/
	@ WALLACE	20MG/ML	N09789 003

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE		
/LILLY/	/EQ/0.1MG/BASE/ML/	/N00734/003/
@ LILLY	EQ 0.1MG BASE/ML	N00734 003
	/EQ/0.2MG/BASE/ML/	/N00734/002/
@	EQ 0.2MG BASE/ML	N00734 002
	/EQ/1MG/BASE/ML/	/N00734/001/
@	EQ 1MG BASE/ML	N00734 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

MYCODONE					
>_ADD_> AA	PENNEX PHARMS	1.5MG/5ML;5MG/5ML	N88008 001		
>_ADD_>			MAR 03, 1983		
>_DLT_>/AA/	/PHARM/BASICS/	/1.5MG/5ML;5MG/5ML/	/N88008/001/		
>_DLT_>			/MAR/03,/1983/		

HYDRALAZINE HYDROCHLORIDE; RESERPINE

/TABLET;/ORAL/

/SERPASIL-APRESOLINE/			
/+//CIBA/	/50MG;0.2MG/	/N09296/002/	
	/25MG;0.1MG/	/N09296/004/	
@ CIBA	25MG;0.1MG	N09296 004	
@	50MG;0.2MG	N09296 002	

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE				
@ PENNEX PHARMS	50MG/5ML	N89661 001		
		JUN 20, 1988		
/PHARM/BASICS/	/50MG/5ML/	/N89661/001/		
		/JUN/20,/1988/		
/ROXANE/	/50MG/5ML/	/N88587/001/		
		/JUL/02,/1984/		
ROXANE	50MG/5ML	N88587 001		
		JUL 02, 1984		

TABLET; ORAL

HYDROCHLOROTHIAZIDE				
/AB/	/INWOOD/	/25MG/	/N84776/001/	
/AB/		/50MG/	/N84776/002/	
@ INWOOD		25MG	N84776 001	
@		50MG	N84776 002	
/AB/	/LEMMON/	/50MG/	/N88923/001/	
			/FEB/07,/1985/	
@ LEMMON		50MG	N88923 001	
			FEB 07, 1985	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

/AB/	/SCHERING/	/25MG;100MG/	/N19046/001/ APR/06,/1987/		
/AB/		/25MG;200MG/	/N19046/002/ APR/06,/1987/		
/AB/+/		/25MG;300MG/	/N19046/003/ APR/06,/1987/		
	+ SCHERING	25MG;300MG	N19046 003 APR 06, 1987		
		25MG;100MG	N19046 001 APR 06, 1987		
		25MG;200MG	N19046 002 APR 06, 1987		

TRANDATE HCT

/AB/	/GLAXO/	/25MG;100MG/	/N19174/001/ APR/10,/1987/		
/AB/		/25MG;200MG/	/N19174/002/ APR/10,/1987/		
/AB/		/25MG;300MG/	/N19174/003/ APR/10,/1987/		
	@ GLAXO	25MG;100MG	N19174 001 APR 10, 1987	> DLT >	
	@	25MG;200MG	N19174 002 APR 10, 1987	> DLT >	
	@	25MG;300MG	N19174 003 APR 10, 1987	> DLT > > ADD > > ADD >	

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC 20/12.5

/AB/	/IMPERIAL/CHEM/	/12.5MG;20MG/	/N19888/001/ /SEP/20,/1990/	
AB	ZENECA	12.5MG;20MG	N19888 001 SEP 20, 1990	

ZESTORETIC 20/25

/AB/	/IMPERIAL/CHEM/	/25MG;20MG/	/N19888/002/ /JUL/20,/1989/	
AB	ZENECA	25MG;20MG	N19888 002 JUL 20, 1989	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/	/UPSHER/SMITH/	/25MG;25MG/	/N87553/001/	
	@ UPSHER SMITH	25MG;25MG	N87553 001	

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	BARRE	2.5%	N89682 001 MAR 10, 1988	
/AT/	/BIOCRAFT/	/0.5%/	/N80400/002/	
/AT/		/1%/	/N80400/003/	
/AT/		/2.5%/	/N80400/004/	
	@ BIOCRAFT	0.5%	N80400 002	
	@	1%	N80400 003	
	@	2.5%	N80400 004	
/AT/	/NASKA/	/2.5%/	/N89682/001/ /MAR/10,/1988/	
/AT/	/PHARMADERM/	/1%/	/N88845/001/ /FEB/27,/1986/	
	@ PHARMADERM	1%	N88845 001 FEB 27, 1986	

LOTION; TOPICAL

ACTICORT

AT	BAKER NORTON	1%	N86535 001	
/AT/	/KEY/PHARMS/	/1%/	/N86535/001/	

BALNEOL-HC

/AT/	/SOLVAY/	/1%/	/N88041/001/ /DEC/03,/1982/	
	@ SOLVAY	1%	N88041 001 DEC 03, 1982	

OINTMENT; TOPICAL

HYDROCORTISONE

AT	FOUGERA	2.5%	N81203 001 MAY 28, 1993	
/AT/	/PHARMADERM/	/1%/	/N88842/001/ /FEB/09,/1987/	
	@ PHARMADERM	1%	N88842 001 FEB 09, 1987	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE & HYDROCORTISONE

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62617/001/ /SEP/18,/1985/	
	@ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001 SEP 18, 1985	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62623/001/	
	@ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001	SEP 24, 1985

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

/BP/	/BEL/MAR/	/25MG/ML/	/N83739/001/	
/BP/		/50MG/ML/	/N83739/002/	
	@ BEL MAR	25MG/ML	N83739 001	
	@	50MG/ML	N83739 002	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL
PRAMOSONE

/FERNDALE/	/0.5%;1%/	/N83213/002/	
@ FERNDALE	0.5%;1%	N83213 002	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
HYDROXOMIN

/AP/	/BEL/MAR/	/1MG/ML/	/N84629/001/	
	@ BEL MAR	1MG/ML	N84629 001	

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	FUJISAWA	25MG/ML	N88184 001	MAR 31, 1983
AP		50MG/ML	N88185 001	MAR 31, 1983
/AP/	/LYPHOMED/	/25MG/ML/	/N88184/001/	/MAR/31,/1983/
/AP/		/50MG/ML/	/N88185/001/	/MAR/31,/1983/

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

>DLT >/AP/	/WYETH/AYERST/	/25MG/ML/	/N86258/001/	
>DLT >/AP/		/50MG/ML/	/N86258/002/	
>ADD >	@ WYETH AYERST	25MG/ML	N86258 001	
>ADD >	@	50MG/ML	N86258 002	

SYRUP; ORAL
HYDROXYZINE HCL

AA	BARRE	10MG/5ML	N88785 001	FEB 03, 1988
/AA/	/NASKA/	/10MG/5ML/	/N88785/001/	/FEB/03,/1988/
>ADD > AA	PENNEX PHARMS	10MG/5ML	N87294 001	APR 12, 1982
>ADD >				
>DLT >/AA/	/PHARM/BASICS/	/10MG/5ML/	/N87294/001/	/APR/12,/1982/
>DLT >				

TABLET; ORAL
HYDROXYZINE HCL

/AB/	/CHELSEA/	/10MG/	/N86827/001/
/AB/		/25MG/	/N86829/001/
/AB/		/50MG/	/N86836/001/
	@ CHELSEA	10MG	N86827 001
	@	25MG	N86829 001
	@	50MG	N86836 001

IBUPROFEN

TABLET; ORAL
IBUPROFEN

AB	NORTON HN	400MG	N71145 001	SEP 23, 1986
AB		600MG	N71146 001	SEP 23, 1986
AB		800MG	N71769 001	MAY 08, 1987

IBUPROFEN

/AB/	/PAR/	/300MG/	/N70328/001/	/AUG/06,/1985/
	@ PAR	300MG	N70328 001	AUG 06, 1985

IBUPROFEN

TABLET; ORAL

	/IFEN/			
/AB/	/LUCHEN/	/400MG/	/N71145/001/	/SEP/23,/1986/
/AB/		/600MG/	/N71146/001/	/SEP/23,/1986/
/AB/		/800MG/	/N71769/001/	/MAY/08,/1987/

IDOXURIDINE

/OINTMENT;/OPHTHALMIC/

	/STOXIL/		
/*/	/SMITHKLINE/BEECHAM/	/0.5%/	/N15868/001/
	ə SMITHKLINE BEECHAM	0.5%	N15868 001

SOLUTION/DROPS; OPHTHALMIC

	/STOXIL/		
/AT/	/SMITHKLINE/BEECHAM/	/0.1%/	/N13934/001/
	ə SMITHKLINE BEECHAM	0.1%	N13934 001

INDAPAMIDE

TABLET; ORAL

	LOZOL		
	RHONE POULENC RORER	1.25MG	N18538 002 APR 29, 1993

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

	IODOHIPPURATE SODIUM I 131			
/AP/	/CIS/	/0.2MCI/ML/	/N17313/001/	
AP	SORIN	0.2MCI/ML	N17313 001	

IOHEXOL

/INJECTABLE;/INJECTION/

	/OMNIPAQUE/180/		
	/STERLING/	/38.8%/	/N18956/001/ /DEC/26,/1985/

/SOLUTION;/INJECTION,/ORAL/

	/OMNIPAQUE/240/		
	/STERLING/	/51.8%/	/N18956/002/ /DEC/26,/1985/

IOHEXOL

/SOLUTION;/INJECTION,/ORAL/

	/OMNIPAQUE/300/		
	/STERLING/	/64.7%/	/N18956/003/ /DEC/26,/1985/

SOLUTION; INJECTION, ORAL, RECTAL

	OMNIPAQUE 180		
+	STERLING	38.8%	N18956 001 DEC 26, 1985
	OMNIPAQUE 240		
+	STERLING	51.8%	N18956 002 DEC 26, 1985
	OMNIPAQUE 300		
+	STERLING	64.7%	N18956 003 DEC 26, 1985

IOTROLAN

/INJECTABLE;/INTRATHECAL/

	/OSMOVIST/		
	/BERLEX/	/EQ/190MG/IODINE/ML/	/N19580/001/ /DEC/07,/1989/
		/EQ/240MG/IODINE/ML/	/N19580/002/ /DEC/07,/1989/
	ə BERLEX	EQ 190MG IODINE/ML	N19580 001 DEC 07, 1989
	ə	EQ 240MG IODINE/ML	N19580 002 DEC 07, 1989

IRON DEXTRAN

INJECTABLE; INJECTION

	INFED		
BP +	SCHEIN PHARM	EQ 50MG IRON/ML	N17441 001
	/IRON/DEXTRAN/		
/BP/	/STERIS/	/EQ/50MG/IRON/ML/	/N17441/001/

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL			
/AN/	/ASTRA/	/0.125%/	/N87938/001/	
			/NOV 15, 1982/	
		/0.062%/	/N87937/001/	
			/NOV 15, 1982/	
	ə ASTRA	0.062%	N87937 001	
			NOV 15, 1982	
	ə	0.125%	N87938 001	
			NOV 15, 1982	
/AN/	/PARKE/DAVIS/	/1%/	/N85889/001/	
		/0.5%/	/N85997/001/	
	ə PARKE DAVIS	0.5%	N85997 001	
	ə	1%	N85889 001	

ISOFLURANE

LIQUID; INHALATION

	FORANE		
AN	+ ANAQUEST	99.9%	N17624 001
	ISOFLURANE		
AN	ABBOTT	99.9%	N74097 001
			JAN 25, 1993

ISONIAZID

INJECTABLE; INJECTION

	NYDRAZID			
>ADD>	+ APOTHECON	100MG/ML	N08662 001	
>DLT>	/SQUIBB/	/100MG/ML/	/N08662/001/	

TABLET; ORAL

	ISONIAZID			
>DLT>/AA/	/EON/LABS/	/100MG/	/N08678/002/	
>ADD> AA	+ EON LABS	100MG	N08678 002	
>DLT>/AA/		/300MG/	/N08678/003/	
>ADD> AA	+	300MG	N08678 003	
	/STANOZIDE/			
/AA/	/EVERYLIFE/	/300MG/	/N80126/002/	
	ə EVERYLIFE	300MG	N80126 002	

ISOPROPAMIDE IODIDE

/TABLET;ORAL/

/DARBID/			
/SMITHKLINE/BEECHAM/	/EQ/5MG/BASE/	/N10744/001/	
ə SMITHKLINE BEECHAM	EQ 5MG BASE	N10744 001	

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

	AEROLONE			
>DLT>/AN/	/LILLY/	/0.25%/	/N07245/001/	
>ADD>	+ LILLY	0.25%	N07245 001	
>DLT>	/ISOPROTERENOL HCL/			
>DLT>/AN/	/PARKE/DAVIS/	/0.125%/	/N85994/001/	
>DLT>/AN/		/0.5%/	/N85540/001/	
>ADD>	ə PARKE DAVIS	0.25%	N85994 001	
>ADD>	ə	0.5%	N85540 001	
	ISUPREL			
>DLT>/AN/	/STERLING/	/0.5%/	/N06327/002/	
>ADD>	+ STERLING WINTHROP	0.5%	N06327 002	
>DLT>	/VAPO-ISO/			
>DLT>/AN/	/FISONS/	/0.5%/	/N16813/001/	
>ADD>	ə FISONS	0.5%	N16813 001	

TABLET; RECTAL, SUBLINGUAL

ISUPREL			
/STERLING/	/15MG/	/N06328/002/	
ə STERLING	15MG	N06328 002	

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE			
/AB/	/ICI/	/20MG/	/N86405/002/	
			/AUG 21, 1990/	
/AB/		/30MG/	/N88124/001/	
			/AUG 21, 1990/	
/AB/		/40MG/	/N88125/001/	
			/AUG 21, 1990/	
AB	ZENECA	20MG	N86405 002	
			AUG 21, 1990	
AB		30MG	N88124 001	
			AUG 21, 1990	
AB		40MG	N88125 001	
			AUG 21, 1990	

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO			
/AB//#//WYETH/	/20MG/	/N19091/001/	
		/DEC 30, 1991/	
BX + WYETH	20MG	N19091 001	
		DEC 30, 1991	

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET

BX	SCHWARZ PHARMA	20MG	N20215 001	JUN 30, 1993
		10MG	N20215 002	JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL
IMDUR

	@ SCHERING PLOUGH	30MG	N20225 001	AUG 12, 1993
		60MG	N20225 002	AUG 12, 1993

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX

	APOTHECON	EQ 500MG BASE	N62726 001	MAR 06, 1987
	/BRISTOL/	/EQ/500MG/BASE/	/N62726/001/	/MAR/06,/1987/

INJECTABLE; INJECTION
KANTREX

AP	APOTHECON	EQ 75MG BASE/2ML	N61901 003	
AP		EQ 500MG BASE/2ML	N61901 001	
AP		EQ 1GM BASE/3ML	N61901 002	
AP	/BRISTOL/	/EQ 75MG BASE/2ML/	/N61901/003/	
AP		/EQ 500MG BASE/2ML/	/N61901/001/	
AP		/EQ 1GM BASE/3ML/	/N61901/002/	
	/KLEBCIL/			
AP	/SMITHKLINE/BEECHAM/	/EQ 75MG BASE/2ML/	/N62170/001/	
AP		/EQ 500MG BASE/2ML/	/N62170/002/	
AP		/EQ 1GM BASE/3ML/	/N62170/003/	
	@ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001	
	@	EQ 500MG BASE/2ML	N62170 002	
	@	EQ 1GM BASE/3ML	N62170 003	

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

AB	LEDERLE	25MG	N74014 001	JAN 29, 1993
AB		50MG	N74014 002	JAN 29, 1993
AB		75MG	N74014 003	JAN 29, 1993

LACTULOSE

SOLUTION; ORAL
/CEPHULAC/

/AA/	/MERRELL/DOW/	/10GM/15ML/	/N17657/001/	
	/ENULOSE/			
/AA/	/BARRE/	/10GM/15ML/	/N71548/001/	/AUG/15,/1988/

EVALOSE

AA	COPLEY	10GM/15ML	N73497 001	MAY 28, 1993

LACTULOSE

	@ PENNEX PHARMS	10GM/15ML	N71841 001	SEP 22, 1988
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71841/001/	/SEP/22,/1988/

/LACTULOSE/

	/SOLVAY/	/10GM/15ML/	/N17906/001/	

LAXILOSE

AA	TECHNILAB	10GM/15ML	N73686 001	MAY 28, 1993

SOLUTION; ORAL, RECTAL
ACILAC

AA	TECHNILAB	10GM/15ML	N73685 001	MAY 28, 1993

CEPHULAC

AA	MERRELL DOW	10GM/15ML	N17657 001	

ENULOSE

AA	BARRE	10GM/15ML	N71548 001	AUG 15, 1988

	@ PENNEX PHARMS	10GM/15ML	N71842 001	SEP 27, 1988
	/GENERLAC/			
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71842/001/	/SEP/27,/1988/

LACTULOSE

SOLUTION; ORAL, RECTAL

	HEPTALAC			
AA	COPLEY	10GM/15ML	N73504 001	MAY 28, 1993
	LACTULOSE			
	∂ SOLVAY	10GM/15ML	N17906 001	
/AA/	/PORTALAC/ /SOLVAY/	/10GM/15ML/	/N72374/001/	/MAR/22,/1989/
	∂ SOLVAY	10GM/15ML	N72374 001	MAR 22, 1989

LEUCOVORIN CALCIUM

TABLET; ORAL

	LEUCOVORIN CALCIUM			
AB	LEDERLE	EQ 10MG BASE	N71962 001	NOV 19, 1987
AB +		EQ 15MG BASE	N71104 001	MAR 04, 1987
AB	ROXANE	EQ 5MG BASE	N72733 001	FEB 22, 1993
AB		EQ 10MG BASE	N72734 001	FEB 22, 1993
AB		EQ 15MG BASE	N72735 001	FEB 22, 1993
AB		EQ 25MG BASE	N72736 001	FEB 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON			
>DLT>	/+//TAP/	/1MG/0.2ML/	/N19610/001/	/APR/09,/1985/
>DLT>				
>ADD>	+ TAP	5MG/ML	N19010 001	APR 09, 1985
>ADD>		5MG/ML	N20263 001	APR 16, 1993
	LUPRON DEPOT			
	+ TAP	3.75MG/VIAL	N20011 001	OCT 22, 1990
	+	7.5MG/VIAL	N19732 001	JAN 26, 1989
		/3.75MG/VIAL/	/N20011/001/	/OCT/22,/1990/
		/7.5MG/VIAL/	/N19732/001/	/JAN/26,/1989/

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON DEPOT-PED			
	+ TAP	3.75MG/VIAL&7.5MG/VIAL	N20263 003	APR 16, 1993
	+	7.5MG/VIAL&7.5MG/VIAL	N20263 004	APR 16, 1993
	+	7.5MG/VIAL	N20263 002	APR 16, 1993

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM			
BIOMETRIC RES	10MG/ML	N20315 001	JUL 09, 1993

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/			
/RAYOCAINE/AND/NOVOCAIN/W/NEO-COBEFRIN/			
/COOK/WAITE/	/0.05MG/ML;2%;0.4%/	/N08592/007/	
∂ STERLING WINTHROP	0.05MG/ML;2%;0.4%	N08592 007	

LIDOCAINE

/SUPPOSITORY;/RECTAL/			
/XYLOCAINE/			
/ASTRA/	/100MG/	/N13077/001/	
∂ ASTRA	100MG	N13077 001	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL			
/AP/	/BEL/MAR/	/1%/	/N80710/001/	
/AP/		/2%/	/N80760/001/	
	∂ BEL MAR	1%	N80710 001	
	∂	2%	N80760 001	
/AP/	/BRISTOL/	/1%/	/N80390/001/	
/AP/		/2%/	/N80390/002/	
AP	FUJISAWA	1%	N80404 002	
AP		2%	N80404 003	
	∂	1%	N80390 001	
	∂	2%	N80390 002	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

/AP/	/LYPHOMED/	/1%/	/N86404/002/
/AP/		/1%/	/N86761/001/
/AP/		/2%/	/N86404/003/
/AP/		/2%/	/N86761/002/
	@ LYPHOMED	1%	N86761 001
	@	2%	N86761 002

JELLY; TOPICAL
LIDOCAINE HCL

AT	COPLEY	2%	N81318 001 APR 29, 1993

SOLUTION; ORAL
MYLOCAINE

>ADD >	AT	PENNEX PHARMS	2%	N87872 001 NOV 18, 1982
>ADD >				
>DLT >/	/AT/	/PHARM/BASICS/	/2%/	/N87872/001/ /NOV/18,/1982/
>DLT >				

SOLUTION; TOPICAL
/MYLOCAINE/

>DLT >				
>DLT >/	/AT/	/PHARM/BASICS/	/4%/	/N87881/001/ /NOV/18,/1982/
>DLT >				
>ADD >		@ PENNEX PHARMS	4%	N87881 001 NOV 18, 1982
>ADD >				

LINDANE

LOTION; TOPICAL
LINDANE

>ADD >	AT	PENNEX PHARMS	1%	N88190 001 AUG 16, 1984
>ADD >				
>DLT >/	/AT/	/PHARM/BASICS/	/1%/	/N88190/001/ /AUG/16,/1984/
>DLT >				

SHAMPOO; TOPICAL
LINDANE

>ADD >	AT	PENNEX PHARMS	1%	N88191 001 SEP 18, 1984
>ADD >				
>DLT >/	/AT/	/PHARM/BASICS/	/1%/	/N88191/001/ /SEP/18,/1984/
>DLT >				

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25
FOREST LABS 0.0125MG;0.0031MG N16807 001
/RHONE/POULENC/RORER//0.0125MG;0.0031MG/ /N16807/001/

THYROLAR-0.5
FOREST LABS 0.025MG;0.00625MG N16807 005
/RHONE/POULENC/RORER//0.025MG;0.00625MG/ /N16807/005/

THYROLAR-1
FOREST LABS 0.05MG;0.0125MG N16807 004
/RHONE/POULENC/RORER//0.05MG;0.0125MG/ /N16807/004/

THYROLAR-2
FOREST LABS 0.1MG;0.025MG N16807 002
/RHONE/POULENC/RORER//0.1MG;0.025MG/ /N16807/002/

THYROLAR-3
+ FOREST LABS 0.15MG;0.0375MG N16807 003
/+//RHONE/POULENC/RORER//0.15MG;0.0375MG/ /N16807/003/

THYROLAR-5
@ FOREST LABS 0.25MG;0.0625MG N16807 006
/@/RHONE/POULENC/RORER//0.25MG;0.0625MG/ /N16807/006/

LISINOPRIL

TABLET; ORAL
ZESTRIL

/AB/	/IMPERIAL/CHEM/	/5MG/	/N19777/001/ /MAY/19,/1988/
/AB/		/10MG/	/N19777/002/ /MAY/19,/1988/
/AB/		/20MG/	/N19777/003/ /MAY/19,/1988/
/AB//+/		/40MG/	/N19777/004/ /MAY/19,/1988/
AB	ZENECA	5MG	N19777 001 MAY 19, 1988
AB		10MG	N19777 002 MAY 19, 1988
AB		20MG	N19777 003 MAY 19, 1988
AB	+	40MG	N19777 004 MAY 19, 1988
		2.5MG	N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL
/ESKALITH/

/AB//+//SMITHKLINE/BEECHAM/	/300MG/	/N17971/001/
@ SMITHKLINE BEECHAM	300MG	N17971 001

LITHIUM CITRATE

SYRUP; ORAL
LITHIUM CITRATE
AA PENNEX PHARMS — EQ 300MG CARBONATE/5ML — N70755 001 MAY 21, 1986
/AA/ /PHARM/BASICS/ /EQ/300MG/CARBONATE/5ML/ /N70755/001/MAY/21,/1986/

LORATADINE

TABLET; ORAL
CLARITIN
+ SCHERING — 10MG — N19658 001 APR 12, 1993

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
+ HICKAM — EQ 85MG BASE/GM — N16763 001
/STERLING/ /EQ/85MG/BASE/GM/ /N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE
FUJISAWA — EQ 0.1MG MANGANESE/ML — N19228 001 MAY 05, 1987
/LYPHOMED/ /EQ/0.1MG/MANGANESE/ML/ /N19228/001/MAY/05,/1987/

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER
AP MCGAW — 10GM/100ML — N20006 002 JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER
AP MCGAW — 15GM/100ML — N20006 003 JUL 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER
AP MCGAW — 20GM/100ML — N20006 004 JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER
AP MCGAW — 5GM/100ML — N20006 001 JUL 26, 1993

MASOPROCOL

CREAM; TOPICAL
ACTINEX
+ BLOCK DRUG — 10% — N19940 001 SEP 04, 1992
/+//CHEMEX/ /10%/ /N19940/001/SEP/04,/1992/

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE;/INJECTION/
/SYNKAYVITE/
/ROCHE/ /5MG/ML/ /N03718/004/
/10MG/ML/ /N03718/006/
/37.5MG/ML/ /N03718/008/
∂ ROCHE 5MG/ML N03718 004
∂ 10MG/ML N03718 006
∂ 37.5MG/ML N03718 008

/TABLET;/ORAL/
/SYNKAYVITE/
/ROCHE/ /5MG/ /N03718/010/
∂ ROCHE 5MG N03718 010

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL
AP ASTRA — 10MG/ML — N81002 001 JUL 30, 1993
>ADD> AP INTL MEDICATION — 10MG/ML — N81309 001 AUG 30, 1993
>ADD>

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
/AA/ /LEE/LABS/ /400MG/ /N89538/001/NOV/25,/1987/
∂ LEE LABS 400MG N89538 001 NOV 25, 1987

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

	PENTASA			
+	MARION MERRELL DOW	250MG	N20049 001	MAY 10, 1993

MESTRANOL; NORETHINDRONE

/TABLET;ORAL-20/

	/NORINYL/			
	/SYNTEX/	/0.1MG;2MG/	/N13625/004/	
∂	SYNTEX	0.1MG;2MG	N13625 004	

TABLET; ORAL-21

	NORETHIN 1/50M-21			
AB	ROBERTS	0.05MG;1MG	N71539 001	APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.05MG;1MG/	/N71539/001/	/APR/12,/1988/

TABLET; ORAL-28

	NORETHIN 1/50M-28			
AB	ROBERTS	0.05MG;1MG	N71540 001	APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.05MG;1MG/	/N71540/001/	/APR/12,/1988/

MESTRANOL; NORETHYNODREL

/TABLET;ORAL/

	/ENOVID/			
	/+//SEARLE/	/0.15MG;9.85MG/	/N10976/005/	
		/0.075MG;5MG/	/N10976/008/	
∂	SEARLE	0.075MG;5MG	N10976 008	
∂		0.15MG;9.85MG	N10976 005	

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE			
>ADD>	∂ PENNEX PHARMS	5%	N72190 001	JUN 07, 1988
>ADD>				
>DLT>/AN/	/PHARM/BASICS/	/5%/	/N72190/001/	/JUN/07,/1988/
>DLT>				

METAPROTERENOL SULFATE

SYRUP; ORAL

	METAPROTERENOL SULFATE			
>ADD> AA	PENNEX PHARMS	10MG/5ML	N71656 001	OCT 13, 1987
>ADD>				
>DLT>/AA/	/PHARM/BASICS/	/10MG/5ML/	/N71656/001/	/OCT/13,/1987/
>DLT>				

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

	METARAMINOL BITARTRATE			
AP	FUJISAWA	EQ 10MG BASE/ML	N80431 001	
AP		EQ 10MG BASE/ML	N80722 001	
/AP/	/LYPHOMED/	/EQ 10MG BASE/ML/	/N80431/001/	
/AP/		/EQ 10MG BASE/ML/	/N80722/001/	

METHADONE HYDROCHLORIDE

TABLET; ORAL

	METHADOSE			
AA	MALLINCKRODT	5MG	N40050 001	APR 15, 1993
AA		10MG	N40050 002	APR 15, 1993

TABLET, DISPERSIBLE; ORAL

	METHADONE HCL			
AA	LILLY	40MG	N17058 001	
	METHADOSE			
AA	MALLINCKRODT	40MG	N74184 001	APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

	/METHAMPEX/			
/AA/	/LEMMON/	/10MG/	/N83889/001/	
∂	LEMMON	10MG	N83889 001	

	METHAMPHETAMINE HCL			
/AA/	/LEMMON/	/5MG/	/N86359/001/	
∂	LEMMON	5MG	N86359 001	
/AA/	/REXAR/	/10MG/	/N84931/002/	
	REXAR	10MG	N84931 002	

METHANTHELINE BROMIDE

TABLET; ORAL

	BANTHINE			
	ROBERTS	50MG	N07390 001	
	/SCHIAPPARELLI/SEARLE/	/50MG/	/N07390/001/	

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE			
AB	COPLEY	25MG	N40001 001	JUN 30, 1993
AB		50MG	N40001 002	JUN 30, 1993
AB	GENEVA	25MG	N40036 001	JUN 30, 1993
AB		50MG	N40036 002	JUN 30, 1993
	NEPTAZANE			
AB	LEDERLE	25MG	N11721 002	NOV 25, 1991
AB +		50MG	N11721 001	

METHICILLIN SODIUM

INJECTABLE; INJECTION

	STAPHCILLIN			
>ADD >	+ APOTHECON	EQ 900MG BASE/VIAL	N61449 001	
>ADD >	+	EQ 3.6GM BASE/VIAL	N61449 002	
>ADD >	+	EQ 5.4GM BASE/VIAL	N61449 003	
>DLT >	/BRISTOL/	/EQ/900MG/BASE/VIAL/	/N61449/001/	
>DLT >		/EQ/3.6GM/BASE/VIAL/	/N61449/002/	
>DLT >		/EQ/5.4GM/BASE/VIAL/	/N61449/003/	

METHOCARBAMOL

TABLET; ORAL

	/DELAXIN/			
/AA/	/FERNDALE/	/500MG/	/N85454/001/	
	∂ FERNDALE	500MG	N85454 001	
	METHOCARBAMOL			
AA	NYLOS TRADING	750MG	N85033 001	

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL			
/AA/	/PIONEER/PHARMS/	/500MG/	/N88731/001/	/DEC/13,/1985/
/AA/		/750MG/	/N89082/001/	/DEC/13,/1985/
	∂ PIONEER PHARMS	500MG	N88731 001	DEC 13, 1985
	∂	750MG	N89082 001	DEC 13, 1985
/AA/	/TABLICAPS/	/750MG/	/N85033/001/	
/AA/	/UPSHER/SMITH/	/500MG/	/N87453/001/	
/AA/		/750MG/	/N87454/001/	
	∂ UPSHER SMITH	500MG	N87453 001	
	∂	750MG	N87454 001	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE SODIUM			
/AP/	/AKORN/	/EQ 25MG BASE/ML/	/N88648/001/	/MAY/09,/1986/
/AP/	/LYPHOMED/	/EQ 25MG BASE/ML/	/N89263/001/	/JUN/13,/1986/
	∂ LYPHOMED	EQ 25MG BASE/ML	N89263 001	JUN 13, 1986
AP	NORBROOK	EQ 25MG BASE/ML	N88648 001	MAY 09, 1986

METHOXYFLURANE

>DLT >	/SOLUTION;/INHALATION/		
>DLT >	/PENTHRANE/		
>DLT >	/ABBOTT/	/99.9%/	/N13056/003/

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	METHYLDOPATE HCL			
/AP/	/LYPHOMED/	/50MG/ML/	/N70652/001/	/JUN/03,/1986/
	∂ LYPHOMED	50MG/ML	N70652 001	JUN 03, 1986

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

/AB/ /CHELSEA/	/4MG/	/N86161/001/ /FEB/09,/1982/
B* CHELSEA	4MG	N86161 001 FEB 09, 1982

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
/M-PREDROL/

/BP/ /BEL/MAR/	/40MG/ML/	/N86666/001/
/BP/	/80MG/ML/	/N87135/001/
ə BEL MAR	40MG/ML	N86666 001
ə	80MG/ML	N87135 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/ /LYPHOMED/	/EQ 40MG BASE/VIAL/	/N89143/001/ /MAR/28,/1986/
/AP/	/EQ 125MG BASE/VIAL/	/N89144/001/ /MAR/28,/1986/
/AP/	/EQ 500MG BASE/VIAL/	/N89187/001/ /MAR/28,/1986/
/AP/	/EQ 1GM BASE/VIAL/	/N89189/001/ /MAR/28,/1986/
ə LYPHOMED	EQ 40MG BASE/VIAL	N89143 001 MAR 28, 1986
ə	EQ 125MG BASE/VIAL	N89144 001 MAR 28, 1986
ə	EQ 500MG BASE/VIAL	N89187 001 MAR 28, 1986
ə	EQ 1GM BASE/VIAL	N89189 001 MAR 28, 1986

METHYLTESTOSTERONE

CAPSULE; ORAL
/METHYLTESTOSTERONE/

/BP/+//HEATHER/	/10MG/	/N84967/001/
ə HEATHER	10MG	N84967 001

TESTRED

/BP/ /ICN/	/10MG/	/N83976/001/
BP + ICN	10MG	N83976 001

METHYPRYLON

/CAPSULE;/ORAL/
/NOLUDAR/

/ROCHE/	/300MG/	/N09660/008/
ə ROCHE	300MG	N09660 008

/TABLET;/ORAL/
/NOLUDAR/

/ROCHE/	/200MG/	/N09660/004/
ə ROCHE	200MG	N09660 004

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

/AP/ /AKORN/	/EQ 10MG BASE/2ML/	/N70892/001/ /AUG/26,/1988/
/AP/ /FUJISAWA/	/EQ 10MG BASE/2ML/	/N70293/001/ /JAN/24,/1986/
ə FUJISAWA	EQ 10MG BASE/2ML	N70293 001 JAN 24, 1986
ə NORBROOK	EQ 10MG BASE/2ML	N70892 001 AUG 26, 1988

SOLUTION; ORAL
METOCLOPRAMIDE HCL

AA	LEMMON	EQ 5MG BASE/5ML	N71315 001 JUN 30, 1993
AA	LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001 JUN 25, 1993
>ADD> AA	PENNEX PHARMS	EQ 5MG BASE/5ML	N70949 001 MAR 06, 1987
>ADD> >DLT> /AA/	/PHARM/BASICS/	/EQ 5MG BASE/5ML/	/N70949/001/ /MAR/06,/1987/
>DLT>			

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	BIOCRAFT	EQ 5MG BASE	N72801 001 JUN 15, 1993
AB	MUTUAL PHARM	EQ 10MG BASE	N71536 001 APR 28, 1993
/AB/	/PAR/	/EQ 10MG BASE/	/N70342/001/ /MAR/25,/1986/
ə PAR		EQ 10MG BASE	N70342 001 MAR 25, 1986

METRONIDAZOLE

TABLET; ORAL
/SATRIC/
/AB/ /SAVAGE/ /250MG/ /N70029/001/ /MAR/19,/1985/
/AB/ /500MG/ /N70731/001/ /JUN/08,/1987/

ə SAVAGE	250MG	N70029 001 MAR 19, 1985
ə	500MG	N70731 001 JUN 08, 1987

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
MILES EQ 1GM BASE/VIAL N62372 005
JAN 13, 1983

MICONAZOLE NITRATE

/CREAM;/VAGINAL/
/MONISTAT/7/
/JOHNSON/RW/ /2%/ /N17456/001/

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK
+ JOHNSON RW 2%;200MG N18888 002
OCT 17, 1988

/LOTION;/TOPICAL/
/MONISTAT-DERM/
/+//JOHNSON/RW/ /2%/ /N17739/001/
ə JOHNSON RW 2% N17739 001

/SUPPOSITORY;/VAGINAL/
/MONISTAT/7/
/JOHNSON/RW/ /100MG/ /N18520/001/ /MAR/15,/1982/

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE
+ STERLING EQ 1MG BASE/ML N19436 001
DEC 31, 1987
/3/ /EQ/1MG/BASE/ML/ /N19436/001/ /DEC/31,/1987/

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVANTRONE
+ IMMUNEX EQ 2MG BASE/ML N19297 001
DEC 23, 1987
/LEDERLE/ /EQ/2MG/BASE/ML/ /N19297/001/ /DEC/23,/1987/

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/DUPONT/ /200MG/ /N19753/001/ /JUN/19,/1990/
/250MG/ /N19753/002/ /JUN/19,/1990/
/300MG/ /N19753/003/ /JUN/19,/1990/

ROBERTS	200MG	N19753 001 JUN 19, 1990
	250MG	N19753 002 JUN 19, 1990
	300MG	N19753 003 JUN 19, 1990

NABILONE

/CAPSULE;/ORAL/
/CESAMET/
/+//LILLY/ /1MG/ /N18677/001/ /DEC/26,/1985/
ə LILLY 1MG N18677 001
DEC 26, 1985

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

> ADD >	AP	APOTHECON	EQ 500MG BASE/VIAL	N62527 001	
> ADD >				AUG 02, 1984	
> ADD >	AP		EQ 1GM BASE/VIAL	N62527 002	
> ADD >				AUG 02, 1984	
> ADD >	AP		EQ 1GM BASE/VIAL	N62732 001	
> ADD >				DEC 23, 1986	
> ADD >	AP		EQ 2GM BASE/VIAL	N62527 003	
> ADD >				AUG 02, 1984	
> ADD >	AP		EQ 2GM BASE/VIAL	N62732 002	
> ADD >				DEC 23, 1986	
> ADD >	AP		EQ 10GM BASE/VIAL	N62527 004	
> ADD >				AUG 02, 1984	
> DLT >	AP	BRISTOL	EQ 500MG BASE/VIAL	N62527 001	
> DLT >				AUG 02, 1984	
> DLT >	AP		EQ 1GM BASE/VIAL	N62527 002	
> DLT >				AUG 02, 1984	
> DLT >	AP		EQ 1GM BASE/VIAL	N62732 001	
> DLT >				DEC 23, 1986	
> DLT >	AP		EQ 2GM BASE/VIAL	N62527 003	
> DLT >				AUG 02, 1984	
> DLT >	AP		EQ 2GM BASE/VIAL	N62732 002	
> DLT >				DEC 23, 1986	
> DLT >	AP		EQ 10GM BASE/VIAL	N62527 004	
> DLT >				AUG 02, 1984	

POWDER FOR RECONSTITUTION; ORAL
UNIPEN

+	WYETH AYERST	EQ 250MG BASE/5ML	N50199 001
	∂ WYETH AYERST	EQ 250MG BASE/5ML	N50199 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE

	ABBOTT	1.5MG/ML	N20200 001
			MAR 12, 1993

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	LYPHOMED	0.02MG/ML	N70661 001	
			NOV 17, 1986	
	∂ LYPHOMED	0.02MG/ML	N70661 001	
			NOV 17, 1986	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NARCAN

AP	DUPONT	0.4MG/ML	N71083 001	
			JUL 28, 1988	
AP		1MG/ML	N71084 001	
			JUL 28, 1988	
AP		1MG/ML	N71311 001	
			JUL 28, 1988	
	∂ DUPONT	0.4MG/ML	N71083 001	
			JUL 28, 1988	
	∂	1MG/ML	N71084 001	
			JUL 28, 1988	
	∂	1MG/ML	N71311 001	
			JUL 28, 1988	

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AD	LYPHOMED	100MG/ML	N88296 001	
			OCT 03, 1983	
AD		200MG/ML	N88317 001	
			OCT 14, 1983	
	∂ LYPHOMED	100MG/ML	N88290 001	
			OCT 03, 1983	
	∂	200MG/ML	N88317 001	
			OCT 14, 1983	

NAPROXEN SODIUM

TABLET; ORAL
ANAPROX

> ADD >	AB	SYNTEX	275MG	N18164 001

ANAPROX DS

> ADD >	AB	+ SYNTEX	550MG	N18164 003
> ADD >				SEP 30, 1987

NAPROXEN SODIUM

> ADD >	AB	HAMILTON	275MG	N74106 001
> ADD >				AUG 31, 1993
> ADD >	AB		550MG	N74106 002
> ADD >				AUG 31, 1993

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA	EON LABS	EQ 350MG BASE	N61586 001	
	∂ EON LABS	EQ 350MG BASE	N61586 001	

NIACIN

/CAPSULE;/ORAL/
/WAMPOCAP/
/WALLACE/ /500MG/ /N11073/003/
∂ WALLACE 500MG N11073 003

TABLET; ORAL
NIACIN
/AA/ /ZENITH/ /500MG/ /N83180/001/
∂ ZENITH 500MG N83180 001

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE
AB FLEMINGTON 10MG N72781 001
JUL 30, 1993

TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
BC MILES 30MG N20198 001
APR 21, 1993
BC 60MG N20198 002
APR 21, 1993
BC 90MG N20198 003
APR 21, 1993

PROCARDIA XL
BC + PFIZER 30MG N19684 001
SEP 06, 1989
BC + 60MG N19684 002
SEP 06, 1989
BC + 90MG N19684 003
SEP 06, 1989
/+/ /30MG/ /N19684/001/
/SEP/06,/1989/
/+/ /60MG/ /N19684/002/
/SEP/06,/1989/
/+/ /90MG/ /N19684/003/
/SEP/06,/1989/

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN
/AB/ /ZENITH/ /50MG/ /N80078/002/
/AB/ /100MG/ /N80078/001/
∂ ZENITH 50MG N80078 002
∂ 100MG N80078 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN
AB ZENITH 50MG N73671 001
JAN 28, 1993
AB 100MG N73652 001
JAN 28, 1993

NITROGLYCERIN

INJECTABLE; INJECTION
NITRO-BID
/MARION/MERRELL/DOW/ /10MG/ML/ /N71159/001/
/FEB/28,/1990/
∂ MARION MERRELL DOW 10MG/ML N71159 001
FEB 28, 1990

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
AB MYLAN EQ 10MG BASE N74234 001
JUL 26, 1993
AB EQ 25MG BASE N74234 002
JUL 26, 1993
AB EQ 50MG BASE N74234 003
JUL 26, 1993
AB EQ 75MG BASE N74234 004
JUL 26, 1993

NYSTATIN

CREAM; TOPICAL
NYSTATIN
AT BARRE 100,000 UNITS/GM N62949 001
JUN 13, 1988
/AT/ /NASKA/ /100,000 UNITS/GM/ /N62949/001/
/JUN/13,/1988/
AT TARO 100,000 UNITS/GM N64022 001
JAN 29, 1993

OINTMENT; TOPICAL
NYSTATIN
AT BARRE 100,000 UNITS/GM N62840 001
NOV 13, 1987
/AT/ /NASKA/ /100,000 UNITS/GM/ /N62840/001/
/NOV/13,/1987/

NYSTATIN

POWDER; ORAL

/AA/	/BARSTATIN 100/ /BARLAN/	/100%/	/N62489/001/ /APR/27,/1988/
	@ BARLAN	100%	N62489 001 APR 27, 1988

SUSPENSION; ORAL

	MYCOSTATIN		
AA	APOTHECON	100,000 UNITS/ML	N61533 001
/AA/	/BRISTOL/MYERS/SQUIBB/	/100,000 UNITS/ML/	/N61533/001/
	NYSTATIN		
AA	BARRE	100,000 UNITS/ML	N62571 001 OCT 29, 1985
/AA/	/NASKA/	/100,000 UNITS/ML/	/N62571/001/ /OCT/29,/1985/
> ADD > AA	PENNEX PHARMS	100,000 UNITS/ML	N62512 001 OCT 29, 1984
> ADD >	@	100,000 UNITS/ML	N62835 001 NOV 19, 1987
> DLT >/AA/	/PHARM/BASICS/	/100,000 UNITS/ML/	/N62512/001/ /OCT/29,/1984/
> DLT >			/N62835/001/
> DLT >/AA/		/100,000 UNITS/ML/	/NOV/19,/1987/
> DLT >			/N62518/001/
/AA/	/PHARMADERM/	/100,000 UNITS/ML/	/JUL/06,/1984/
	@ PHARMADERM	100,000 UNITS/ML	N62518 001 JUL 06, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE		
AT	BARRE	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988
/AT/	/NASKA/	/100,000 UNITS/GM;0.1%/	/N63010/001/ /DEC/20,/1988/
	NYSTATIN-TRIAMCINOLONE ACETONIDE		
/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.1%/	/N62596/001/ /OCT/08,/1985/
	@ PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001 OCT 08, 1985

OINTMENT; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE		
AT	TARO	100,000 UNITS/GM;0.1%	N63305 001 MAR 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

	SANDOSTATIN		
/SANDOZ/		/EQ/50UGM/BASE/ML/	/N19667/001/ /OCT/21,/1988/
	SANDOZ	EQ 0.05MG BASE/ML	N19667 001 OCT 21, 1988
		/EQ/100UGM/BASE/ML/	/N19667/002/ /OCT/21,/1988/
		EQ 0.1MG BASE/ML	N19667 002 OCT 21, 1988
		EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
		/EQ/500UGM/BASE/ML/	/N19667/003/ /OCT/21,/1988/
		EQ 0.5MG BASE/ML	N19667 003 OCT 21, 1988
		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

	OCUFLOX		
+	ALLERGAN	0.3%	N19921 001 JUL 30, 1993

OXACILLIN SODIUM

CAPSULE; ORAL

	PROSTAPHLIN		
> ADD > AB	APOTHECON	EQ 250MG BASE	N61450 002
> ADD > AB		EQ 500MG BASE	N61450 001
> DLT >/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61450/002/
> DLT >/AB/		/EQ 500MG BASE/	/N61450/001/

POWDER FOR RECONSTITUTION; ORAL

	PROSTAPHLIN		
> ADD > AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001
> DLT >/AA/	/BRISTOL/	/EQ 250MG BASE/5ML/	/N61457/001/

OXPRENOLOL HYDROCHLORIDE

/CAPSULE;ORAL/
/TRASICOR/
/+//CIBA/

/160MG/	/N18166/004/ /DEC/28,/1983/
/20MG/	/N18166/001/ /DEC/28,/1983/
/40MG/	/N18166/002/ /DEC/28,/1983/
/80MG/	/N18166/003/ /DEC/28,/1983/
∂ CIBA 20MG	N18166 001 DEC 28, 1983
∂ 40MG	N18166 002 DEC 28, 1983
∂ 80MG	N18166 003 DEC 28, 1983
∂ 160MG	N18166 004 DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL

>DLT >/AA/ /PARKE/DAVIS/	/100MG/5ML/	/N09268/012/ /NOV/27,/1984/
>DLT >		
>ADD > PARKE DAVIS	100MG/5ML	N09268 012 NOV 27, 1984
>ADD >		
>DLT > /OXTRIPHYLLINE/		
>DLT >/AA/ /PHARM/BASICS/	/100MG/5ML/	/N88243/001/ /DEC/05,/1983/
>DLT >		
>ADD > ∂ PENNEX PHARMS	100MG/5ML	N88243 001 DEC 05, 1983
>ADD >		

SYRUP; ORAL
CHOLEDYL

>DLT >/AA/ /PARKE/DAVIS/	/50MG/5ML/	/N09268/011/
>ADD > PARKE DAVIS	50MG/5ML	N09268 011
>DLT > /OXTRIPHYLLINE PEDIATRIC/		
>DLT >/AA/ /PHARM/BASICS/	/50MG/5ML/	/N88242/001/ /DEC/05,/1983/
>DLT >		
>ADD > ∂ PENNEX PHARMS	50MG/5ML	N88242 001 DEC 05, 1983
>ADD >		

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA

+ CIBA GEIGY	60MG/VIAL	N20036 003 MAY 06, 1993
+	90MG/VIAL	N20036 004 MAY 06, 1993

PARAMETHASONE ACETATE

TABLET; ORAL
HALDRONE

/+//LILLY/	/2MG/	/N12772/006/
	/1MG/	/N12772/005/
∂ LILLY	1MG	N12772 005
∂	2MG	N12772 006

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL

/+//SMITHKLINE/BEECHAM/	/EQ/10MG/BASE/	/N20031/001/ /DEC/29,/1992/
/+/	/EQ/50MG/BASE/	/N20031/004/ /DEC/29,/1992/
∂ SMITHKLINE BEECHAM	EQ 10MG BASE	N20031 001 DEC 29, 1992
	/EQ/40MG/BASE/	/N20031/005/ /DEC/29,/1992/
∂	EQ 40MG BASE	N20031 005 DEC 29, 1992
∂	EQ 50MG BASE	N20031 004 DEC 29, 1992

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION
BICILLIN L-A

/+//WYETH/AYERST/	/300,000/UNITS/ML/	/N50131/001/
+ WYETH AYERST	300,000 UNITS/ML	N50141 003
∂	300,000 UNITS/ML	N50131 001
	/300,000/UNITS/ML/	/N50141/003/

/TABLET;ORAL/
/BICILLIN/

/+//WYETH/AYERST/	/200,000/UNITS/	/N50128/001/
∂ WYETH AYERST	200,000 UNITS	N50128 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	PENICILLIN			
/AA/	/BIOCRAFT/	/200,000 UNITS/5ML/	/N60307/002/	
	BIOCRAFT	200,000 UNITS/5ML	N60307 002	
	/PENTIDS '200'/			
/AA/	/SQUIBB/	/200,000 UNITS/5ML/	/N62149/001/	
	@ APOTHECON	200,000 UNITS/5ML	N62149 001	
	/PENTIDS '400'/			
/AA/	/SQUIBB/	/400,000 UNITS/5ML/	/N62149/002/	
	@ APOTHECON	400,000 UNITS/5ML	N62149 002	

TABLET; ORAL

	PENICILLIN G POTASSIUM			
	@ APOTHECON	250,000 UNITS	N60392 003	
/AB/	/SQUIBB/	/250,000 UNITS/	/N60392/003/	
	/PENTIDS '200'/			
/AB/	/SQUIBB/	/200,000 UNITS/	/N62155/001/	
	@ APOTHECON	200,000 UNITS	N62155 001	
	/PENTIDS '250'/			
/AB/	/SQUIBB/	/250,000 UNITS/	/N62155/002/	
	@ APOTHECON	250,000 UNITS	N62155 002	
	/PENTIDS '400'/			
/AB/	/SQUIBB/	/400,000 UNITS/	/N60392/004/	
/AB/		/400,000 UNITS/	/N62155/003/	
	@ APOTHECON	400,000 UNITS	N60392 004	
	@	400,000 UNITS	N62155 003	
	/PENTIDS '800'/			
/AB/	/SQUIBB/	/800,000 UNITS/	/N60392/005/	
/AB/		/800,000 UNITS/	/N62155/004/	
	@ APOTHECON	800,000 UNITS	N60392 005	
	@	800,000 UNITS	N62155 004	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	/DURACILLIN A.S./			
/AP/	/LILLY/	/300,000 UNITS/ML/	/N60093/001/	
	@ LILLY	300,000 UNITS/ML	N60093 001	

PENICILLIN V

>_DLT_>	/POWDER/FOR/RECONSTITUTION;/ORAL/			
>_DLT_>	/V-CILLIN/			
>_DLT_>	/+//LILLY/	/125MG/0.6ML/	/N60002/001/	
>_ADD_>	@ LILLY	125MG/0.6ML	N60002 001	

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	/VEETIDS '125'/			
/AA/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N61206/001/	
/AA/		/EQ 125MG BASE/5ML/	/N62153/001/	
	@ APOTHECON	EQ 125MG BASE/5ML	N61206 001	
	@	EQ 125MG BASE/5ML	N62153 001	
	/VEETIDS '250'/			
/AA/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N61206/002/	
/AA/		/EQ 250MG BASE/5ML/	/N62153/002/	
	@ APOTHECON	EQ 250MG BASE/5ML	N61206 002	
	@	EQ 250MG BASE/5ML	N62153 002	

TABLET; ORAL

	BETAPEN-VK			
>_ADD_> AB	APOTHECON	EQ 250MG BASE	N61411 001	
>_ADD_> AB		EQ 500MG BASE	N61411 002	
>_DLT_>/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61411/001/	
>_DLT_>/AB/		/EQ 500MG BASE/	/N61411/002/	
	/VEETIDS '250'/			
/AB/	/SQUIBB/	/EQ 250MG BASE/	/N61164/001/	
/AB/		/EQ 250MG BASE/	/N62156/002/	
	@ APOTHECON	EQ 250MG BASE	N61164 001	
	@	EQ 250MG BASE	N62156 002	
	/VEETIDS '500'/			
/AB/	/SQUIBB/	/EQ 500MG BASE/	/N61164/002/	
/AB/		/EQ 500MG BASE/	/N62156/001/	
	@ APOTHECON	EQ 500MG BASE	N61164 002	
	@	EQ 500MG BASE	N62156 001	

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

>_DLT_>	/PENTOBARBITAL SODIUM/			
>_DLT_>/AP/	/ELKINS/SINN/	/50MG/ML/	/N83270/001/	
>_ADD_>	@ ELKINS SINN	50MG/ML	N83270 001	

>_ADD_> PERFLUBRON

>_ADD_>	LIQUID; ORAL		
>_ADD_>	IMAGENT		
>_ADD_>	+ ALLIANCE PHARM	100%	N20091 001
>_ADD_>			AUG 13, 1993

PERMETHRIN

/LOTION;/TOPICAL/
/NIX/
/AT//+//BURROUGHS/WELLCOME/ /1%/ /N19435/001/
/MAR/31,/1986/
@ BURROUGHS WELLCOME 1% N19435 001
MAR 31, 1986

PERPHENAZINE

/TABLET;/EXTENDED/RELEASE;/ORAL/
/TRILAFON/
/+//SCHERING/ /8MG/ /N11361/002/
@ SCHERING 8MG N11361 002

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
/STATOBEX/
/AA/ /LEMMON/ /35MG/ /N85507/001/
@ LEMMON 35MG N85507 001

TABLET; ORAL
/ADPHEN/
/AA/ /FERNDALE/ /35MG/ /N83655/001/
@ FERNDALE 35MG N83655 001
/METRA/
/AA/ /FOREST/PHARMS/ /35MG/ /N83754/001/
@ FOREST PHARMS 35MG N83754 001

PHENDIMETRAZINE TARTRATE
/AA/ /ANABOLICS/ /35MG/ /N86020/001/
@ ANABOLICS 35MG N86020 001
/AA/ /FERNDALE/ /35MG/ /N86834/001/
/SEP/15,/1983/
@ FERNDALE 35MG N86834 001
SEP 15, 1983

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
ADIPEX-P
/AA/ /LEMMON/ /30MG/ /N86911/001/
/OBESTIN-30/
/AA/ /FERNDALE/ /30MG/ /N87144/001/
@ FERNDALE 30MG N87144 001

PHENTERMINE HCL
@ LEMMON 30MG N86911 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL
/AA/ /ZENITH/ /30MG/ /N86329/001/
@ ZENITH 30MG N86329 001

PHENYLBUTAZONE

CAPSULE; ORAL
PHENYLBUTAZONE
/AB/ /CHELSEA/ /100MG/ /N87756/001/
/DEC/17,/1982/
B* CHELSEA 100MG N87756 001
DEC 17, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC PLAIN
@ PENNEX PHARMS 5MG/5ML;6.25MG/5ML N88897 001
JAN 04, 1985
> ADD >
> ADD >
> DLT >/AA/ /PHARM/BASICS/ /5MG/5ML;6.25MG/5ML/ /N88897/001/
> DLT > /JAN/04,/1985/

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
/BP/ /MSD/ /10MG/ML/ /N12223/001/
BP + MSD 10MG/ML N12223 001
KONAKION
/BP/+//ROCHE/ /10MG/ML/ /N11745/003/
BP ROCHE 10MG/ML N11745 003

PINDOLOL

TABLET; ORAL
PINDOLOL
AB GENEVA 5MG N73608 001
MAR 29, 1993
AB 10MG N73609 001
MAR 29, 1993
AB PUREPAC 5MG N74125 001
APR 28, 1993
AB 10MG N74125 002
APR 28, 1993

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	ZENITH	5MG	N73687 001 FEB 26, 1993
AB		10MG	N73687 002 FEB 26, 1993

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	MEPHA AG	10MG	N74116 001 JUN 15, 1993
AB		20MG	N74118 001 JUN 15, 1993
AB	MUTUAL PHARM	10MG	N73535 001 MAR 12, 1993
AB		20MG	N73536 001 MAR 12, 1993
AB	ROXANE	10MG	N73651 001 FEB 26, 1993
AB		20MG	N73651 002 FEB 26, 1993

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
PEG-LYTE

> ADD >	AA	INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993
> ADD >				
> ADD >				

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE

/AB/	/ADRIA/	/8MEQ/	/N73398/001/ /JAN/28/1992/
/AB/		/10 MEQ/	/N72427/001/ /MAR/28/1990/
AB	SAVAGE	8MEQ	N73398 001 JAN 28, 1992
AB		10 MEQ	N72427 001 MAR 28, 1990

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N84290 001
AP		2MEQ/ML	N87787 001 APR 20, 1982
/AP/	/LUITPOLD/	/2MEQ/ML/	/N80221/001/
/AP/		/2MEQ/ML/	/N80736/001/
∂	LUITPOLD	2MEQ/ML	N80221 001
∂		2MEQ/ML	N80736 001
/AP/	/LYPHOMED/	/2MEQ/ML/	/N84296/001/
/AP/		/2MEQ/ML/	/N87787/001/ /APR/20/1982/

TABLET, EXTENDED RELEASE; ORAL
K+8

AB	ALRA	8MEQ	N70998 001 JAN 25, 1993
	KAON CL /ADRIA/	/6.7MEQ/	/N17046/001/
	SAVAGE	6.7MEQ	N17046 001
	KAON CL-10		
/BC/	/ADRIA/	/10MEQ/	/N17046/002/
BC	SAVAGE	10MEQ	N17046 002

POTASSIUM CITRATE

/POWDER/FOR/RECONSTITUTION;/ORAL/
/POTASSIUM/CITRATE/

/+//UNIV/TX/		/20MEQ/PACKET/	/N19647/001/ /OCT/13/1988/
		/10MEQ/PACKET/	/N19647/002/ /OCT/13/1988/
∂	UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988
∂		20MEQ/PACKET	N19647 001 OCT 13, 1988

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

/+//UNIV/TX/		/5MEQ/	/N19071/001/ /AUG/30/1985/
+	UNIV TX	10MEQ	N19071 002 AUG 31, 1992
		5MEQ	N19071 001 AUG 30, 1985

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL
/+//BRISTOL/MYERS/SQUIBB/20MG/ /N19898/003/ /OCT/31,/1991/
+ BRISTOL MYERS SQUIBB 40MG N19898 004 MAR 22, 1993
20MG N19898 003 OCT 31, 1991

PRAZEPAM

/TABLET;/ORAL/
/CENTRAX/
/+//PARKE/DAVIS/ /10MG/ /N17415/001/
@ PARKE DAVIS 10MG N17415 001

PREDNICARBATE

OINTMENT; TOPICAL
/DERMATOP/
/HOECHST/ROUSSEL/ /0.1%/ /N19568/001/ /SEP/23,/1991/
@ HOECHST ROUSSEL 0.1% N19568 001 SEP 23, 1991

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE
/BX/ /WEST/WARD/ /5MG/ /N80324/001/
@ WEST WARD 5MG N80324 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
>ADD> CETAPRED
>ADD> ALCON 0.25%;10% N87771 001 AUG 06, 1993
>ADD>

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
AT STERIS EQ 0.23% PHOSPHATE;10% N73630 001 MAY 27, 1993

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
VASOCIDIN
AT IOLAB EQ 0.23% PHOSPHATE;10% N18988 001 AUG 26, 1988

PREDNISONE

SOLUTION; ORAL
PREDNISONE
>ADD> @ PENNEX PHARMS 5MG/5ML N89726 001 AUG 02, 1988
>ADD>
>DLT> /AA/ /PHARM/BASICS/ /5MG/5ML/ /N89726/001/ /AUG/02,/1988/
>DLT>
>DLT> /AA/ /ROXANE/ /5MG/5ML/ /N88703/001/ /NOV/08,/1984/
>DLT>
>ADD> ROXANE 5MG/5ML N88703 001 NOV 08, 1984
>ADD>

TABLET; ORAL
DELTASONE
AB UPJOHN 2.5MG N09986 005
/BX/ /2.5MG/ /N09986/005/
PREDNISONE
/AA/ /HEATHER/ /10MG/ /N84341/001/
>DLT> /AB/ /20MG/ /N84417/001/
/AB/ /20MG/ /N85543/001/
/AB/ /50MG/ /N86946/001/
@ HEATHER 10MG N84341 001
>ADD> @ 20MG N84417 001
@ 20MG N85543 001
@ 50MG N86946 001
/BX/ /KV/ /5MG/ /N84236/001/
@ KV 5MG N84236 001
BX NYLOS TRADING 5MG N85115 001
/BX/ /TABLICAPS/ /5MG/ /N85115/001/
/BX/ /UPSHER/SMITH/ /5MG/ /N87471/001/
/BX/ /20MG/ /N87470/001/
@ UPSHER SMITH 5MG N87471 001
@ 20MG N87470 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL
PRONESTYL
>ADD> AB APOTHECON 250MG N07335 001
>ADD> AB 375MG N07335 004
>ADD> AB + 500MG N07335 003

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PRONESTYL

>DLT >/AB/	/SQUIBB/	/250MG/	/N07335/001/	
>DLT >/AB/		/375MG/	/N07335/004/	
>DLT >/AB//+/		/500MG/	/N07335/003/	

INJECTABLE; INJECTION

PROCAINAMIDE HCL

/AP/	/LYPHOMED/	/100MG/ML/	/N89415/001/	
/AP/		/500MG/ML/	/N89416/001/	
ə LYPHOMED		100MG/ML	N89415 001 NOV 17, 1986	
ə		500MG/ML	N89416 001 NOV 17, 1986	

PRONESTYL

>ADD > AP +	APOTHECON	100MG/ML	N07335 002	
>ADD > AP +		500MG/ML	N07335 005	
>DLT >/AP/	/SQUIBB/	/100MG/ML/	/N07335/002/	
>DLT >/AP/		/500MG/ML/	/N07335/005/	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

/AP/	/BEL/MAR/	/1%/	/N80711/001/	
/AP/		/2%/	/N80756/001/	
ə BEL MAR		1%	N80711 001	
ə		2%	N80756 001	

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

PROCHLORPERAZINE EDISYLATE

>ADD >	ə PENNEX PHARMS	EQ 10MG BASE/ML	N88598 001 OCT 25, 1984	
>ADD > >DLT > >DLT >	/ə/PHARM/BASICS/	/EQ/10MG/BASE/ML/	/N88598/001/ /OCT/25,/1984/	

SYRUP; ORAL

PROCHLORPERAZINE EDISYLATE

>ADD >	ə PENNEX PHARMS	EQ 5MG BASE/5ML	N88597 001 OCT 25, 1984	
>ADD > >DLT > >DLT >	/ə/PHARM/BASICS/	/EQ/5MG/BASE/5ML/	/N88597/001/ /OCT/25,/1984/	

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

/BURROUGHS/WELLCOME/	/2MG/	/N09818/005/	
ə BURROUGHS WELLCOME	2MG	N09818 005	

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHACON

/BR/	/ALCON/	/25MG/	/N84901/001/	
/BR/		/50MG/	/N84902/001/	
BR	POLYMEDICA	25MG	N84901 001	
BR		50MG	N84902 001	

SYRUP; ORAL

PROMETHAZINE PLAIN

	ə PENNEX PHARMS	6.25MG/5ML	N87953 001 NOV 15, 1982	
>ADD > >ADD > >DLT >/AA/ >DLT >	/PHARM/BASICS/	/6.25MG/5ML/	/N87953/001/ /NOV/15,/1982/	

TABLET; ORAL

PROMETHAZINE HCL

/BP/	/CIRCA/	/25MG/	/N83204/001/	
	ə CIRCA	25MG	N83204 001	
/BP/	/ZENITH/	/50MG/	/N83613/001/	
	ə ZENITH	50MG	N83613 001	

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

	/ICI/	/10MG/ML/	/N19627/001/ /OCT/02,/1989/	
	+ ZENECA	10MG/ML	N19627 001 OCT 02, 1989	

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL

PROPRANOLOL HCL

>ADD >	ə PENNEX PHARMS	20MG/5ML	N71984 001 MAR 03, 1989	
>ADD > >ADD > >ADD >	ə	40MG/5ML	N71985 001 MAR 03, 1989	

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
PROPRANOLOL HCL

>DLT>	/S/PHARM/BASICS/	/20MG/5ML/	/N71984/001/	/MAR/03,/1989/
>DLT>				
>DLT>	/S/	/40MG/5ML/	/N71985/001/	/MAR/03,/1989/
>DLT>				

/SUSPENSION;/ORAL/
/INDERAL/

	/WYETH/AYERST/	/10MG/ML/	/N19536/001/ /DEC/12,/1986/
	ə WYETH AYERST	10MG/ML	N19536 001 DEC 12, 1986

TABLET; ORAL
PROPRANOLOL HCL

/AB/	/MYLAN/	/60MG/	/N72275/001/ /JUN/09,/1989/
	ə MYLAN	60MG	N72275 001 JUN 09, 1989

PROPYLIODONE

/SUSPENSION;/INTRATRACHEAL/
/DIONOSIL/OILY/

	/GLAXO/	/60%/	/N09309/002/
	ə GLAXO	60%	N09309 002

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/AP/	/QUAD/	/10MG/ML/	/N89306/001/	/MAY/30,/1986/
	ə QUAD	10MG/ML	N89306 001	MAY 30, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
/HISTAFED/

/AA/	/LIFE/LABS/	/30MG/5ML;1.25MG/5ML/	/N88283/001/	/APR/20,/1984/
	ə CENCI	30MG/5ML;1.25MG/5ML	N88283 001	APR 20, 1984

PYRANTEL PAMOATE

/SUSPENSION;/ORAL/
/ANTIMINTH/

	/*//ROERIG/	/EQ/250MG/BASE/5ML/	/N16883/001/

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

/AP/	/ICN/	/5MG/ML/	/N09830/001/
AP	ROCHE	5MG/ML	N09830 001

SYRUP; ORAL
MESTINON

/ICN/	/60MG/5ML/	/N15193/001/
ROCHE	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

/*//ICN/	/60MG/	/N09829/002/
+ ROCHE	60MG	N09829 002

TABLET, EXTENDED RELEASE; ORAL
MESTINON

/*//ICN/	/180MG/	/N11665/001/
+ ROCHE	180MG	N11665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
/HEXA-BETALIN/

/AP/	/LILLY/	/100MG/ML/	/N80854/001/
	ə LILLY	100MG/ML	N80854 001

PYRIDOXINE HCL

/AP/	/BEL/MAR/	/100MG/ML/	/N80761/001/
	ə BEL MAR	100MG/ML	N80761 001
AP	FUJISAWA	100MG/ML	N80618 001
/AP/	/LYPHOMED/	/100MG/ML/	/N80618/001/

QUAZEPAM

TABLET; ORAL
DORAL
/+//BAKER/NORTON/ /15MG/ /N18708/001/ /DEC/27,/1985/
/7.5MG/ /N18708/003/ /FEB/26,/1987/
+ WALLACE 15MG N18708 001 DEC 27, 1985
7.5MG N18708 003 FEB 26, 1987

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
/DURAQUIN/
/PARKE/DAVIS/ /330MG/ /N17917/001/
@ WARNER CHILCOTT 330MG N17917 001

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
/AB/ /PARKE/DAVIS/ /200MG/ /N83879/001/
@ WARNER CHILCOTT 200MG N83879 001

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUDIXIN
>ADD> BP APOTHECON 50MG N08842 001
>ADD> BP + 100MG N08842 002
>DLT> /BP/ /SQUIBB/ /50MG/ /N088842/001/
>DLT> /BP/+/ /100MG/ /N088842/002/

RESERPINE

TABLET; ORAL
RESERPINE
/BP/ /LEMMON/ /0.1MG/ /N89020/001/ /MAR/07,/1985/
/BP/ /0.25MG/ /N89019/001/ /MAR/07,/1985/
@ LEMMON 0.1MG N89020 001 MAR 07, 1985
@ 0.25MG N89019 001 MAR 07, 1985

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
/NAQUIVAL/
/BP/+//SCHERING/ /0.1MG;4MG/ /N12265/003/
@ SCHERING 0.1MG;4MG N12265 003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
/AP/ /QUAD/ /10MG/ML/ /N070700/001/ /OCT/06,/1986/
@ QUAD 10MG/ML N70700 001 OCT 06, 1986

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
>ADD> @ PENNEX PHARMS 2.5% N88228 001 SEP 01, 1983
>ADD>
>DLT> /AT/ /PHARM/BASICS/ /2.5%/ /N088228/001/ /SEP/01,/1983/
>DLT>

SERACTIDE ACETATE

/INJECTABLE;/INJECTION/
/ACTHAR/GEL-SYNTHETIC/
/ARMOUR/ /40/UNITS/ML/ /N17861/001/
/80/UNITS/ML/ /N17861/002/
@ ARMOUR 40 UNITS/ML N17861 001
@ 80 UNITS/ML N17861 002

SILVER SULFADIAZINE

/DRESSING;/TOPICAL/
/SILDIMAC/
@ BIOPLASTY 1% N19608 001 NOV 30, 1989
/SILDIMAC/
/ENQUAY/ /1%/ /N19608/001/ /NOV/30,/1989/

SODIUM BICARBONATE

/INJECTABLE;/INJECTION/
/SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/

	/ABBOTT/	/0.9MEQ/ML/	/N19443/001/
			/JUN/03,/1986/
		/1MEQ/ML/	/N19443/002/
			/JUN/03,/1986/
	@ ABBOTT	0.9MEQ/ML	N19443 001 JUN 03, 1986
	@	1MEQ/ML	N19443 002 JUN 03, 1986

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	FUJISAWA	9MG/ML	N88911 001 FEB 07, 1985
/AP/	/LYPHOMED/	/9MG/ML/	/N88911/001/ /FEB/07,/1985/

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

	@ FUJISAWA	234MG/ML	N19329 001 APR 22, 1987
	/@/LYPHOMED/	/234MG/ML/	/N19329/001/ /APR/22,/1987/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

	/SQUIBB/	/2MCI/VIAL/	/N13993/002/
	@ SQUIBB	2MCI/VIAL	N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131

	/@/CIS/	/50/UCI/	/N17316/001/
	@ CIS	50 UCI	N17316 001
		/100/UCI/	/N17316/002/
		100 UCI	N17316 002

SOLUTION; ORAL
SODIUM IODIDE I 131

	/CIS/	/50MCI/ML/	/N17315/001/
	CIS	50MCI/ML	N17315 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

>ADD>	@ PENNEX PHARMS	453.6GM/BOT		N88786 001 SEP 11, 1984
>ADD>				
>DLT>/AA/	/PHARM/BASICS/	/453.6GM/BOT/		/N88786/001/ /SEP/11,/1984/
>DLT>				

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

>ADD>	@ PENNEX PHARMS	15GM/60ML	N88717 001 SEP 11, 1984
>ADD>			
>DLT>/AA/	/PHARM/BASICS/	/15GM/60ML/	/N88717/001/ /SEP/11,/1984/
>DLT>			

SOYBEAN OIL

INJECTABLE; INJECTION
NUTRILIPID 10%

AP	MCGAW	10%	N19531 001 MAY 28, 1993

NUTRILIPID 20%

AP	MCGAW	20%	N19531 002 MAY 28, 1993

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

/AB/	/CHELSEA/	/25MG/	/N87078/001/
B*	CHELSEA	25MG	N87078 001
/AB/	/UPSHER/SMITH/	/25MG/	/N87554/001/
	@ UPSHER SMITH	25MG	N87554 001

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON

	MEDI PHYSICS	1MCI/ML	N20134 001 JUN 18, 1993

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE

	/ABBOTT/	/300MG/	/N04125/005/
	@ ABBOTT	300MG	N04125 005

SULFAMETHIZOLE

TABLET; ORAL
THIOSULFIL
/WYETH/AYERST/ /250MG/ /N008565/001/
@ WYETH AYERST 250MG N08565 001

SULFAMETHOXAZOLE

TABLET; ORAL
/GANTANOL-DS/
/ROCHE/ /1GM/ /N012715/003/
@ ROCHE 1GM N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

AB	BARRE	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988
AB		200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988
/AB/	/NASKA/	/200MG/5ML;40MG/5ML/	/N072289/001/ /MAY/23,/1988/
/AB/		/200MG/5ML;40MG/5ML/	/N072398/001/ /MAY/23,/1988/

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
/AB/ /HEATHER/ /500MG/ /N080189/001/
@ HEATHER 500MG N80189 001

SULFISOXAZOLE ACETYL

/EMULSION;ORAL/
/LIPO/GANTRISIN/
/ROCHE/ /EQ/1GM/BASE/5ML/ /N009182/009/
@ ROCHE EQ 1GM BASE/5ML N09182 009

SULFISOXAZOLE DIOLAMINE

/OINTMENT;OPHTHALMIC/
/GANTRISIN/
/ROCHE/ /EQ/4%/BASE/ /N008414/002/
@ ROCHE EQ 4% BASE N08414 002

SULINDAC

TABLET; ORAL
SULINDAC

AB	MYLAN	150MG	N73038 001 JUN 22, 1993
AB		200MG	N73039 001 JUN 22, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
/+//STUART/ /EQ/10MG/BASE/ /N017970/001/
+ ZENECA EQ 10MG BASE N17970 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
/A-N/STANNOUS/AGGREGATED/ALBUMIN/
/BS/ /NORTH/AM/CHEM/ /N/A/ /N017916/001/
@ NORTH AM CHEM N/A N17916 001

AN-MAA
BS SORIN N/A N17792 001
/N/A/ /N017792/001/
/TECHNETIUM/TC/99M/MAA/
/BS/ /MEDI/PHYSICS/ /N/A/ /N017773/001/
@ MEDI PHYSICS N/A N17773 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
> DLT > /AMERSCAN MDP KIT/
> DLT > /AB/ /AMERSHAM/ /N/A/ /N018335/001/
> DLT > /AUG/05,/1982/
> ADD > @ AMERSHAM N/A N18335 001
> ADD > AUG 05, 1982

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
/MINITEC/
/SQUIBB/ /0.22-2.22CI/GENERATOR/ /N017339/001/
@ SQUIBB 0.22-2.22CI/GENERATOR N17339 001

TEMAZEPAM

CAPSULE; ORAL

	TEMAZEPAM		
AB	DANBURY PHARMA	15MG	N71446 001 MAY 21, 1993
AB		30MG	N71447 001 MAY 21, 1993

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

	TESTOSTERONE PROPIONATE		
/AO/	/BEL/MAR/	/25MG/ML/	/N80741/001/
/AO/		/50MG/ML/	/N80742/001/
/AO/		/100MG/ML/	/N80743/001/
	@ BEL MAR	25MG/ML	N80741 001
	@	50MG/ML	N80742 001
	@	100MG/ML	N80743 001
/AO/	/STERIS/	/25MG/ML/	/N80188/001/
/AO/		/25MG/ML/	/N85490/001/
/AO/		/100MG/ML/	/N80188/003/
/AO/		/100MG/ML/	/N83595/003/
	+ STERIS	25MG/ML	N80188 001
	+	100MG/ML	N80188 003
		25MG/ML	N85490 001
		100MG/ML	N83595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL		
>DLT >/AB/	/ICN/	/250MG/	/N60471/001/
>ADD >	@ ICN	250MG	N60471 001

TABLET; ORAL

	SUMYCIN		
AB	APOTHECON	50MG	N61147 003
AB		100MG	N61147 002
AB		250MG	N61147 001
AB	+	500MG	N61147 004
/AB/	/SQUIBB/	/50MG/	/N61147/003/
/AB/		/100MG/	/N61147/002/
/AB/		/250MG/	/N61147/001/
/AB/		/500MG/	/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

	THALLOUS CHLORIDE TL 201		
/AF/	/SQUIBB/	/1MCI/ML/	/N18548/001/ /DEC/30,/1982/
	@ SQUIBB	1MCI/ML	N18548 001 DEC 30, 1982

THEOPHYLLINE

ELIXIR; ORAL

	/THEOPHYL-225/ /JOHNSON/RW/	/112.5MG/15ML/	/N86485/001/
	@ JOHNSON RW	112.5MG/15ML	N86485 001
	THEOPHYLLINE		
AA	BARRE	80MG/15ML	N89223 001 MAY 27, 1988
/AA/	/NASKA/	/80MG/15ML/	/N89223/001/ /MAY/27,/1988/
>ADD > AA	PENNEX PHARMS	80MG/15ML	N86748 001
>DLT >/AA/	/PHARM/BASICS/	/80MG/15ML/	/N86748/001/

TABLET; ORAL

	QUIBRON-T /+//BRISTOL/MYERS/	/300MG/	/N88656/001/ /AUG/22,/1985/
	+ ROBERTS	300MG	N88656 001 AUG 22, 1985
	/THEOPHYL-225/ /JOHNSON/RW/	/225MG/	/N84726/001/
	@ JOHNSON RW	225MG	N84726 001
	/TABLET,/CHEWABLE;/ORAL/ /THEOPHYL/ /JOHNSON/RW/	/100MG/	/N86506/001/ /SEP/12,/1985/
	@ JOHNSON RW	100MG	N86506 001 SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR		
/BC/	/BRISTOL/MYERS/	/300MG/	/N87563/001/ /JUN/21,/1983/
BC	ROBERTS	300MG	N87563 001 JUN 21, 1983

THEOPHYLLINE SODIUM GLYCINATE

/ELIXIR;/ORAL/
/SYNOPHYLATE/
/CENTRAL/PHARMS/ /EQ/165MG/BASE/15ML/ /N06333/008/
∂ CENTRAL PHARMS EQ 165MG BASE/15ML N06333 008

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

/AP/	/BEL/MAR/	/100MG/ML/	/N80718/001/
/AP/		/200MG/ML/	/N80712/001/
	∂ BEL MAR	100MG/ML	N80718 001
	∂	200MG/ML	N80712 001
AP	FUJISAWA	100MG/ML	N80556 001
/AP/	/LYPHOMED/	/100MG/ML/	/N80556/001/
/AP/	/STERIS/	/200MG/ML/	/N80571/002/
/AP/		/200MG/ML/	/N83534/002/
	+ STERIS	200MG/ML	N80571 002
		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

>ADD >	∂ PENNEX PHARMS	30MG/ML	N88258 001 JUL 25, 1983
>ADD >			
>ADD >	∂	100MG/ML	N88227 001 JUL 05, 1983
>ADD >			
>DLT >/AA/	/PHARM/BASICS/	/30MG/ML/	/N88258/001/ /JUL/25,/1983/
>DLT >			
>DLT >/AA/		/100MG/ML/	/N88227/001/ /JUL/05,/1983/
>DLT >			

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

/AB/	/PAR/	/10MG/	/N88351/001/ /DEC/05,/1983/
/AB/		/15MG/	/N88352/001/ /DEC/05,/1983/
/AB/		/25MG/	/N88336/001/ /DEC/05,/1983/
/AB/		/50MG/	/N88322/001/ /DEC/05,/1983/
/AB/		/100MG/	/N88480/001/ /DEC/29,/1983/
	∂ PAR	10MG	N88351 001 DEC 05, 1983
	∂	15MG	N88352 001 DEC 05, 1983
	∂	25MG	N88336 001 DEC 05, 1983
	∂	50MG	N88322 001 DEC 05, 1983
	∂	100MG	N88480 001 DEC 29, 1983
/AB/	/ZENITH/	/100MG/	/N88273/001/ /OCT/03,/1983/
	∂ ZENITH	100MG	N88273 001 OCT 03, 1983

THIOTEPA

INJECTABLE; INJECTION
/THIO-TEPA/
/LEDERLE/ /15MG/VIAL/ /N11683/001/
THIOTEPA
+ LEDERLE 15MG/VIAL N11683 001

TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TICAR

+ SMITHKLINE BEECHAM	EQ 20GM BASE/VIAL	N50497 004
+	EQ 30GM BASE/VIAL	N50497 005 APR 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
+ SYNTEX 250MG N19979 002 OCT 31, 1991
@ 125MG N19979 001 MAR 24, 1993
/250MG/ /N19979/002/ /OCT/31,/1991/

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE
AB NOVOPHARM 5MG N72648 001 JUN 16, 1993
AB 10MG N72649 001 JUN 16, 1993
AB 20MG N72650 001 JUN 16, 1993

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM
AB MYLAN EQ 400MG BASE N73393 001 MAY 27, 1993

>ADD> TORSEMIDE

>ADD> INJECTABLE; INJECTION
>ADD> DEMADEX
>ADD> + BOEHRINGER MANNHEIM 10MG/ML N20137 002 AUG 23, 1993
>ADD>

>ADD> TABLET; ORAL
>ADD> DEMADEX
>ADD> + BOEHRINGER MANNHEIM 100MG N20136 004 AUG 23, 1993
>ADD>
>ADD> 5MG N20136 001 AUG 23, 1993
>ADD>
>ADD> 10MG N20136 002 AUG 23, 1993
>ADD>
>ADD> 20MG N20136 003 AUG 23, 1993
>ADD>

>ADD> TRANYLCYPROMINE SULFATE

>ADD> TABLET; ORAL
>ADD> PARNATE
>ADD> + SKF EQ 10MG BASE N12342 003 AUG 16, 1985
>ADD>

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL
>ADD> AB APOTHECON 50MG N18207 001
>ADD> AB + 100MG N18207 002
>ADD> AB 150MG N18207 003 MAR 25, 1985
>ADD>
>ADD> 300MG N18207 004 NOV 07, 1988
>ADD>
>DLT> /AB/ /BRISTOL/MYERS/ /50MG/ /N18207/001/
>DLT> /AB//+/ /100MG/ /N18207/002/
>DLT> /AB/ /150MG/ /N18207/003/ /MAR/25,/1985/
>DLT>
>DLT> /300MG/ /N18207/004/ /NOV/07,/1988/
>DLT>

TRAZODONE HCL
AB MUTUAL PHARM 50MG N73136 001 MAR 24, 1993
AB 100MG N73137 001 MAR 24, 1993

TRETINOIN

/SWAB;/TOPICAL/
/RETIN-A/
/+//JOHNSON/RW/ /0.05%/ /N16921/002/
@ JOHNSON RW 0.05% N16921 002

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION
AZMACORT
+ RHONE POULENC RORER 0.1MG/INH N18117 001 APR 23, 1982
/+/ /0.25MG/INH/ /N18117/001/ /APR/23,/1982/

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>ADD >		@ PENNEX PHARMS	0.025%	N88094 001 SEP 01, 1983
>ADD >				
>ADD >		@	0.1%	N88095 001 SEP 01, 1983
>ADD >				
>ADD >		@	0.5%	N88096 001 SEP 01, 1983
>ADD >				
>DLT >		/@/PHARM/BASICS/	/0.025%/	/N88094/001/ /SEP/01,/1983/
>DLT >				
>DLT >		/@/	/0.1%/	/N88095/001/ /SEP/01,/1983/
>DLT >				
>DLT >		/@/	/0.5%/	/N88096/001/ /SEP/01,/1983/
>DLT >				
	/AT/	/PHARMADERM/	/0.025%/	/N87990/001/ /JUL/07,/1983/
	/AT/		/0.1%/	/N87991/001/ /JUL/07,/1983/
	/AT/		/0.5%/	/N87992/001/ /JUL/07,/1983/
		@ PHARMADERM	0.025%	N87990 001 JUL 07, 1983
		@	0.1%	N87991 001 JUL 07, 1983
		@	0.5%	N87992 001 JUL 07, 1983

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

>ADD >	AT	PENNEX PHARMS	0.025%	N88450 001 APR 01, 1985
>ADD >				
>ADD >	AT		0.1%	N88451 001 APR 03, 1985
>ADD >				
>DLT >	/AT/	/PHARM/BASICS/	/0.025%/	/N88456/001/ /APR/01,/1985/
>DLT >				
>DLT >	/AT/		/0.1%/	/N88451/001/ /APR/03,/1985/
>DLT >				

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT	BARRE	0.5%	N89913 001 DEC 23, 1988
	/AT/	/NASKA/	/0.5%/	/N89913/001/ /DEC/23,/1988/

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>ADD >		@ PENNEX PHARMS	0.025%	N88090 001 SEP 01, 1983
>ADD >				
>ADD >		@	0.1%	N88091 001 SEP 01, 1983
>ADD >				
>ADD >		@	0.5%	N88092 001 SEP 01, 1983
>ADD >				
>DLT >		/@/PHARM/BASICS/	/0.025%/	/N88090/001/ /SEP/01,/1983/
>DLT >				
>DLT >		/@/	/0.1%/	/N88091/001/ /SEP/01,/1983/
>DLT >				
>DLT >		/@/	/0.5%/	/N88092/001/ /SEP/01,/1983/
>DLT >				
	/AT/	/PHARMADERM/	/0.025%/	/N88692/001/ /AUG/02,/1984/
	/AT/		/0.1%/	/N88690/001/ /AUG/02,/1984/
		@ PHARMADERM	0.025%	N88692 001 AUG 02, 1984
		@	0.1%	N88690 001 AUG 02, 1984

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

/TEP/

/AA/		/GENEVA/	/EQ 10MG BASE/ML/	/N85787/001/ /APR/15,/1982/

TRIFLUOPERAZINE HCL

AA	GENEVA	EQ 10MG BASE/ML	N85787 001 APR 15, 1982

TRIFLUOPERAZINE HCL

>ADD >		@ PENNEX PHARMS	EQ 10MG BASE/ML	N88143 001 JUL 26, 1983
>ADD >				
>DLT >	/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N88143/001/ /JUL/26,/1983/
>DLT >				

TABLET; ORAL

/TEP/

/AB/		/GENEVA/	/EQ 1MG BASE/	/N85785/001/
/AB/			/EQ 2MG BASE/	/N85786/001/
/AB/			/EQ 5MG BASE/	/N85789/001/
/AB/			/EQ 10MG BASE/	/N85788/001/

TRIFLUOPERAZINE HCL

AB	GENEVA	EQ 1MG BASE	N85785 001
AB		EQ 2MG BASE	N85786 001
AB		EQ 5MG BASE	N85789 001
AB		EQ 10MG BASE	N85788 001

TRIFLUPROMAZINE

/SUSPENSION;/ORAL/
/VESPRIN/
/SQUIBB/ /EQ/50MG/HCL/5ML/ /N11491/004/
@ APOTHECON EQ 50MG HCL/5ML N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
VESPRIN
> ADD > AP + APOTHECON 10MG/ML N11325 004
> ADD > AP + 20MG/ML N11325 001
> DLT >/AP/ /SQUIBB/ /10MG/ML/ /N11325/004/
> DLT >/AP/ /20MG/ML/ /N11325/001/

/TABLET;/ORAL/
/VESPRIN/
/+//SQUIBB/ /50MG/ /N11123/003/
/10MG/ /N11123/001/
/25MG/ /N11123/002/
@ SQUIBB 10MG N11123 001
@ 25MG N11123 002
@ 50MG N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL
AA NYLOS TRADING 5MG N85622 001
/AA/ /TABLICAPS/ /5MG/ /N85622/001/

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE
> ADD > @ PENNEX PHARMS EQ 2.5MG BASE/5ML N88285 001
APR 11, 1985
> ADD >
> DLT > /@/PHARM/BASICS/ /EQ/2.5MG/BASE/5ML/ /N88285/001/
> DLT > /APR/11,/1985/

TRIOXSALEN

TABLET; ORAL
TRISORALEN
/ELDER/ /5MG/ /N12697/001/
ICN 5MG N12697 001

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL
/AA/ /HEATHER/ /50MG/ N83989 001
@ HEATHER 50MG
AA NYLOS TRADING 50MG N85412 001
/AA/ /TABLICAPS/ /50MG/ /N85412/001/

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
/AP/ /QUAD/ /3MG/ML/ /N89442/001/
/AUG/12,/1988/
@ QUAD 3MG/ML N89442 001
AUG 12, 1988

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID
AB PHARMACAPS 250MG N73484 001
JUN 29, 1993

SYRUP; ORAL
MYPROIC ACID
> ADD > AA PENNEX PHARMS 250MG/5ML N70868 001
JUL 01, 1986
> ADD >
> DLT >/AA/ /PHARM/BASICS/ /250MG/5ML/ /N70868/001/
> DLT > /JUL/01,/1986/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOCIN HCL IN PLASTIC CONTAINER
+ LILLY EQ 500MG BASE/100ML N50671 001
APR 29, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL
AP MARSAM 2.5MG/ML N72233 001
FEB 26, 1993

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL
VERAPAMIL HCL

AB	WATSON LABS	40MG	N72923 001	JUN 29, 1993
AB		40MG	N72924 001	JUN 29, 1993

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE

	FUJISAWA	1MG/ML	N89515 001 APR 29, 1987
	/LYPHOMED/	/1MG/ML/	/N89515/001/ /APR/29,/1987/

VITAMIN A PALMITATE

CAPSULE; ORAL
AFAXIN

	ə STERLING	EQ 50,000 UNITS BASE	N83187 001

VITAMIN A

/AA/	/WHARTON/	/EQ 50,000 UNITS BASE/	/N83665/001/
	ə WHARTON	EQ 50,000 UNITS BASE	N83665 001
/AA/	/ZENITH/	/EQ 50,000 UNITS BASE/	/N83035/001/
/AA/		/EQ 50,000 UNITS BASE/	/N83190/001/
	ə ZENITH	EQ 50,000 UNITS BASE	N83035 001
	ə	EQ 50,000 UNITS BASE	N83190 001

INJECTABLE; INJECTION
AQUASOL A

/AP/	/ASTRA/	/EQ 50,000 UNITS BASE/ML/	/N06823/001/
	ASTRA	EQ 50,000 UNITS BASE/ML	N06823 001

VITAMIN A PALMITATE

/AP/	/BEL/MAR/	/EQ 50,000 UNITS BASE/ML/	/N80819/001/
	ə BEL MAR	EQ 50,000 UNITS BASE/ML	N80819 001

WARFARIN SODIUM

TABLET; ORAL
COUMADIN

>DLT>	/BX/	/DUPONT/	/2MG/		/N09218/013/
>DLT>	/BX/		/2.5MG/		/N09218/018/
>DLT>	/BX/+/		/5MG/		/N09218/007/
>DLT>	/BX/+/		/10MG/		/N09218/005/
>ADD>		+ DUPONT	2MG		N09218 013
>ADD>			5MG		N09218 007
>ADD>		+	10MG		N09218 005
>ADD>			2.5MG		N09218 018
>ADD>			4MG		N09218 023
>ADD>					AUG 24, 1993
>DLT>		/PANWARFIN/			
>DLT>	/BX/	/ABBOTT/	/2MG/		/N17020/001/
>DLT>	/BX/		/2.5MG/		/N17020/002/
>DLT>	/BX/		/5MG/		/N17020/003/
>DLT>	/BX/		/7.5MG/		/N17020/004/
>DLT>	/BX/		/10MG/		/N17020/005/
>ADD>		ə ABBOTT	2MG		N17020 001
>ADD>		ə	2.5MG		N17020 002
>ADD>		ə	5MG		N17020 003
>ADD>		ə	7.5MG		N17020 004
>ADD>		ə	10MG		N17020 005

XENON, XE-133

GAS; INHALATION
XENON XE 133

>DLT>	/AA/	/DUPONT/	/40MCI/VIAL/		/N17284/004/
>DLT>	/AA/		/40MCI/VIAL/		/N17284/005/
>DLT>	/AA/		/50MCI/VIAL/		/N17284/006/
>DLT>	/AA/		/60MCI/VIAL/		/N17284/007/
>DLT>	/AA/		/100MCI/VIAL/		/N17284/003/
AA		MEDI PHYSICS	10MCI/VIAL		N17687 002
AA			20MCI/VIAL		N17687 003

XYLOSE

POWDER; ORAL
XYLO-PFAN

/AA/	/ADRIA/	/25GM/BOT/		/N17605/001/
AA	SAVAGE	25GM/BOT		N17605 001

ZINC SULFATE

/INJECTABLE;/INJECTION/
/ZINC/SULFATE/
/LYPHOMED/ /EQ/1MG/ZINC/ML/ /N19229/002/
/MAY/05,/1987/

a LYPHOMED	EQ 1MG ZINC/ML	N19229 002 MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL
NEOPAP
/ALCON/ /120MG/ /N16401/001/
POLYMEDICA 120MG N16401 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
/ALUMINUM/HYDROXIDE/AND/MAGNESIUM/TRISILICATE/
/PENNEX/ /80MG;20MG/ /N89449/001/
/NOV/27,/1987/
@ PENNEX 80MG;20MG N89449 001
NOV 27, 1987

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
HIBISTAT
/STUART/ /0.5%/ /N18300/001/
+ ZENECA 0.5% N18300 001

TINCTURE; TOPICAL
HIBITANE
/@/STUART/ /0.5%/ /N18049/001/
@ ZENECA 0.5% N18049 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ISOCLOR
CIBA 8MG;120MG N18747 001
MAR 06, 1986
/FISONS/ /8MG;120MG/ /N18747/001/
/MAR/06,/1986/

CLOTRIMAZOLE

>ADD< CREAM; TOPICAL
>ADD< CLOTRIMAZOLE
>ADD< TARO 1% N72640 002
AUG 31, 1993

CLOTRIMAZOLE

CREAM; VAGINAL
CLOTRIMAZOLE
NMC 1% N74165 001
JUL 16, 1993

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN COMBINATION PACK
+ SCHERING PLOUGH 1%;100MG N20289 002
APR 26, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHEN
>ADD< PENNEX PHARMS 12.5MG/5ML N70118 001
>ADD< OCT 01, 1985
>DLT< /PHARM/BASICS/ /12.5MG/5ML/ /N70118/001/
>DLT< /OCT/01,/1985/

DIPHENHYDRAMINE HCL
BARRE 12.5MG/5ML N70497 001
APR 25, 1989
/NASKA/ /12.5MG/5ML/ /N70497/001/
/APR/25,/1989/

IBUPROFEN

TABLET; ORAL
IBUPROFEN
/LUCHEN/ /200MG/ /N72901/001/
/DEC/19,/1991/
/200MG/ /N72903/001/
/DEC/19,/1991/

IBUPROFEN
NORTON HN 200MG N71144 001
JAN 20, 1987
200MG N72901 001
DEC 19, 1991
200MG N72903 001
DEC 19, 1991

/IBUPROFEN/
/OHM/ /200MG/ /N71214/001/
/DEC/01,/1986/

IBUPROFEN
/ZENITH/ /200MG/ /N71154/001/
/OCT/27,/1987/
@ ZENITH 200MG N71154 001
OCT 27, 1987

IBUPROFEN

TABLET; ORAL

IBUPROHM		
OHM	200MG	N71214 001 DEC 01, 1986
/NEUVIL/		
/LUCHEM/	/200MG/	/N71144/001/ /JAN/20,/1987/

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HCL		
WATSON LABS	1MG/5ML	N73062 001 MAY 28, 1993

TABLET; ORAL

LOPERAMIDE HCL		
NOVOPHARM	2MG	N73254 001 JUL 30, 1993

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT 7 COMBINATION PACK		
+ ADVANCED CARE	2%;100MG	N20288 002 APR 26, 1993

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE;/ORAL/

/ACTIFED/		
/BURROUGHS/WELLCOME/	/60MG;2.5MG/	/N19268/001/ /JAN/15,/1985/

/SYRUP;/ORAL/

/ACTIFED/		
/BURROUGHS/WELLCOME/	/30MG/5ML;1.25MG/5ML/	/N11935/003/ /NOV/26,/1982/
/TRIOFED/		
/BARRE/	/30MG/5ML;1.25MG/5ML/	/N88115/001/ /MAR/04,/1983/
/TRIPOSED/		
/HALSEY/	/30MG/5ML;1.25MG/5ML/	/N88213/002/ /MAR/30,/1984/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/TABLET;/ORAL/

/ACTIFED/		
/BURROUGHS/WELLCOME/	/60MG;2.5MG/	/N11936/002/ /NOV/26,/1982/
/TRI-SUDO/		
/MD/PHARM/	/60MG;2.5MG/	/N85024/002/ /JAN/10,/1984/
/TRIPODRINE/		
/DANBURY/PHARMA/	/60MG;2.5MG/	/N88112/001/ /JAN/20,/1983/
/TRIPOSED/		
/HALSEY/	/60MG;2.5MG/	/N88192/002/ /MAY/01,/1984/
/TRIPROLIDINE/HCL/AND/PSEUDOEPHEDRINE/HCL/		
/CHELSEA/	/60MG;2.5MG/	/N88118/002/ /JAN/26,/1984/

INDIUM^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM N/A N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru August 1993]

NAME *Generic/Chemical* *TN=Trade Name*	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD=Date Designated* *MA=Marketing Approval*
8-METHOXSALEN TN= UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
AMINOSALICYLATE SODIUM TN=	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
AMINOSIDINE TN= GABBROMICINA	TREATMENT OF TUBERCULOSIS.	UNIVERSITY OF ILLINOIS AT CHICAGO 833 SOUTH WOOD STREET M/C 886 ROOM 176 CHICAGO IL 60612 DD 05/14/93 MA / /
AMIODARONE TN= AMIO-AQUEOUS	TREATMENT OF INCESSANT VENTRICULAR TACHYCARDIA.	ACADEMIC PHARMACEUTICALS, INC. 25720 SAUNDERS ROAD NORTH LAKE FOREST IL 60045 DD 08/17/93 MA / /
ANTI-THYMOCYTE SERUM TN= NASHVILLE RABBIT ANTI-THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
APOMORPHINE HCL INJECTION TN=	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
ATOVAQUONE TN= MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
ATOVAQUONE TN= MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /
COLFOSCERIL PALMITATE, CETYL ALCOHOL, TYLOXAPOL TN= EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TN=	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	KIM, SINIL M.D. UCSD CANCER CENTER/0812 SAN DIEGO CA 92103 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT,INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
INTERFERON BETA (RECOMBINANT HUMAN) TN=	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
LIPOSOMAL DAUNORUBICIN TN= DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
METHOTREXATE TN= RHEUMATREX	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	LEDERLE LABORATORIES 401 N. MIDDLETOWN ROAD PEARL RIVER NY 10965-1299 DD 08/23/93 MA / /
MODAFINIL TN=	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /
MONOCLONAL ANTIBODY FOR IMMUNIZATION AGAINST LUPUS NEPHRITIS TN=	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
MONOLAURIN TN= GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC. 371 BEL MARIN KEYS, SUITE 210 NOVATO CA 94949 DD 04/29/93 MA / /
MYTOMYCIN-C TN=	TREATMENT OF REFRACTORY GLAUCOMA AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY.	IOP INCORPORATED 3100 AIRWAY AVENUE COSTA MESA CA 92626 DD 08/23/93 MA / /
NITRIC OXIDE TN=	TREATMENT OF PERSISTENT PULMONARY HYPERTENSION IN THE NEWBORN.	ANAQUEST, INCORPORATED 110 ALLEN ROAD LIBERTY CORNER NJ 07938 DD 06/22/93 MA / /
PRIMAQUINE PHOSPHATE TN=	FOR USE IN COMBINATION WITH CLINDAMYCIN HYDROCHLORIDE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	STERLING WINTHROP INC. 90 PARK AVENUE NEW YORK NY 10016 DD 07/23/93 MA / /
PROTEIN C CONCENTRATE TN= PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH CORP. 750 LEXINGTON AVENUE, 19TH FLOOR NEW YORK NY 10022 DD 04/22/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
PROTIRELIN TN=	PREVENTION OF INFANT RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH PREMATURITY.	UCB PHARMACEUTICALS, INC. 5505-A ROBIN HOOD ROAD NORFOLK VA 23513 DD 08/24/93 MA / /
PULMONARY SURFACTANT REPLACEMENT, PORCINE TN= CUROSURF	FOR THE TREATMENT AND PREVENTION OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	CHIESI PHARMACEUTICALS, INC. 150 DANBURY ROAD RIDGEFIELD CT 06877 DD 08/02/93 MA / /
RII RETINAMIDE TN=	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 05/06/93 MA / /
RILUZOLE TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /
ROQUINIMEX TN= LINOMIDE	TO PROLONG TIME TO RELAPSE IN LEUKEMIA PATIENTS WHO HAVE UNDERGONE AUTOLOGOUS BONE MARROW TRANSPLANTATION.	KABI PHARMACIA, INC. 800 CENTENNIAL AVENUE PISCATAWAY NJ 08855-1327 DD 07/01/93 MA / /
SECALCIFEROL TN= OSTEO-D	TREATMENT OF FAMILIAL HYPOPHOSPHATEMIC RICKETS.	LEMMON COMPANY 650 CATHILL ROAD SELLERSVILLE PA 18960 DD 07/26/93 MA / /
SOMATROPIN TN= BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /
SUCRALFATE TN=	TREATMENT OF ORAL MUCOSITIS AND STOMATITIS FOLLOWING RADIATION THERAPY FOR HEAD AND NECK CANCER.	FUISZ TECHNOLOGIES, LTD. 3810 CONCORDE PARKWAY, SUITE 100 CHANTILLY VA 22021 DD 07/15/93 MA / /
THALIDOMIDE TN=	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /
TOREMIFENE TN= ESTRINEX	TREATMENT OF DESMOID TUMORS.	ADRIA LABORATORIES P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 08/17/93 MA / /
TRETINOIN TN= TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN 1 TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN II TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
VASOACTIVE INTESTINAL POLYPEPTIDE TN=	TREATMENT OF ACUTE ESOPHAGEAL FOOD IMPACTION.	RESEARCH TRIANGLE PHARMACEUTICALS 200 WESTPARK CORPORATE CENTER DURHAM NC 27713 DD 06/23/93 MA / /

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
FELBAMATE TN= FELBATOL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	WALLACE LABORATORIES 301B COLLEGE ROAD EAST PRINCETON NJ 08540 DD 01/24/89 MA 07/29/93
INTERFERON BETA, RECOMBINANT HUMAN TN=BETASERON	TREATMENT OF MULTIPLE SCLEROSIS.	CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE CA 94608 DD 11/17/88 MA 07/23/93
LEUPROLIDE ACETATE TN= LUPRON INJECTION	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.	TAP PHARMACEUTICALS, INC. 2355 WAUKEGAN ROAD DEERFIELD IL 60015 DD 07/25/88 MA 04/16/93
LEVOMETHADYL ACETATE HYDROCHLORIDE TN=ORLAAM	TREATMENT OF HEROIN ADDICTS SUITABLE FOR MAINTENANCE ON OPIATE AGONISTS.	BIODEVELOPMENT CORPORATION 1300 NORTH 17TH STREET, SUITE 300 ARLINGTON VA 22209-2306 DD 01/24/84 MA 07/09/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

BUMETANIDE (TABLET)	APR 23, 1993
BUSIPRONE HYDROCHLORIDE (TABLET)	AUG 13, 1993
CEFACLOR (CAPSULE AND SUSPENSION)	APR 23, 1993
CAPTOPRIL (TABLET)	MAY 13, 1993
CHOLESTRYRAMINE (POWDER)	JUL 15, 1993
GLIPIZIDE (TABLET)	APR 23, 1993
GLYBURIDE (TABLET)	APR 23, 1993
GUANABENZ ACETATE (TABLET)	APR 23, 1993
INDAPAMIDE (TABLET)	APR 23, 1993
KETOPROFEN (CAPSULE)	APR 23, 1993
ORAL EXTENDED (CONTROLLED RELEASE)	SEP 09, 1993
PINDOLOL (TABLET)	APR 23, 1993
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993
TRIAZOLAM (TABLET)	DEC 24, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993
CARBOPLATIN INJECTABLE; INJECTION	10MG/ML (5ML/VIAL) (15ML/VIAL) (45ML/VIAL)	92 P-0467/ CP1	BULL	NEW DOSAGE FORM	APPROVED MAY 20, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993
PREDNISOLONE SYRUP; ORAL	10MG/5ML	92 P-0439/ CP1	WE PHARMS	NEW STRENGTH	APPROVED MAY 20, 1993
TRIMETHOPRIM SOLUTION; ORAL	25MG/5ML	92 P-0500/ CP1	ASCENT PHARMS	NEW DOSAGE FORM	APPROVED MAY 20, 1993

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-20	SINGLE 32MG DOSE

REFERENCES
NEW INDICATION

I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]

REFERENCES
PATENT USE CODE

U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18473 001	ALBUTEROL; VENTOLIN				I-93	JUL 20, 1996
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS				I-93	JUL 20, 1996
	19604 001	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005			
	19604 002	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005		NS	DEC 23, 1995
	20258 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	4517199	MAY 14, 2002	U-15		
	19402 001	ASTEMIZOLE; HISMANAL	4219559	AUG 26, 1999		NCE	DEC 29, 1993
	20045 001	AVOBENZONE; SHADE UVAGUARD	4522807	JUN 11, 2002		NC	DEC 07, 1995
			4387089	JUN 07, 2002			
	19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	20186 001	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
						NC	FEB 26, 1996
	20186 002	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
						NC	FEB 26, 1996
	20186 003	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
						NC	FEB 26, 1996
>ADD>	20210 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
>ADD>	20210 002	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20229 001	CLADRIBINE; LEUSTATIN				NCE	FEB 26, 1998
						ODE	FEB 26, 2000
	19287 001	DIAZEPAM; DIZAC				NDF	JUN 18, 1996
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	18651 001	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 002	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 003	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	19616 004	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	19616 005	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	20164 001	ENOXAPARIN SODIUM; LOVENOX				NCE	MAR 29, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20189 001	FELBAMATE; FELBATOL				NCE	JUL 29, 1998
>ADD>						ODE	JUL 29, 2000
	20189 002	FELBAMATE; FELBATOL				NCE	JUL 29, 1998
>ADD>						ODE	JUL 29, 2000
	20189 003	FELBAMATE; FELBATOL				NCE	JUL 29, 1998
>ADD>						ODE	JUL 29, 2000
	20073 001	FLUMAZENIL; MAZICON	4316839	MAR 03, 2003		NCE	DEC 20, 1996
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001			
			4194009	APR 19, 1994			
			4018895	APR 19, 1994	U-12		
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4215113	JUN 06, 2000	U-64	NCE	SEP 27, 1996
	20123 001	GADODIAMIDE; OMNISCAN	4687659	AUG 18, 2004	U-76	NCE	JAN 08, 1998
>ADD>	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4957939	MAR 03, 2004		I-94	AUG 17, 1996
	17783 003	GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994
	19726 001	GOSERELIN ACETATE; ZOLADEX				I-88	FEB 02, 1996
	19032 001	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19032 002	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	18538 002	INDAPAMIDE; LOZOL				NS	APR 29, 1996
						NCE	JUL 06, 1993
	19710 005	IOVERSOL; OPTIRAY 350				I-48	JUL 27, 1996
	20215 001	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
	20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
						NS	JUN 30, 1996
>ADD>	20225 001	ISOSORBIDE MONONITRATE; IMDUR				NCE	DEC 30, 1996
>ADD>						NDF	AUG 12, 1996
>ADD>	20225 002	ISOSORBIDE MONONITRATE; IMDUR				NCE	DEC 30, 1996
>ADD>						NDF	AUG 12, 1996
	19084 001	KETOCONAZOLE; NIZORAL	4335125	JUN 15, 1999		I-30	JAN 27, 1996
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	5110493	MAY 05, 2009	U-75	NCE	NOV 30, 1994
			4454151	JUN 12, 2001	U-75	NDF	NOV 09, 1995
			4089969	MAY 16, 1997	U-75		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20263 001	LEUPROLIDE ACETATE; LUPRON	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
18948 001	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
					ODE	DEC 16, 1999
18948 002	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
					ODE	DEC 16, 1999
20315 001	LEVOMETHADYL ACETATE HYDROCHLORIDE; ORLAAM				NCE	JUL 09, 1998
					ODE	JUL 09, 2000
19558 001	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
19558 002	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
19558 003	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
19558 004	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19777 001	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 002	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 003	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 004	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 005	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE	FEB 21, 1997
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE	APR 12, 1998
	20049 001	MESALAMINE; PENTASA	4496553	JAN 29, 2002	U-78	NP	MAY 10, 1996
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
	19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 2000		NCE	MAR 01, 1993
	20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NCE	JAN 13, 1994
	20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	19921 001	OFLOXACIN; OCUFLOX	4382892	MAY 10, 2000			
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996
>ADD>						I-9	AUG 13, 1996
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
>ADD>	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996	U-53		
>DLT>	~~20036 001~~	~~PAMIDRONATE DISODIUM; AREDIA~~	~~3962432~~	~~FEB 01, 1997~~	~~U-53~~		
>ADD>	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
>ADD>			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
>ADD>	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
>ADD>			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
>ADD>	20091 001	PERFLUBRON; IMAGENT				NCE	AUG 13, 1998
	20014 001	PIRBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004			
	19795 001	PODOFILOX; CONDYLOX				NCE	DEC 13, 1995
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19627 001	PROPOFOL; DIPRIVAN				I-90	MAR 08, 1996
						ODE	DEC 23, 1999
	50689 001	RIFABUTIN; MYCOBUTIN	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR				NCE	JUN 18, 1998
	20134 001	STRONTIUM CHLORIDE, SR-89; METASTRON				NR	MAR 19, 1996
	19050 001	SUFENTANIL CITRATE; SUFENTA				I-89	MAR 19, 1996
	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 28, 2006	U-72		
	19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				I-87	NOV 27, 1995
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
	18163 003	TEMAZEPAM; RESTORIL	5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
			4051141	SEP 27, 1996		NCE	OCT 31, 1996
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
			4051141	SEP 27, 1996		NCE	OCT 31, 1996
>ADD>	136 001	TORSEMIDE; DEMADEX				NCE	AUG 23, 1998
>ADD>	20136 002	TORSEMIDE; DEMADEX				NCE	AUG 23, 1998
>ADD>	20136 003	TORSEMIDE; DEMADEX				NCE	AUG 23, 1998
>ADD>	20136 004	TORSEMIDE; DEMADEX				NCE	AUG 23, 1998
>ADD>	20137 002	TORSEMIDE; DEMADEX				NCE	AUG 23, 1998
	18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
			4215104	JUL 29, 1997			
	18776 003	VECURONIUM BROMIDE; NORCURON	4297351	OCT 27, 1998			
			4237126	DEC 02, 1997		NCE	APR 30, 1994
	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997
	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19862 001	INDIUM 111 CHLORIDE; INDICLOR				NCE	DEC 29, 1997
841207 001	PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%; PENTASPAN				ODE	MAY 19, 1994
860909 001	PERFLUORODECALIN; FLUOSOL	3911138	OCT 07, 1994		NCE	DEC 26, 1994
		4252827	FEB 24, 1998			
900278 001	SATUMOMAB PENDETIDE; ONCOSCINT				ODE	DEC 29, 1999

*U.S. Government Printing Office: 1993 — 301-[illegible]0002

New 13th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7023

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (04/93)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 783-3238.